Get the free congress App for your smartphone

Quickly find your way through the most up-to-date congress schedule of scientific sessions.

- Mark your favorite sessions and personalise your experience.
- Find information on sponsors and exhibitors involved in the WFSBP Congress 2017.
- Access vital information around the congress.

Further information is given at www.wfsbp-congress.org/app.
<table>
<thead>
<tr>
<th>Page</th>
<th>Table of Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Welcome to the 13th World Congress of Biological Psychiatry</td>
</tr>
<tr>
<td>5</td>
<td>About WFSBP</td>
</tr>
<tr>
<td></td>
<td>About the WFSBP Congress 2017</td>
</tr>
<tr>
<td>6</td>
<td>Congress Administration</td>
</tr>
<tr>
<td>6</td>
<td>WFSBP Executive Committee</td>
</tr>
<tr>
<td>6</td>
<td>Honorary Committee</td>
</tr>
<tr>
<td>6</td>
<td>International Scientific Programme Committee</td>
</tr>
<tr>
<td>7</td>
<td>National Presidents</td>
</tr>
<tr>
<td>8</td>
<td>Chairs of the Local Organising Committee</td>
</tr>
<tr>
<td>8</td>
<td>Congress Ambassadors</td>
</tr>
<tr>
<td>8</td>
<td>Administrative Meetings</td>
</tr>
<tr>
<td>9</td>
<td>Task Force Meetings</td>
</tr>
<tr>
<td>11</td>
<td>Floor Plan</td>
</tr>
<tr>
<td>12</td>
<td>WFSBP Awards</td>
</tr>
<tr>
<td>13</td>
<td>Format Descriptions</td>
</tr>
<tr>
<td></td>
<td>Scientific Information</td>
</tr>
<tr>
<td>14</td>
<td>Topics</td>
</tr>
<tr>
<td>15</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>16</td>
<td>CME Accreditation</td>
</tr>
<tr>
<td>16</td>
<td>Colour Legend</td>
</tr>
<tr>
<td>17</td>
<td>Scientific Programme Schedules</td>
</tr>
<tr>
<td>22</td>
<td>Scientific Programme</td>
</tr>
<tr>
<td>27</td>
<td>Sunday, 18 June 2017</td>
</tr>
<tr>
<td>27</td>
<td>Monday, 19 June 2017</td>
</tr>
<tr>
<td>38</td>
<td>Tuesday, 20 June 2017</td>
</tr>
<tr>
<td>50</td>
<td>Wednesday, 21 June 2017</td>
</tr>
<tr>
<td>63</td>
<td>Thursday, 22 June 2017</td>
</tr>
<tr>
<td>72</td>
<td>Congress Information</td>
</tr>
<tr>
<td>76</td>
<td>List of Exhibitors / Exhibition Floor Plan</td>
</tr>
<tr>
<td>77</td>
<td>Acknowledgements</td>
</tr>
<tr>
<td>78</td>
<td>Industry Sessions</td>
</tr>
<tr>
<td>79</td>
<td>List of Chairpersons, Authors and Co-Authors</td>
</tr>
</tbody>
</table>
Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13th World Congress of Biological Psychiatry in Copenhagen, 18 – 22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsychosocio-spiritual aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of biological psychiatry is expanding by the development of bioinformatics (genomics, transcriptomics, proteomics) identifying importance of glycome, lipidome, metabolome, and brain activity mapping methodology.

Looking back at a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders.

The field of biological psychiatry is rapidly developing, reaching a new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive trans-cranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and decoded neurofeedback (DecNef) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti-epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders.

We are confident that the 13th World Congress of Biological Psychiatry in Copenhagen will be a superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia/Workshops and 83 independent Symposia/Workshops are forming the core scientific programme; all of them on very interesting topics to be presented by prominent researchers-scientists in their respective fields.

We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda
Congress President

Prof. Constantin R. Soldatos
Chair of the International Scientific Programme Committee

Prof. Gregers Wegener
Chair of the Local Organising Committee
Founded in 1974 in Buenos Aires, Argentina, the World Federation of Societies of Biological Psychiatry is a non-profit world wide organization composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.

With this multitude of countries represented in its worldwide community, the World Federation has built an international network of over 4,500 opinion leaders, the majority of which are key opinion-leaders in the practice of Biological Psychiatry.

**WFSBP members by continent**

*As of May 2017*

- Europe: 57.6%
- Africa: 7.1%
- Asia: 24.5%
- South America: 6.6%
- North America: 3.7%
- Oceania: 0.5%

**The principle objectives of WFSBP are:**
- To foster and encourage scientific research and advancement in the field of Biological Psychiatry
- To improve the quality of training spanning all the biological psychiatry sciences
- To promote education and achieve the highest level of knowledge and understanding within the field
- To provide information and guidance to all institutions, societies or individuals with an interest in biological psychiatry
- To establish, build, and maintain solid collaboration with international and national organisations related to biological psychiatry

Educational activities, regional, international and world congresses, the interactive website [www.wfsbp.org](http://www.wfsbp.org), and The World Journal of Biological Psychiatry build the World Federation’s portfolio and insure its worldwide influence. The development of worldwide treatment guidelines is one of WFSBP’s main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation’s Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities.

**WFSBP members by field of activity:**

- Clinicians: 88%
- Researchers: 12%
The 13th World Congress of Biological Psychiatry is organised by the World Federation of Societies of Biological Psychiatry (WFSBP).

**WFSBP EXECUTIVE COMMITTEE**  
**President (2015 – 2019)**  
Masatoshi Takeda, Japan

**Vice President (2013 – 2017)**  
Tudor Udristoiu, Romania

**Past President (2015 – 2017)**  
Constantin R. Soldatos, Greece

**Secretary (2013 – 2017)**  
Lakshmi N. Yatham, Canada

**Treasurer (2013 – 2017)**  
Martin Hatzinger, Switzerland

**Vice Secretary (2013 – 2017)**  
Ladislav Hosak, Czech Republic

**Vice Treasurer (2013 – 2017)**  
Victoria Valdez, Ecuador

**INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC)**  
**Chair**  
Constantin R. Soldatos, Greece

**Vice Chairs**  
Peter Falkai, Germany  
Lakshmi Yatham, Canada

**Deputy Chairs**  
Dimitris Dikeos, Greece  
Yoshio Hirayasu, Japan  
Tudor Udristoiu, Romania

**Secretary**  
Georgios Kiosterakis, Greece

**Members of ISPC**  
G. Alexopoulos, USA*  
C. A. Altamura, Italy*  
C. Arango, Spain  
E. Baca Garcia, Spain  
M. Bauer, Germany*  
E. Belfort, Venezuela  
A. Benyamina, France  
M. Berk, Australia*  
J. Bobes, Spain  
A. Bozkurt, Cyprus  
N. Boutros, USA  
C. L. Bowden, USA  
P. Boyer, France  
J. Bradford, Canada  
P. Brambilla, Italy  
M. Bras, Croatia  
M. S. Buchsbaum, USA  
A. Burns, UK  
R. Castilla-Puentes, USA*  
D. Castle, Australia*  
E. Ceskova, Czech Republic*  
M. Cetkovich-Bakmas, Argentina  
Y. Hwa Chou, Taiwan*  
H. Correa, Brazil*  
P. Cosyns, Belgium  
P. Courtet, France*  
B. Dean, Australia*  
J. de Buitleara, The Netherlands  
M. Dierick, Belgium  
B. Dubois, France  
K. Fountoulakis, Greece*  
S. Frangou, UK  
W. Gaebel, Germany  
F. D. Garcia, Brazil*  
W. F. Gattaz, Brazil  
P. Gejman, USA  
A. Germanavicious, Lithuania  
M. George, USA*  
A. H. Glassman, USA  
B. Glenthoj, Denmark  
G. M. Goodwin, UK  
D. Gorelick, USA  
P. Gorwood, France*  
A. Grace, USA*  
H. Grunze, UK*  
G. Hajak, Germany  
A. Halaris, USA*  
A. Hasan, Germany  
S. Heckers, USA  
C. Hiemke, Germany  
E. Hollander, USA  
E. Holsboer-Trachsler, Switzerland*  
W. G. Honer, Canada  
J. Horacek, Czech Republic  
A. Jablensky, Australia  
R. Kahn, The Netherlands  
J. Kane, USA  
S. Kanba, Japan*  
T. Kato, Japan  
C. Katona, UK  
W. Kaye, USA  
J. Kennedy, Canada*  
L. Konopka, USA  
H. R. Kranzler, USA*  
C. Krieg, Germany  
T. Kudo, Japan  
J. Soo Kwon, Korea  
S. Lamy, France  
R. Lanzengerber, Austria*  
V. Larach, Chile

* Special correspondents of ISC Core Group
About the WFSBP Congress 2017

M. Leboyer, France
M.S. Lee, Korea*
M. Lejoyeux, France
B. Leonard, Ireland*
Y. Levkovitz, Israel
A. Lopez Mato, Argentina*
C. Lyketsos, USA
R. McCarley, USA
P. Mc Gorry, Australia
P. Mc Guire, UK
M. Maes, Belgium*
J.-L. Martinot, France
V. Matei, Romania*
H. Mayberg, USA
H. Y. Meltzer, USA
M. Meyer-Lindenberg, Germany
A. Kant Mital, India
E. Mohan Das, India
N. Müller, Germany
T. Murai, Japan*
Z. Nahas, Lebanon
D. Nutt, UK
J. Ospina-Duque, Colombia*
N. Ozaki, Japan
C. Pantelis, Australia*
G. Papadimitriou, Greece
T. Paparrigopoulos, Greece*
G. Parker, Australia
L. Pezewas, Austria
O. Pogarell, Germany
S. G. Potkin, USA
R. Post, USA*
M. Rapaport, USA
M.S. Reddy, India*
E. Richelson, USA
P. Riederer, Germany
D. Rujescu, Germany
R. Rupprecht, Germany
J. Rybakowski, Poland
H. Sackeim, USA
T. Saito, Japan
P. Salgado Pineda, Spain
M. Sarchiapone, Italy
T. Schlaepfer, Germany*
A. Schmitt, Germany
L. Schneider, USA
C. Schulz, USA
T. G. Schulze, Germany*

S. Seedat, South Africa*
E. Seifritz, Switzerland
A. Serretti, Italy*
E. Serfaty, Argentina
W. W. Shen, Taiwan
L. Siever, USA
D. St. Clair, UK
N. Stefanis, Greece*
J. Steiner, Germany
T. Suhara, Japan
M. Taleb, France/Algeria
T. Tanelli, USA
J. Tellez-Vargas, Colombia
J. Treasure, UK
N. A. Uranoa, Russia
P. Udomratn, Thailand*
I. Udrisstoiu, Romania*
W. van den Brink, The Netherlands*
J. van Os, The Netherlands
D. Velakoulis, Australia*
N. Venizelos, Sweden*
E. Vieta, Spain*
J. Waddington, Ireland
A. Weinstein Israel
P. Whybrow, USA
X. Yu, China
M. Zanarini, USA
Y. Zervas, Greece*
J. Zohar, Israel

NATIONAL PRESIDENTS
A. Corrales, Argentina
A. Boyajyan, Armenia
D. Eyles, Australia
C. Geretsegger, Austria
S. Claes, Belgium
N. D. Noya-Tapia, Bolivia
A. B. Mehmedbašić, Bosnia-Hercegovina
A. Marcolin, Brazil
O. A. Mikova-Demireva, Bulgaria
R. W. Lam, Canada
E. Olea, Chile
C. Gutierrez, Columbia
R. Castro, Costa Rica
M. Jakovljevic, Croatia
Ladislav Hosak, Czech Republic
W. van den Brink, The Netherlands*
J. van Os, The Netherlands
D. Velakoulis, Australia*
N. Venizelos, Sweden*
E. Vieta, Spain*
J. Waddington, Ireland
A. Weinstein Israel
P. Whybrow, USA
X. Yu, China
M. Zanarini, USA
Y. Zervas, Greece*
J. Zohar, Israel

S.-K. Lin, Taiwan
P. Udomratn, Thailand
B. Tanelli, Turkey
A. V. Kalueff, Ukraine
G. B. Raggio de Suaya, Uruguay
J. Ibáñez-Domínguez, Venezuela

* Special correspondents of ISC Core Group
About the WFSBP Congress 2017

CHAIRS OF THE LOCAL ORGANISING COMMITTEE (LOC)

Chair
Gregers Wegener, Denmark

Deputy Chairs
Ida Hagman Pedersen, Denmark
Søren Dinesen Østergaard, Denmark

Members of LOC
Kjeld Andersen, Denmark
Ole A. Andreassen, Norway
Lone Baandrup, Denmark
Per Bech, Denmark
Nils Bilenberg, Denmark
Bjørn Ebdrup, Denmark
Jesper Ekelund, Finland
Anders Fink-Jensen, Denmark
Birte Glenthøj, Denmark
Simon Glerup, Denmark
Jaanus Harro, Estonia
Torsten Bjørn Jacobsen, Denmark
Martin Balslev Jørgensen, Denmark
Olli Kampman, Finland
Lars Kessing, Denmark
Gitte Moos Knudsen, Denmark
Rasmus Licht, Denmark
Pall Mathiasson, Iceland
Tanja Michel, Denmark
Thomas Middelboe, Denmark
Ole Mors, Denmark
Merete Nordentoft, Denmark
Kerstin Plessen, Denmark
Andreas Reif, Germany
Dan Rujescu, Germany
Bo Söderpalm, Sweden
Per Hove Thomsen, Denmark
Jari Tiihonen, Sweden
Anders Tingström, Sweden
Poul Videbech, Denmark
Thomas Werge, Denmark

CONGRESS AMBASSADORS
Carlo Altamura, Italy
Ajit Avasthi, India
Charles Baddoura, Lebanon
Robert Belmaker, Israel
Michael Berk, Australia
István Bitter, Hungary
David Castle, Australia
Enrique Galli, Peru
Peter Gaszner, Hungary
Bai Han, China
Gerhard Heinze, Mexico
Daniela Jezova, Slovakia
Nick Kates, Canada
Valery Krasnov, Russia
Donatella Marazziti, Italy
Giorgio Racagni, Italy
M.S. Reddy, India
Pedro Ruiz, USA
Dan Rujesu, Germany
Janusz Rybakowski, Poland
Dan Stein, South Africa
Andi J. Tanra, Indonesia
Si Tian-Mei, China
Nikolaos Venizelos, Sweden
Eduard Vieta, Spain
Shigeto Yamawaki, Japan
Yukio Yoneda, Japan
Allan Young, UK

ADMINISTRATIVE MEETINGS
By invitation only

WFSBP Individual Membership Section Meeting
Wednesday, 21 June 2017
10:15 – 10:45, Room B3 M3-M4

WFSBP Council Meeting
Wednesday, 21 June 2017
11:00 – 12:30, Room B3 M3-M4

WFSBP General Assembly
Wednesday, 21 June 2017
13:00 – 15:00, Auditorium 11
**TASK FORCE MEETINGS (by invitation only)**

**Conference Room 6**

**Sunday, 18 June 2017**
- Addiction Disorders (Guidelines)  
  08:00 – 09:30
- Child and Adolescence Psychiatry  
  09:45 – 11:15
- Dementia (Guidelines)  
  11:30 – 13:00
- Nosology and Psychopathology (Consensus Paper)  
  13:15 – 14:45
- Pain Management  
  15:00 – 16:30

**Monday, 19 June 2017**
- Meeting of the Task Force Chairs  
  09:00 – 10:30
- Anxiety Disorders and OCD (Guidelines)  
  10:45 – 12:15
- Eating Disorders (Guidelines)  
  12:30 – 14:00

**Tuesday, 20 June 2017**
- Neuroimaging  
  08:00 – 09:30
- Women’s Mental Health  
  09:45 – 11:15
- Brain Pathology  
  11:30 – 13:00
- Tools for Optimising Pharmacotherapy in Psychiatry  
  13:15 – 14:45
- Personality Disorders (Guidelines)  
  15:00 – 16:30

**Wednesday, 21 June 2017**
- Biological Markers (Consensus Paper)  
  16:45 – 18:15
- Genetics  
  08:00 – 09:30
- Men’s Mental Health  
  09:45 – 11:15
- Sexual Disorders (Guidelines)  
  11:30 – 13:00
- Unipolar Depressive Disorders (Guidelines)  
  15:00 – 16:30

**Thursday, 22 June 2017**
- Neuroimaging  
  08:00 – 09:30
- Women’s Mental Health  
  09:45 – 11:15
- Brain Pathology  
  11:30 – 13:00
- Tools for Optimising Pharmacotherapy in Psychiatry  
  13:15 – 14:45
- Personality Disorders (Guidelines)  
  15:00 – 16:30

Meeting dates and times are subject to change (please check with the staff at the registration counter).
CPO HANSER SERVICE is specialist in the field of Conference, Event and Destination Management organizing events of any size throughout Germany and also abroad for more than 35 years.

CPO HANSER SERVICE
CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design

BERLIN
Paulsborner Str. 44
14193 Berlin, Germany
Phone: +49 – (0)30 – 30 06 69-0
Fax: +49 – (0)30 – 30 57 39-1
Email: berlin@cpo-hanser.de

HAMBURG
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – (0)40 – 67 08 82-0
Fax: +49 – (0)40 – 67 03 28-3
Email: hamburg@cpo-hanser.de

www.cpo-hanser.de
The following WFSBP Awards will be delivered and presented during the 13th World Congress of Biological Psychiatry 2017 in Copenhagen.

**WFSBP Award for Scientific Excellence of the WFSBP Host**
The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding researcher in the field of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award consists of a monetary award of EUR 1,000.

**Awardee 2017:**
Per Bech, Denmark

**WFSBP Research Award**
The WFSBP Research Award is intended for WFSBP members (MD, PhD or equivalent) whose current scientific work has had an important impact in the field of clinical and/or basic research in the area of biological psychiatry. This award consists of a monetary award of EUR 1,000.

**Awardee 2017:**
Eduard Vieta, Spain

**WFSBP Award for Excellence in Education**
The WFSBP Award for Excellence in Education is to acknowledge outstanding and innovative education in biological psychiatry including the implementation of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.

**Awardee 2017:**
Florence Thibaut, France

**WFSBP Young Investigator Awards for the 8 Best Posters (Under 40 Year-Old)**
All posters will be evaluated at the congress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

**WFSBP Young Investigator Awards**
WFSBP provides Educational Grants for young investigators to attend the WFSBP biennial congress and the special educational sessions. These sessions are especially designed for young researchers (under 40 year-old) which have been pre-selected via an application process. The grant includes a travel grant of EUR 400 plus free registration to the WFSBP Congress.

**Awardees 2017:**
- Melanie Ashton, Australia
- Sofi Atshemyan, Armenia
- Lucie Bartova, Austria
- Chiara Cristina Bortolasci, Australia
- Julius Burkaukas, Lithuania
- Trisha Chakrabarty, Canada
- Michaela Filiou, Germany
- Firoz Kazhungil, India
- Srisaiyini Kidnapillai, Australia
- Bruno Kluwe-Schiavon, Switzerland
- Karishma Kulkarni, India
- Sagar Lavana, India
- Chieh-Hsin Lin, Taiwan
- Amanda Lyall, USA
- Eleonora Maggioni, Italy
- Maddalena Mauri, Italy
- Ahmed Mhalla, Tunisia
- Blazej Misiak, Poland
- Narayan R. Muralik, India
- Pradip Paul, India
- Alessandro Pignoni, Italy
- Gopinath Sathyanarayanan, India
- André Schmidt, Switzerland
- Leigh van den Heuvel, South Africa
- Nora S. Vyas, United Kingdom
- Gwyneth Zai, Canada
- Clement Zai, Canada
- Roksana Zakharyan, Armenia
- Mikhail Zastrozhin, Russia
- Julia Zaytseva, Czech Republic
OPENING LECTURE
The Opening Lecture will be held during the Opening Ceremony on 18 June 2017.

PLENARY LECTURES
Plenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen among the most prominent researchers in the respective field.

DEBATES
Debates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.

WFSBP TASK FORCE SYMPOSIA
A good number of WFSBP Task Forces have submitted Symposia organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

WFSBP TASK FORCE WORKSHOPS
A good number of WFSBP Task Forces have submitted Workshops organised by their key members on issues related to their field of special expertise. All of them have been included in the scientific programme and pertain to Treatment Guidelines, Consensus Statements and other hot topics in their respective thematic areas.

SYMPOSIA
Symposia are selected, covering basic, clinical, interface, and conceptual topics of Biological Psychiatry. Symposia are 90-minute sessions and will be organised and chaired by the experts whose proposals are accepted by the International Scientific Programme Committee.

WORKSHOPS
Workshops are 90-minute highly interactive sessions with an educational focus. This format is designed to give specific regions a platform for presentation and networking.

FREE COMMUNICATIONS
Authors were invited to submit abstracts on their latest research findings. All submitted abstracts were reviewed and the best were selected and allocated to Free Communication Sessions.

GUIDED POSTER TOURS
Poster Exhibition
The poster exhibition is located in Congress Hall A1. Posters will be changed daily and are on display for the entire day of the respective poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster exhibition times for P-01 to P-05
Monday, 19 June 2017 09:00 – 17:00
Guided Poster Tours 13:00 – 14:30

Poster exhibition times for P-06 to P-10
Tuesday, 20 June 2017 09:00 – 17:00
Guided Poster Tours 13:00 – 14:30

Poster exhibition times for P-11 to P-17
Wednesday, 21 June 2017 09:00 – 17:00
Guided Poster Tours 13:00 – 14:30

Poster exhibition times for P-18 to P-22
Thursday, 22 June 2017 09:00 – 17:00
Guided Poster Tours 13:00 – 14:30

BEST POSTER AWARDS (SEE YOUNG INVESTIGATOR AWARDS)
All posters will be evaluated on site by the WFSBP Prize Committee. The WFSBP Prize Committee will shortlist 5 posters per day that will be exhibited at a Best Poster area in Congress Hall A1 in the afternoon. Two of these will win a Best Poster Award which will be announced on the day of the session. A total of 8 Best Poster Awards for young investigators under 40 years will be presented. All Best Poster Award winners will also be mentioned during the Closing Ceremony on Thursday, 22 June 2017.

EDUCATIONAL SESSIONS
These sessions are dedicated to young researchers up to 40 years of age which will be preselected via an application process. Herewith the WFSBP is promoting education for talented young researchers. Interactional and practical learning is in the focus of these sessions. The educational grant sessions are open to all congress delegates.

INDUSTRY SPONSORED SATELLITE SYMPOSIA
These 90-minute sessions are fully integrated into the congress. The sessions are organised and executed by the pharmaceutical industry by unrestricted educational grants.
The scientific programme of the WFSBP 2017 Congress will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

- T1 Addictive Disorders
- T2 Antidepressants: Basic/Clinical
- T3 Antipsychotics: Basic/Clinical
- T4 Anxiety Disorders: Basic/Clinical
- T5 Anxiolytics: Basic/Clinical
- T6 Bipolar Disorders: Basic/Clinical
- T7 Childhood & Adolescent Disorders: Basic/Clinical
- T8 Chronobiology and Psychiatry
- T9 Cognitive Neuroscience
- T10 Dementia: Basic/Clinical
- T11 Depression: Basic/Clinical
- T12 Eating Disorders: Basic/Clinical
- T13 Emergency Psychiatry
- T14 Epidemiology
- T15 Ethics in Biological Psychiatry
- T16 Forensic Psychiatry
- T17 Genetics
- T18 Hypnotics: Basic/Clinical
- T19 Inflammation Psychiatry
- T20 Liaison Psychiatry
- T21 Mental Retardation or Chromosomal Aberrations: Basic/Clinical
- T22 Molecular Neurobiology
- T23 Mood Stabilisers: Basic/Clinical
- T24 Neuropathology
- T25 Neuroimaging: Genetic, Functional, Structural
- T26 Neurophysiology
- T27 Obsessive-Compulsive Disorders: Basic/Clinical
- T28 Pain: Basic/Clinical
- T29 Panic Disorders: Basic/Clinical
- T30 Personality Disorders: Basic/Clinical
- T31 Pharmacoeconomics
- T32 Pharmacogenetics
- T33 Pharmacology
- T34 Phototherapy
- T35 Posttraumatic Stress: Basic/Clinical
- T36 Pregnancy, post partum and new born: Basic/Clinical
- T37 Premenstrual Syndrome: Basic/Clinical
- T38 Psychogeriatrics
- T39 Psychoneuroimmunology
- T40 Psychopharmacology
- T41 Psychopathology
- T42 Psycho-Oncology
- T43 Schizophrenia: Basic/Clinical
- T44 Sexual Disorders: Basic/Clinical
- T45 Sleep Disorders: Basic/Clinical
- T46 Somatoform Disorders: Basic/Clinical
- T47 Stimulation Methods (ECT, TMS, VNS, DBS)
- T48 Stress: Basic/Clinical
- T49 Suicide: Basic/Clinical
- T50 Violence: Basic/Clinical
- T51 Miscellaneous
Sunday, 18 June 2017
18:00 – 19:15

Master of Ceremony
Dr. Søren Dinesen Østergaard, Denmark, Local Organising Committee Deputy Chair

WELCOME ADDRESSES
Prof. Gregers Wegener, Denmark, Local Organising Committee Chair
Prof. Ralf Hemmingsen, Denmark, Immediate Past Rector of the University of Copenhagen

OPENING ADDRESS
Prof. Masatoshi Takeda, Japan, WFSBP President

SCIENTIFIC PROGRAMME COMMITTEE CHAIR ADDRESS
Prof. Constantin R. Soldatos, Greece, WFSBP Immediate Past President

PRESENTATION OF AWARDS AND DISTINCTIONS
Awards presented by Prof. Constantin R. Soldatos
Prof. Eduard Vieta, Spain, WFSBP Research Award
Prof. Florence Thibaut, France, WFSBP Award for Excellence in Education
Prof. Per Bech, Denmark, WFSBP Award for Scientific Excellence of the WFSBP Host

Distinctions presented by Prof. Masatoshi Takeda
Prof. Peter Riederer, Germany, being presented with Presidential Commendation
Prof. Constantin R. Soldatos, Greece, being pronounced WFSBP Honorary President

OPENING LECTURE
“The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan”
Speaker: Prof. John F. Cryan, Ireland
Chair: Prof. Masatoshi Takeda, Japan

Culture Programme by Chris Minh Doky, Denmark, Bass Player

The Opening Ceremony is followed by a Networking Reception in the Auditorium Foyer.
CME ACCREDITATION
The ‘13th World Congress of Biological Psychiatry’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The ‘13th World Congress of Biological Psychiatry’ is designated for a maximum of 29 hours of European external CME credits. Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

COLOUR CODES OF SESSIONS (SCIENTIFIC PROGRAMME)

| OP | Opening Lecture | TFW | Task Force Workshops | ES | Educational Sessions |
| PL | Plenary Lectures | S | Symposia | P | Guided Poster Tours |
| D | Debates | WS | Workshops | SA | Satellite Symposia |
| TFS | Task Force Symposia | FC | Free Communications | GA | General Assembly |
## Sunday, 18 June 2017 / Scientific Programme Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium 10 – 12</th>
<th>Auditorium 15</th>
<th>Congress Hall A3</th>
<th>B3 M1 – M2</th>
<th>B3 M3 – M4</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>S-01 Towards novel rapid-acting antidepressants</td>
<td>S-02 Psychiatric services in emergency departments: Challenges and solutions</td>
<td>S-03 Dissecting the role of the neuropeptide Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies</td>
<td>WS-01 Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience</td>
<td>FC-01 Treatment of depression</td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>S-04 Pathways of neuroprogression in Bipolar Disorder (BP)</td>
<td>S-05 Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers</td>
<td>S-06 Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?</td>
<td>WS-02 New investigations on the relationship between working memory and ADHD</td>
<td>FC-02 Molecular neurobiology</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>S-07 Social cognition and neuronal correlates in patients with schizophrenia</td>
<td>S-08 Inflammation markers of peripheral blood in depression spectrum</td>
<td>FC-03 Schizophrenia &amp; dementia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>S-09 Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions</td>
<td>S-10 Effects and side effects of electroconvulsive therapy</td>
<td>S-11 Abnormal neurogenesis in schizophrenia</td>
<td>S-12 New approaches into diagnosis and treatment of psychotic Bipolar Disorder (BP)</td>
<td>ES-01 How to build an academic career</td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>Opening Ceremony 18:00 – 19:00 (Auditorium 10 – 12) (incl. OP-01 The microbiome-gut-brain axis: A key regulator of brain &amp; behaviour across the lifespan)</td>
<td>Networking Reception 19:00 – 20:00 (Auditorium Foyer)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Registration Counter** 07:30 – 19:00
### Scientific Programme Schedule / Monday, 19 June 2017

| 8:30 | S-14 Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations | S-15 Posttraumatic Stress Disorder (PTSD) and gender | S-16 The elephant in the room: The role of glial cells in psychiatric disorders | S-17 Psychosis is disrespectful to diagnostic boundaries | S-18 Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide | S-19 Psychedelics: Mechanisms and applications in psychiatry | S-20 Affective and psychotic psychopathology from pregnancy to early adulthood |
| 9:00 |  |  |  |  |  |  |  |
| 9:30 |  |  |  |  |  |  |  |
| 10:00 | Coffee Break |  |  |  |  |  |  |
| 10:30 | PL-01 Drug discovery in neuroscience |  |  |  |  |  |  |
| 11:00 | D-01 Antidepressants are effective for treating acute bipolar depression | TFS-01 Therapeutic drug monitoring, pharmaco-genetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry | S-21 Measurement-based psychiatry: Toward rating scale-based assessments in the real world | S-22 Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder | S-23 Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity? | WS-03 Current status of electroconvulsive therapy in the treatment of major psychiatric disorders | S-24 Serotonin and anxiety disorders: Recent evidence from neuroimaging studies |
| 11:30 |  |  |  |  |  |  |  |
| 12:00 |  |  |  |  |  |  |  |
| 12:30 |  |  |  |  |  |  |  |
| 13:00 |  | SA-01 Sunovion Satellite Symposium |  |  |  |  |  |
| 13:30 |  |  |  |  |  |  |  |
| 14:00 |  |  |  |  |  |  |  |
| 14:30 |  |  |  |  |  |  |  |
| 15:00 | S-25 tDCS: From research to clinical practice | TFS-02 Post-mortem findings across psychiatric disorders and their association with cognitive symptoms | TFW-01 Workshop of the WFSBP Task Force on Genetics: Focus on pharmacogenomics | S-26 Into novel drugs for depression | S-27 Beyond unitary models of psychosis: Confronting complex etiology and dimensionality | WS-04 Redefining depression in the Century XXI: Where are we now in biological psychiatry? | S-28 Wake and sleep electroencephalogram biomarkers of depression |
| 15:30 |  |  |  |  |  |  |  |
| 16:00 |  |  |  |  |  |  |  |
| 16:30 | Coffee Break |  |  |  |  |  |  |
| 17:00 | TFS-03 Update biomarkers in psychiatry | S-29 Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology |  |  | FC-04 Neuroimaging I | FC-05 Psychoneuroimmunology |  |
| 17:30 |  |  |  |  |  |  |  |
| 18:00 |  |  |  |  |  |  |  |
| 18:30 |  |  |  |  |  |  |  |

**Guided Poster Tours**

P-01 – P-05

**Poster Exhibition**

09:00 – 17:00

**Technical Exhibition**

09:00 – 17:00

**Registration Counter**

08:00 – 18:30
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>S-30 Recent insights in schizophrenia physiopathology and treatments</td>
</tr>
<tr>
<td>09:00</td>
<td>S-31 Duration of untreated psychosis: From neuroimaging to clinical trials</td>
</tr>
<tr>
<td>09:30</td>
<td>S-32 New perspectives on transcranial magnetic stimulation in psychiatric disorders</td>
</tr>
<tr>
<td></td>
<td>S-33 Epigenetic biomarkers for the diagnosis of mood disorders</td>
</tr>
<tr>
<td></td>
<td>S-34 Sex hormones and their wide-ranging effects on psychopathology</td>
</tr>
<tr>
<td>09:00</td>
<td>WS-05 Gesture as window to psychosis pathobiology: From aberrant body experience to social interaction</td>
</tr>
<tr>
<td>09:30</td>
<td>S-35 New insights into the neurobiology and treatment aspects of OCD comorbid with schizophrenia and bipolar disorder</td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:30</td>
<td>PL-02 Ketamine in mood disorders</td>
</tr>
<tr>
<td>11:00</td>
<td>D-02 The Research Domain Criteria (RDc) can create a new kind of taxonomy holding greater promise compared to the traditional ...</td>
</tr>
<tr>
<td>11:30</td>
<td>TFS-04 Steep in depression and cognition – from research to clinical practice</td>
</tr>
<tr>
<td>12:00</td>
<td>S-36 The role of the nucleus accumbens in psychiatry</td>
</tr>
<tr>
<td>12:30</td>
<td>S-37 Neurologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography</td>
</tr>
<tr>
<td>13:00</td>
<td>S-38 Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment</td>
</tr>
<tr>
<td>13:30</td>
<td>WS-06 Neurobiology of suicidal behaviour</td>
</tr>
<tr>
<td>14:00</td>
<td>WS-08 Functional neuroanatomy of hallucinations</td>
</tr>
<tr>
<td>14:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:00</td>
<td>WS-07 Merging evidence and clinical practice in management of depression: The CANMAT experience</td>
</tr>
<tr>
<td>15:30</td>
<td>TFS-05 Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on biological markers</td>
</tr>
<tr>
<td>16:00</td>
<td>TFW-02 WFSBP Consensus on the management of agitation in psychiatry</td>
</tr>
<tr>
<td>16:30</td>
<td>S-39 Current research on the use of cannabinoids</td>
</tr>
<tr>
<td>17:00</td>
<td>S-40 Alzheimer’s Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?</td>
</tr>
<tr>
<td>17:30</td>
<td>S-41 Electroconvulsive therapy for depression -- optimising treatment and maintaining recovery</td>
</tr>
<tr>
<td>18:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>18:30</td>
<td>Registration Counter 08:00–18:30</td>
</tr>
<tr>
<td></td>
<td>Poster Exhibition 09:00–17:00</td>
</tr>
<tr>
<td></td>
<td>Technical Exhibition 09:00–17:00</td>
</tr>
</tbody>
</table>
## Scientific Programme Schedule / Wednesday, 21 June 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Auditorium 15</th>
<th>Congress Hall A3</th>
<th>Auditorium 12</th>
<th>Auditorium 10</th>
<th>Auditorium 11</th>
<th>B3 M1 – M2</th>
<th>B3 M3 – M4</th>
<th>Congress Hall A1</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30</td>
<td>S-43 Novel approaches in mechanisms of action of antidepressant treatment</td>
<td>S-44 Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders</td>
<td>FC-09 Depression 1</td>
<td>S-45 Behavioral Addictions: Diagnosis, co-morbidity and neurobiology</td>
<td>S-46 Neurobiology and psychopharmacology of aggressive behaviour: Where are we?</td>
<td>S-47 Catecolamines, anhedonia and depression</td>
<td>FC-10 Antipsychotics 2</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>PL-03 Epigenetic consequences of early adversity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>D-03 Deep brain stimulation is a worthwhile treatment method in psychiatry</td>
<td>TFS-07 Enhancing the role of primary care in looking after people with mental health problems</td>
<td>S-48 Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans</td>
<td>S-49 Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world</td>
<td>S-50 Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies</td>
<td>WS-09 Schizophrenia research in Chile</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>S-51 Advances in biomarker development for neurostimulation</td>
<td>TFS-08 Men’s mental health: Contemplatory aspects</td>
<td>TFW-03 WFSBP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?</td>
<td>S-52 The G protein coupled receptors as a target for psychotropic drugs</td>
<td>S-55 Rediscovering Lithium</td>
<td>WS-10 Evidence for brain stimulation methods in schizophrenia</td>
<td>S-53 Suicidal behavior: Neuropsychological and genetic determinants</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>FC-12 Schizophrenia</td>
<td>TFS-09 Providing acute inpatient care for children, adolescents and young adults from a men’s mental health perspective</td>
<td>S-54 Lithium as a neuroprotective agent: When and how?</td>
<td>FC-13 Genetics</td>
<td>FC-11 Inflammation</td>
<td>FC-14 Neuroimaging 2</td>
<td>FC-15 Addictive disorders</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Registration Counter 08:00–18:30</td>
<td>Poster Exhibition 09:00–17:00</td>
<td>Technical Exhibition 09:00–17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>S-56 Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>S-57 Causes and consequences of inflammation in Bipolar Disorder (BP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>S-58 Novel therapeutics for neurodegenerative disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>S-59 The relevance of Neuregulin1–ErbB4 signaling for neuropsychiatric pathomechanisms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>PL-04 Lithium in mood disorders: a Danish homage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>S-62 Innovative approaches in suicide research</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>S-63 Atypical neurotransmitters in psychiatry: Relevance for future therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>S-64 Operationalizing the disconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>S-68 Dynamical brain: How brain complexity changes with aging and mental illness?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>S-69 Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>S-70 Current use of EEG-based techniques in psychiatry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>S-71 Sex-specific neuroendocrinological findings in conduct disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>S-72 Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>S-73 Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Guided Poster Tours
P-18 – P-22

Registration Counter
08:00 – 17:30

Poster Exhibition
09:00 – 17:00
T2: ANTIDEPRESSANTS: BASIC / CLINICAL

S-01 SYMPOSIUM
08:30–10:00 Auditorium 10+11+12
Towards novel rapid-acting antidepressants
Chair: Tomi Rantamäki, Finland
Co-Chair: Gregers Wegener, Denmark

001 Rapid acting antidepressants in chronic pain
Ipek Yalcin, France

002 Morphological and structural alterations following rapid acting antidepressants
Gregers Wegener, Denmark

003 Antidepressant potential of cannabidiol: Preclinical evidence
Sâmia Joca, Brazil

004 Anesthetics as rapid-acting antidepressants
Tomi Rantamäki, Finland

T20: LIAISON PSYCHIATRY

S-02 SYMPOSIUM
08:30–10:00 Auditorium 15
Psychiatric services in emergency departments: Challenges and solutions
Chair: Ruby Castilla-Puentes, USA
Co-Chair: Tatiana Falcone, USA

001 Psychiatric consultations in rural general hospitals – Latinos vs. Anglos
Bernardo Ng, USA

002 A study of insomnia and comorbid psychiatric conditions in rehabilitation clinics
Franklin Escobar, Colombia

003 Depression and medical comorbidity in emergency departments in Mexico
Ricardo Secin, Mexico

004 Self-inflicted injury in children and adolescents: A study in a tertiary care hospital in Santiago de Chile
Arturo Grau, Chile

T1: ADDICTIVE DISORDERS

S-03 SYMPOSIUM
08:30–10:00 Congress Hall A 3
Dissecting the role of the neurotrophin Brain Derived Neurotrophic Factor in cocaine addiction: Clues from clinical and preclinical studies
Chair: Fabio Fumagalli, Italy

001 Acute exposure to cocaine during brain development evokes depressive-like behaviors via downregulation of Brain Derived Neurotrophic Factor signaling
Fabio Fumagalli, Italy

002 Cocaine and orbitofrontal cortical Brain Derived Neurotrophic Factor deficiency induce habit-based decision-making: Blockade by trkB stimulation
Shannon Gourley, USA

003 Systemic administration of the brain-penetrant TrkB antagonist cyclotraxin-b reduces short and long access cocaine intake
Michel Verheij, The Netherlands

004 Brain Derived Neurotrophic Factor and cocaine in clinical samples: A useful biomarker for treatment?
Lisia von Diemen, Brazil

T51: MISCELLANEOUS

WS-01 WORKSHOP
08:30–10:00 B3 M1-M2
Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience
Chair: Miquel Bernardo, Spain
Co-Chair: Ana Gonzalez Pinto, Spain

001 Agitation consensus
Eduard Vieta, Spain

002 ECT consensus
Mikel Urretavizcaya, Spain

003 Clinical guidelines for adult patients with a severe mental disorder and a comorbid substance use
Luis San, Spain

FC-01 FREE COMMUNICATION SESSION
08:30–10:00 B3 M3-M4
Treatment of depression
Chair: Tom Bolwig, Denmark
Co-Chair: Eva Ceskova, Czech Republic

001 Optimization of therapy with antidepressants
Eva Ceskova, Czech Republic
P. Silhán
002 The efficacy of minocycline as an adjunctive treatment for major depressive disorder: A double blind, randomised, placebo controlled trial
Olivia Dean, Australia
B. Kanchanatawan, M. Ashton, M. Maes, L. Berk, A. Sughondhabiroon, S. Tangwongchai, C. Ng, K. Hasebe, C. Bortofasci, K. Walder, M. Berk

003 Expression and subcellular localization of serotonin transporter in LCLs as putative biomarker for antidepressant response
Abdul-Karim Barakat, Germany

004 The place of Electroconvulsive Therapy in the treatment of depression in France: A comparison of practices with international recommendations
Pierre-Michel Iltorra, France
T. Charpeaud, A. Tremey, B. Aouizerate, P. Courtet

005 Prediction of electroconvulsive therapy response and remission in major depression: A meta-analysis
Linda van Diermen, Belgium
S. Van Den Ameele, A. M. Kamperman, B. C. G. Sabbe, V. Tom, D. Schrijvers, T. K. Birkenhager

006 rTMS long-term prevention of depressive relapse/recurrence does not increase risk of switching to mania even in patients with first depressive episode: A randomised controlled trial
Zhang-Jin Zhang, Hong Kong

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

001 Indicators or risk and resilience in the high-risk offspring of bipolar parents
Anne Duffy, Canada

002 Lithium compared to quetiapine in the maintenance phase after a first episode of mania
Michael Berk, Australia

003 Biological rhythms and illness progression in Bipolar Disorder (BP)
Benicio Frey, Canada

004 Illness trajectories and neuroprogression in Bipolar Disorder (BP)
Flavio Kapczinski, Brazil

T22: MOLECULAR NEUROBIOLOGY

S-05 SYMPOSIUM
10:15–11:45 Auditorium 15
Extracellular vesicles in neuropsychiatric diseases: Basic mechanisms and biomarkers
Chair: Takashi Kudo, Japan
Co-Chair: Dimitrios Kapogiannis, USA

001 Extracellular vesicles as a source of biomarkers for Alzheimer’s Disease
Dimitrios Kapogiannis, USA

002 Tau inside neutrally-derived exosome
Dominic Walsh, USA

003 Mechanisms of exosome involvement in neurodegenerative diseases
Andrew Hill, Australia

004 Changes in exosomes proteins by the degree of stress
Takashi Kudo, Japan

T22: MOLECULAR NEUROBIOLOGY

S-06 SYMPOSIUM
10:15–11:45 Congress Hall A3
Drug addiction and GPCR heteroreceptor complexes: What goes wrong in receptor plasticity as addiction develops?
Chair: Kjell Fuxe, Sweden
Co-Chair: Anita Harsson, Germany

001 Neurochemical mechanisms underlying goal-directed and habitual drug seeking and how these mechanisms produce compulsions: Focus on Gq-coupled glutamate receptors
Kjell Fuxe, Sweden

002 Homo and heteroreceptor complexes participate in learning and memory and as an emerging target for treatment of cocaine addiction
Dasiel Borroto-Escuela, Sweden

003 Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction
Malgorzata Filip, Poland

004 Dopamine D4-MOR interactions prevent nigrostriatal dopamine pathway activation by morphine: Relevance for drug addiction
Alicia Rivera, Spain
### T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

#### WS-02 WORKSHOP

<table>
<thead>
<tr>
<th>Time</th>
<th>Place</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15–11:45</td>
<td>B3 M1-M2</td>
<td><strong>New investigations on the relationship between working memory and ADHD</strong></td>
<td><strong>Joseph Biederman, USA</strong></td>
</tr>
</tbody>
</table>

**001** Clinical correlates of working memory deficits in youth with and without ADHD  
Ronna Fried, USA

**002** Are working memory deficits and ADHD dissociable?: An fMRI study  
Joseph Biederman, USA

**003** Reduced prefrontal efficiency for visuospatial working memory in attention-deficit/hyperactivity disorder  
Jeffrey Newcorn, USA

**005** Plasma Oxytocin in OCD  
Donatella Marazziti, Italy  
F. Mucci, S. Baroni, A. Piccinni

**006** Plasma lipid peroxides level in schizophrenia patients  
Sagar Lavania, India  
A. Pattojoshi, A. H. Khan

#### FC-02 FREE COMMUNICATION SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Place</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15–11:45</td>
<td>B3 M3-M4</td>
<td><strong>Molecular neurobiology</strong></td>
<td><strong>Sagar Lavania, India</strong></td>
</tr>
</tbody>
</table>

**001** Anxiety is triggered by elevated levels of the GDNF sorting receptor SorLA  
Camilla Gustafsen, Denmark  
D. Demontis, J. Lundhede, M. Kaas, H. Buttenschøn, S. Mølgaard, C. M. Petersen, A. Nykjær, S. Glerup

**002** Does mitochondrial function underpin the efficacy of polypharmacy for Bipolar Disorder (BP)?  
Chiara Bortolasci, Australia  

**003** Proteome-wide study of cerebrospinal fluid biomarkers for Bipolar Disorder and other neuropsychiatric disorders  
Jessica Holmén Larsson, Sweden  
M. Hölttä, C. Seligren, H. Zetterberg, K. Blennow, M. Landén, J. Gobom

**004** Caudate neurochemistry in unmedicated OCD (obsessive compulsive disorder) patients: A 3 Tesla 1H-MRS study  
Arpit Parmar, India  
A. Parmar, P. Sharan, S. Khandelwal, U. Sharma, N. Jagannathan

### T43: SCHIZOPHRENIA: BASIC / CLINICAL

#### S-07 SYMPOSIUM

<table>
<thead>
<tr>
<th>Time</th>
<th>Place</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
</table>
| 12:30–14:00 | Auditorium 10+11+12 | **Social cognition and neuronal correlates in patients with schizophrenia** | **Gabriele Sachs, Austria**  
**Co-Chair:** Armida Mucci, Italy |

**001** Neurocognitive predictors of social cognition  
Vijaya Lakshmi Valaparla, India

**002** Emotional intelligence in patients suffering from schizophrenia and unaffected siblings  
Alex Hofer, Austria

**003** Social cognition and negative symptoms in schizophrenia: Constructs, assessment and relationships with functional outcome  
Armida Mucci, Italy  
S. Galderisi, A. Rossi, P. Rocca, A. Bertolino, M. Maj

**004** Neurobiological correlates of the treatment of emotion processing in schizophrenia  
Gabriele Sachs, Austria

### T19: INFLAMMATION PSYCHIATRY

#### S-08 SYMPOSIUM

<table>
<thead>
<tr>
<th>Time</th>
<th>Place</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
</table>
| 12:30–14:00 | Congress Hall A 3 | **Inflammation markers of peripheral blood in depression spectrum** | **Piotr Galecki, Poland**  
**Co-Chair:** Angelo Halaris, USA |

**001** (Auto)immune biomarkers of depression and subtypes  
Michael Maes, Thailand

**002** Targeting inflammation to prevent depression  
Michael Berk, Australia

**003** Stratification of depressed patients by means of blood markers of inflammation, growth factors and kynurenine metabolites  
Angelo Halaris, USA
**Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application**

Kuan-Pin Su, Taiwan

**Clinical usefulness of the Screen for Cognitive Impairment in Psychiatry (SCIP) in patients with schizophrenia and affective disorder before and after cognitive remediation**

Andreas Erfurth, Austria
E. Maihofer, M. Neuwirth, H. Swoboda, G. Sachs

**Association of plasma brain-derived neurotrophic factor level with neurocognitive functions in patients with at-risk mental state and first-episode psychosis**

Kenji Sanada, Japan
S. Ruiz de Azúa, S. Mesa, S. Matsuzaki, A. Takahashi, K. Saïto, M. Martínez-Cengotitabengoa, A. Iwanami, A. Gonzalez Pinto

**The effects of Donepezil on Alzheimer's Diseased (AD) rats' model with intestinal endotoxemia**

Bai Han, People’s Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

**Differential association of depression level with cognitive function according to cognitive domains of mild cognitive impairment and Alzheimer's Disease**

Do-Hoon Kim, Republic of Korea
C. H. Lee, Y.-S. Moon

**D-amino acid oxidase level in the peripheral blood is higher in patients with age-related cognitive decline**

Chieh-Hsin Lin, Taiwan
H. Y. Lane

**How to get published**

Gregers Wegener, Denmark
Søren Dinesen Østergaard, Denmark

**How to combine research and clinical work**

Klaus Munkholm, Denmark

**How to combine research and clinical work**

David Erritzoe, United Kingdom

**How to get funded**

Michael Berk, Australia

**Inflammatory and innate immune markers of neuroprogression in depressed and teenage suicide brain**

Chanshyam Pandey, USA

**Major depression as a prelude to dementia: What is the evidence?**

Brian Leonard, Ireland

**Neuroimaging of microglia activation in major depression**

Jeffrey Meyer, Canada

**Promising neuroprotective and anti-inflammatory interventions to arrest neuroprogression**

Angelos Halaris, USA

**How to build an academic career**

Ida Hageman Pedersen, Denmark

**How to get published**

Gregers Wegener, Denmark
Søren Dinesen Østergaard, Denmark

**How to combine research and clinical work**

Klaus Munkholm, Denmark

**How to combine research and clinical work**

David Erritzoe, United Kingdom

**How to get funded**

Michael Berk, Australia

**Mechanisms contributing to neuroprogression in psychiatric disorders and promising interventions**

Angelos Halaris, USA

**Effects and side effects of electroconvulsive therapy**

Michael Grözinger, Germany

**DNA methylation of P11/S100A10: A putative marker of response to ECT?**

Helge Frielings, Germany

**Electroconvulsive therapy enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression**

Alexander Sartorius, Germany

**The EFFECT-Dep Trial (ISRCTN23577151): Immediate and long-term cognitive outcomes**

Declan McLoughlin, Ireland
T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-11 SYMPOSIUM
14:30–16:00 Congress Hall A 3
Abnormal neurogenesis in schizophrenia
Chair: Dragos Inta, Germany
Co-Chair: Guo-Li Ming, USA

001 Modeling predisposition to schizophrenia using hiPSCs
Kristen Brennand, USA

002 Neurogenesis and psychiatric neurodevelopmental disorders
Guo-Li Ming, USA

003 Precise activation of the Reelin pathway controls dendritic maturation, synapse formation and glial ensheathment of adult-generated granule cells
Eduardo Soriano, Spain

004 Adult neurogenesis in the striatum: Effect of psychiatric treatment
Dragos Inta, Germany

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-13 SYMPOSIUM
16:30–18:00 B3 M1-M2
Biomarkers for early diagnosis of Alzheimer’s Disease (AD) and other neurodegenerating diseases: Advantages and limitations
Chair: Piotr Lewczuk, Germany
Co-Chair: Henrik Zetterberg, Sweden

001 New developments in the biomarkers for Alzheimer's Disease (AD)
Kaj Blennow, Sweden

002 Amyloid beta 42/40 Ratio in diagnosis of AD: Do we need it?
Piotr Lewczuk, Germany

003 Sensitive technologies for blood biomarkers in neurodegeneration
Henrik Zetterberg, Sweden

004 Current diagnostic approaches in frontotemporal lobar degeneration
Markus Otto, Germany

T10: DEMENTIA: BASIC / CLINICAL

S-13 SYMPOSIUM
16:30–18:00 B3 M1-M2
Biomarkers for early diagnosis of Alzheimer’s Disease (AD) and other neurodegenerating diseases: Advantages and limitations
Chair: Piotr Lewczuk, Germany
Co-Chair: Henrik Zetterberg, Sweden

001 New developments in the biomarkers for Alzheimer's Disease (AD)
Kaj Blennow, Sweden

002 Amyloid beta 42/40 Ratio in diagnosis of AD: Do we need it?
Piotr Lewczuk, Germany

003 Sensitive technologies for blood biomarkers in neurodegeneration
Henrik Zetterberg, Sweden

004 Current diagnostic approaches in frontotemporal lobar degeneration
Markus Otto, Germany

OPENING SESSION
18:00–19:00 Auditorium 10+11+12
Opening Ceremony
Chair: Masatoshi Takeda, Japan

001 The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan
John F. Cryan, Ireland

Please see page 15.
Monday, 19 June 2017 / Scientific Programme

**T1: ADDICTIVE DISORDERS**

**S-14 SYMPOSIUM**

08:30–10:00  
Auditorium 15  
**Problematic sexual behaviors: Diagnostic, categorical, epidemiological, imaging, psychopathological and treatment considerations**

*Chair:* Marc Potenza, USA  
*Co-Chair:* Florence Thibaut, France

001  
**Classification and clinical issues relating to hypersexuality**  
Marc Potenza, USA  
S. Kraus

002  
**Sexual impulsivity, psychopathology and trauma: Gender-related differences**  
Galit Erez, Israel

003  
**Advances in pharmacological treatments for sex offenders**  
Florence Thibaut, France

004  
**Neurobiology of compulsive sexual behaviors**  
Valerie Voon, United Kingdom

**T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL**

**S-15 SYMPOSIUM**

08:30–10:00  
Congress Hall A 3  
**Posttraumatic Stress Disorder (PTSD) and gender**

*Chair:* Hans-Jürgen Möller, Germany  
*Co-Chair:* Victoria Valdez, Ecuador

001  
**Clinical issues: PTSD and gender violence**  
Victoria Valdez, Ecuador

002  
**Course and prognosis PTSD**  
Kayihan Oguz Karamustafa, Turkey

003  
**Biological aspects and PTSD**  
Soraya Seедин, South Africa

004  
**Genetics and PTSD**  
Sian Hermann, South Africa

**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**S-16 SYMPOSIUM**

08:30–10:00  
Auditorium 12  
**The elephant in the room: The role of glial cells in psychiatric disorders**

*Chair:* Sabina Berretta, USA  
*Co-Chair:* Mikhail Pletnikov, USA

001  
**Psychiatric genetic risk factors in healthy and diseased astrocytes**  
Mikhail Pletnikov, USA

002  
**Glia-extracellular matrix interactions in the pathophysiology of schizophrenia and Bipolar Disorder (BD)**  
Sabina Berretta, USA

003  
**Abnormalities of glutamate transporter localization in severe mental illness**  
Robert McCullumsmith, USA

004  
**Evidence for neuroinflammation, gliosis and leaky brain in people with schizophrenia**  
Cyndi Shannon Weickert, Australia

**S-17 SYMPOSIUM**

08:30–10:00  
Auditorium 10  
**Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of psychoses beyond the schizophrenia spectrum**

*Chair:* John Waddington, Ireland  
*Co-Chair:* Sidney Kennedy, Canada

001  
**Reconciling the diversity of psychotic illness and dimensional concepts with current diagnostic algorithms**  
Rajiv Tandon, USA

002  
**Psychosis in major depressive disorder: Systematic comparisons with and beyond the schizophrenia spectrum**  
John Waddington, Ireland

003  
**Psychosis in Bipolar Disorder (BP): Genetics and relationships to paternal age**  
Sidney Kennedy, Canada

004  
**Post-stroke psychosis: Pathobiology and behavioral susceptibility**  
Eileen Joyce, United Kingdom  
P. Malhotra, M. Devine
T49: SUICIDE: BASIC / CLINICAL

S-18 SYMPOSIUM
08:30–10:00 Auditorium 11
Epigenetic modification, effect of early life stress, and signaling mechanisms in suicide
Chair: Ghanshyam Pandey, USA
Co-Chair: Victoria Arango, USA
001 Impact of the early-life environment on the epigenetic regulation of the anterior cingulate gyrus
Gustavo Turecki, Canada
002 Expression and methylation of glucocorticoid receptors and FKBP5 in teenage and adult suicide
Ghanshyam Pandey, USA
003 Genome-wide epigenetic changes in suicide attempters
Jussi Jokinen, Sweden
004 5-HT1A receptor anti-apoptotic transduction pathways in suicide
Victoria Arango, USA

T11: DEPRESSION: BASIC / CLINICAL

S-19 SYMPOSIUM
08:30–10:00 B3 M1-M2
Psychedelics: Mechanisms and applications in psychiatry
Chair: Tomas Palenicek, Czech Republic
Co-Chair: Katrin Preller, Switzerland
001 Role of 5-HT2A receptors in the mechanism of action of psilocybin and LSD and the treatment of affective disorders
Katrin Preller, Switzerland
002 The effect of psilocybin on brain connectivity and emotional processing in healthy volunteers
Tomas Palenicek, Czech Republic
003 Psilocybin for the treatment of depression
Robin Carhart-Harris, United Kingdom
004 Exploring the therapeutic potential of ayahuasca in the treatment of psychiatric disorders
Jordi Riba, Spain

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

S-20 SYMPOSIUM
08:30–10:00 B3 M3-M4
Affective and psychotic psychopathology from pregnancy to early adulthood: The dynamic developmental interplay between genes, structures and functions
Chair: Paolo Brambilla, Italy
Co-Chair: Michael Kaess, Germany
001 Can personality and parental care impact on brain development?
Paolo Brambilla, Italy
002 Neurodevelopmental trajectories and psychopathology in adults who were born very preterm
Chiara Nosarti, United Kingdom
003 Grin2b mediates susceptibility to affective problems in children and adolescents
Maria Nobile, Italy
004 Corollary discharge auditory hallucinations and schizophrenia: A structural network analysis
Romy Hemze, Germany

PL-01 PLENARY SESSION
10:15–11:00 Auditorium 15
Drug discovery in neuroscience: Promises, barriers and opportunities
Chair: Lakshmi Yatham, Canada
Speaker: Husseini Manji, USA

D-01 DEBATE
11:15–12:45 Auditorium 15
Antidepressants are effective for treating acute bipolar depression
Chair: Lakshmi Yatham, Canada
Proponent: Glenda MacQueen, Canada
Opponent: Robert Post, USA
## T51: MISCELLANEOUS

**TFS-01 WFSBP TASK FORCE SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:45</td>
<td>Congress Hall A 3</td>
<td>Therapeutic drug monitoring, pharmacogenetics and brain imaging methods as tools for optimizing pharmacotherapy in psychiatry</td>
<td>Chin B. Eap, Switzerland</td>
<td>Christoph Hiemke, Germany</td>
</tr>
</tbody>
</table>

001 Pharmacogenetics in psychiatry  
Chin B. Eap, Switzerland

002 Therapeutic drug monitoring in psychiatry  
Christoph Hiemke, Germany

003 Brain imaging in psychiatry  
Gerhard Gründer, Germany

004 Strategies for the implementation of genetic biomarkers in clinical practice  
Daniel Müller, Canada

## T11: DEPRESSION: BASIC / CLINICAL

**S-21 SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:45</td>
<td>Auditorium 12</td>
<td>Measurement-based psychiatry: Toward rating scale-based assessments in the real world</td>
<td>Christoph U. Correll, USA</td>
<td>Søren Dinesen Østergaard, Denmark</td>
</tr>
</tbody>
</table>

001 Measurement-based care psychiatry: Where are we at and where should we head?  
Andrew A. Nierenberg, USA

002 Measurement-based care versus standard care for major depression: Conducting a successful randomized controlled trial with blind raters  
Christoph U. Correll, USA

003 The role for measurement-based care for Bipolar Disorder (BP) in current and future clinical practice  
Eduard Vieta, Spain

004 PANSS-6: A new rating scale for both research and clinical care in schizophrenia  
Søren Dinesen Østergaard, Denmark

## T43: SCHIZOPHRENIA: BASIC / CLINICAL

**S-22 SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:45</td>
<td>Auditorium 10</td>
<td>Dissecting the shared and non-shared biological features in schizophrenia and autism spectrum disorder</td>
<td>Kenji Tsuchiya, Japan</td>
<td>Manabu Makinodan, Japan</td>
</tr>
</tbody>
</table>

001 Comparative genetic analysis of autism spectrum disorder and schizophrenia: Focus on rare variants  
Branko Aleksic, Japan

002 The genetic overlap between autism and schizophrenia: Focus on common variation  
Jakob Grove, Denmark

003 Neurobiological findings in schizophrenia and autism spectrum disorder  
Manabu Makinodan, Japan

004 Advanced paternal age at birth is associated with autism and schizophrenia  
Kenji Tsuchiya, Japan

## T9: COGNITIVE NEUROSCIENCE

**S-23 SYMPOSIUM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15 – 12:45</td>
<td>Auditorium 11</td>
<td>Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuroplasticity?</td>
<td>Martin Lepage, Canada</td>
<td>Kamilla Miskowiak, Denmark</td>
</tr>
</tbody>
</table>

001 Neural markers and predictors of therapeutic change with cognitive enhancement therapy  
Matcheri Keshavan, USA

002 Short-term working memory training for individuals with psychosis: Cognitive and neurophysiological effects  
Christopher Bowie, Canada

003 Randomised trial of low support cognitive training for schizophrenia: Cortical and behavioural outcomes  
Gary Donohoe, Ireland

004 SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data  
Martin Lepage, Canada
Scientific Programme / Monday, 19 June 2017

T4: ANXIETY DISORDERS: BASIC / CLINICAL

S-24 SYMPOSIUM
11:15 – 12:45 B3 M3-M4
Serotonin and anxiety disorders: Recent evidences from neuroimaging studies
Chair: Eduard Maron, Estonia
Co-Chair: Tomas Furmark, Sweden

001 Serotonin system and panic disorder
Eduard Maron, Estonia

002 Serotonin system and social anxiety disorder
Tomas Furmark, Sweden

003 Serotonin system and obsessive-compulsive disorder
Oliver Pogarell, Germany

004 Serotonin regulation of anxiety neuronal network
Andreas Frick, Sweden

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

WS-03 WORKSHOP
11:15 – 12:45 B3 M1-M2
Current status of electroconvulsive therapy in the treatment of major psychiatric disorders
Chair: Yong-Sik Kim, Republic of Korea
Co-Chair: Pascal Sienaert, Belgium

001 Current status on efficacy of ECT
Hans Mørch Jensen, Denmark

002 Mechanism of ECT focused on psychosis
Ung-Gu Kang, Republic of Korea

003 ECT for the treatment resistant psychosis
In-Won Chung, Republic of Korea

004 ECT in catatonia
Pascal Sienaert, Belgium

P-01 POSTER TOUR
13:00 – 14:30 Congress Hall A 1
Addictive disorders
Chair: Fabricio Moreira, Brazil

001 Investigating the role of one-carbon metabolism pathway in complicated alcohol withdrawal states
Karishma Kulkarni, India
M. Purushottam, P. Sharma, B. Viswanath, P. Chand, S. Jain, P. Murthy

002 Binge drinking, mood and psychological well being in university students
Thomas Heffernan, United Kingdom

003 Brain activation patterns associated with cue reactivity in Internet gaming disorder
Dai Jin Kim, Republic of Korea

006 The study on antidepressant-like effect of Acamprosate for depression with alcohol use disorder
Masaya Tayama, Japan
T. Saito

010 Study of dopamine transporter gene DAT1 / SLC6A3 Variable Number of Tandem Repeats (VNTR) polymorphism in complicated alcohol withdrawal and alcohol dependence syndrome in South Indian population: Case-control Genetic Association study
Brij Kishore, Australia
P. Murthy, S. Jain, V. Benegal, M. Purushottam, K. Thennarasu, S. Devasenapathy, B. Shankarappa, A. Dahale

011 DNA methylation signatures of chronic alcohol dependence in purified CD3+ T cells of patients undergoing alcohol treatment
Vanessa Nieratschker, Germany
C. Brückmann, S. Islam, A. Batra, M. Kobor

014 Reduced amplitude of executive control and front parietal networks reflects duration of illness in gambling disorder patients
Kosuke Tsurumi, Japan
R. Kawada, J. Miyata, T. Murai, H. Takahashi

015 Prescription opioid abuse disorder, comparing outcomes of different approaches
Susana Patricia Gomes da Costa, Spain

017 A new vaccine for cocaine addiction: Preliminary results of the UFMG-VAC4N2 molecule
Frederico García, Brazil
P. Augusto, Á. de Fátima, L. Silva Neto, A. Godín, A. Freitas

020 Hair cortisol concentration as risk marker for increased alcohol use following traumatic experiences
Sebastian Trautmann, Germany
M. Muehlhan, S. Steude-Schmiedgen

023 Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea
Eun-Jin Na, Republic of Korea
K. Kim, H. Lee, H.-J. Jeon
P-02 POSTER TOUR
13:00–14:30 Congress Hall A 1
Antipsychotics
Chair: Ofer Agid, Canada

001 Weight gain and gut hormones in patients initiating clozapine
Marina Garriga, Spain
A. Mallorqui, L. Serrano, C. Oliveira, M. Salamero, E. Vieta, M. Bernardo, C. García Rizo

002 Cost- efficacy study in patients with psychotic disorder treated with an atypical depot antipsychotic
Aída Alvarez Pedrero, Spain
B. Bote, C. Marin, R. De Alarcón, C. Lorenzo, J. Matías

003 Toxicity after paliperidone overdose in an Asian patient: A case report
María Marta Jalon Urbina, Spain
L. Gómez de Segura Iriarte, C. M. Rodríguez Mercado, L. Pérez Gomez, L. García González, Emeterio Delgado, A. González Fernández

004 Frequency of NMS diagnosis in calls to a National Telephone Information Service
Ronald Gurrera, USA
G. Mortillaro, V. Velamoor, S. Caroff

006 DECIDE Study: Effectiveness of shared decision making in treatment planning at discharge of inpatient with schizophrenia: 3 years of recruitment, full sample preliminary analysis
Jose María Villagran Moreno, Spain
J. I. Pérez Revuelta, J. M. Mongil San Juan, J. Mestre Morales, F. González Sáiz

007 DECIDE Study: Influence of share decisions making strategy on the antipsychotic treatment profile. Comparison of antipsychotic polytherapy in patients discharged after acute episode – UHSM, after one year follow up
Jose Maria Villagran Moreno, Spain
F. González Sáiz, J. I. Pérez Revuelta, J. Mestre Morales, J. M. Pascual Paño

008 Patient perceived participation in decision-making on their antipsychotic treatment: Evidence of validity and reliability of the Spanish version of COMRADE scale in a sample of schizophrenia spectrum disorder patients
Jose Ildefonso Pérez Revuelta, Spain
C. Gutiérrez Santaló, G. Vaz Domínguez, J. M. Mongil San Juan, J. M. Villagran Moreno

009 Satisfaction with antipsychotic as a medication: The role of the therapeutic alliance and patient perceived participation in decision making in a sample of schizophrenia spectrum disorder patients
Jose Ildefonso Pérez Revuelta, Spain
M. L. Moreno Sánchez, F. J. Puerto Garrido, J. M. Pascual Paño, J. M. Villagran Moreno

010 Assessment of the evidences regarding predictive biomarkers in clozapine-treated patients: A focus on research methodology
Ferdinando Cerrato, Italy
L. Guizzaro, P. Scudellari, D. De Ronchi, M. Fabrazzo, A. R. Atti

011 Genetic polymorphisms associated with constipation and anticholinergic symptoms in clozapine-treated patients
Anssi Solismaa, Finland
O. Kampman, L.-P. Lyytikäinen, N. Seppälä, M. Viikki, N. Mononen, T. Lehtimäki, E. Leinonen

013 How to combine risperidone with low-potency First Generation Antipsychotics (FGA): Decision making based on pharmacokinetic considerations
Georgios Schoretsanitis, Switzerland
E. Haen, B. Stegmann, C. Hiemke, G. Gründer, M. Paulzen

014 A case presentation of the reintroduction of clozapine in a patient who developed neutropenia: Taking risks for a greater benefit
Jose Maria Villagran Moreno, Spain
J. I. Pérez Revuelta, C. Rodríguez Gómez

015 Detoxifying enzymes are increased in aripiprazole-treated PC12 cells
Miyuki Ota, Japan
G. Takami, Y. Kaneko, H. Nagasaki, Y. Kodani, A. Nakashima, K. Mori, A. Ota

016 Control of symptoms and safety with the administration of paliperidone palmitate 3-month formulation
José Ángel Alcalá Partera, Spain
A. B. Rico del Viejo, J. L. Prados Ojeda

018 Efficacy of Lurasidone in schizophrenia: A systematic review and meta-analysis of RCTs with active comparators
Tadashi Nosaka, Japan
K. Hagi, K. Hagi, A. Pikalov, A. Loebel, J. Kane

019 Safety of Lurasidone in schizophrenia: A systematic review and meta-analysis of RCTs with active comparators
Katsuhiro Hagi, Japan
T. Nosaka, A. Pikalov, A. Loebel, J. Kane
### Molecular Neurobiology

**Chair:** Simon Glerup, Denmark

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>001</td>
<td>In vivo mitochondrial targeting exerts anxiolytic effects</td>
<td>Michaela Filiou, Germany M. Nussbaumer, A. Teplytska, A. Chen, C. Turck</td>
</tr>
<tr>
<td>002</td>
<td>Prenatal androgen exposure, OPRM1, and alcohol dependence in adulthood</td>
<td>Jordan Gegenhuber, Germany C. Mühle, B. Lenz</td>
</tr>
<tr>
<td>003</td>
<td>Binge drinking: A consequence of increased prenatal androgen exposure?</td>
<td>Christiane Mühle, Germany P. Bouna-Pyrrou, B. Lenz</td>
</tr>
<tr>
<td>004</td>
<td>Estradiol levels and variants in the estrogen receptor 1 gene in alcohol dependence</td>
<td>Christiane Mühle, Germany B. Barry, C. Weinland, B. Braun, C. Mühle, B. Lenz</td>
</tr>
<tr>
<td>007</td>
<td>Seasonality-resilient individuals downregulate their cerebral serotonin transporter binding in winter while 5-HT levels appear unchanged: A longitudinal combined 11C-DASB and 11C-SB207145 PET study</td>
<td>Brenda Elvira Munk McMahon, Denmark M. Nørgaard, C. Svarer, A. Kolevzon</td>
</tr>
<tr>
<td>008</td>
<td>No evidence for a role of the serotonin 4 receptor in normal personality traits: A positron emission tomography study</td>
<td>Vibeke Høyrup Dam, Denmark D. S. Stenbaek, P. Fisher, M. Hubert, V. G. Frokjaer, A. Sterchele, A. Cohen, A. Walther, A. Kolevzon</td>
</tr>
<tr>
<td>009</td>
<td>Sex-related changes of plasma oxytocin levels in humans</td>
<td>Donatella Marazziti, Italy S. Baroni, F. Mucci, A. Piccinni, V. Falaschi, M. Lackshmana, R. Cacabelos</td>
</tr>
<tr>
<td>011</td>
<td>Hippocampal gene expression profiling of a transgenic mice model of Alzheimer Disease (3xTg APP/Bin1/COP55)</td>
<td>Iván Carrera, Spain L. Fernandez Novoa, S. Seoane, C. Sampedro, M. Lackshmana, R. Cacabelos</td>
</tr>
<tr>
<td>012</td>
<td>Effects of chronic ethanol abuse on endogenous retinoid homeostasis</td>
<td>Vera Clemens, Germany F. Regen, I. Heuser, J. Hellmann-Regen</td>
</tr>
</tbody>
</table>

### Childhood & Adolescent Disorders

**Chair:** Pradeep Rao, Australia

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>001</td>
<td>The effect of a behavioral level reward system on rates of agitation pro re nata medication administration, seclusion and restraints on an acute inpatient psychiatric unit for children and adolescents</td>
<td>Timothy Rice, USA Y. Kufert, E. Feldman, A. Walther, A. Anagbos, A. Kolevzon</td>
</tr>
<tr>
<td>003</td>
<td>Pre- and perinatal complications in relation to oppositional-defiant and conduct disorder symptoms in the Avon Longitudinal Study of parents and children</td>
<td>Hyun Ruisch, The Netherlands A. Dietrich, J. Glennon, J. Buitelaar, P. Hoekstra</td>
</tr>
<tr>
<td>004</td>
<td>Collecting youths’ drawings as a diagnostic aid in acute care demonstrates feasibility</td>
<td>Timothy Rice, USA S. Berkson, Y. Kufert, A. Walther, M. Hubert, A. Sterchele, A. Cohen, M. Abroms, T. Goltz</td>
</tr>
<tr>
<td>006</td>
<td>Impulsivity in adult ADHD patients across schizophrenia and substance use disorders groups: A cross-sectional analysis</td>
<td>Srinivas Kandakonda, India S. K. Jaiswal</td>
</tr>
<tr>
<td>007</td>
<td>Grand rounds and professional development in adult psychiatry residency training: Illustration concerning a presentation of an adolescent with gender dysphoria and severe nonsuicidal self-injury</td>
<td>Timothy Rice, USA Y. Kufert, E. Feldman, P. Rosenfield</td>
</tr>
<tr>
<td>008</td>
<td>Factors affecting psychiatric disorders in offspring of parents with Bipolar Disorder (BP) in South Korea</td>
<td>Se-Hoon Shim, Republic of Korea S.-W. Hahn</td>
</tr>
<tr>
<td>010</td>
<td>Gender dysphoria and Autism spectrum disorder: A literature review</td>
<td>Gabriela Safyer, USA M. P. Trelles, T. Rice</td>
</tr>
</tbody>
</table>
011 SorcS2 transduces Gaba(A) receptor subunit identity of inhibitory synapses
Simon Mølgaard, Denmark

012 fNIRS and emotional dysregulation: Effect of Methylphenidate in children with Attention-Deficit Hyperactivity Disorder (ADHD)
Maddalena Mauri, Italy
E. Maggioni, C. Sacchi, A. Crippa, E. Gatti, P. Brambilla, M. Molteni, M. Nobile

014 Neuronal networks underlying emotional processing in children with Attention Deficit Hyperactivity Disorder (ADHD): An EEG study
Eleonora Maggioni, Italy
M. Mauri, A. Crippa, C. Sacchi, E. Gatti, M. Molteni, M. Nobile, P. Brambilla

016 The Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS): How safe is methylphenidate or psychotherapy? Analysis of the adverse event data
Bernhard Kis, Germany
M. Abdel-Hamid, E. Graf, M. Berger, L. Tebartz van Elst, H. Müller, A. Philipsen

017 The relationship between symptomatic and functional changes of Korean children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) treated with OROS methylphenidate
Dong-Ho Song, Republic of Korea
S.-B. Lee

019 Sensory modulation and behavioral phenotypes observed in individuals with Williams syndrome in Japan
Tomonari Awaya, Japan

020 The Michigan peer-to-peer depression awareness campaign: School-based prevention to reduce the impact of depression among teens
Sagar Parikh, USA
D. Taubman, L. Salazar, S. Salazar

021 Altered fetal steroidogenesis and dysregulated placental immune response in a developmental vitamin D deficient rat model of autism
Asad Ali, Australia
X. Cui, D. Eyles
013 **Effective antidepressant treatment with alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report**
Lucie Bartova, Austria

014 **The use of psychopharmacological augmentations and combination strategies in depressive patients treated in tertiary psychiatric centers: A systematic evaluation among 8 European countries**
Markus Dold, Austria

015 **The efficacy, safety and tolerability of probiotics on depressive symptoms: Pilot study results**
Caroline Wallace, Canada
J. Foster, S. Kennedy, R. Milev

016 **A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6)**
Nina Timmerby, Denmark
J. Husted Andersen, S. Søndergaard, S. Dinesen Østergaard, P. Bech

017 **Relationship between rapheal hypoechogenicity and personality as possible markers of a disposition to develop depressive and anxiety disorders**
Petr Silhán, Czech Republic
L. Hošák, M. Hyža, D. Pernicková, J. Vantuch, M. Jelinková, D. Skoloudík

019 **Aerobic exercise as add-on treatment in depressed inpatients improves cognitive domains but has no additional effect on emotional symptoms**
Christian Imboden, Switzerland
M. Gerber, J. Beck, U. Pühse, M. Hatzinger, E. Holsboer-Trachsler

020 **Cognitive complaints and predictors of perceived cognitive dysfunction in adults with major depressive disorder: Findings from the Cognitive Dysfunction in Asians with Depression (CogDAD) study**
Manit Srisurapanont, Thailand

021 **Discrepancy between objective and subjective cognition in adults with major depressive disorders**
Manit Srisurapanont, Thailand
S. Suttajit, K. Eurviriyanukul, P. Varnado

022 **Increased blood BDNF in healthy individuals with a family history of depression**
Ulla Knorr, Denmark
M. Greisen Søndergaard, P. Koefoed, A. Jørgensen, M. Fauerholt-Jepsen, M. Vinberg, L. Kessing

023 **Interaction of genetic risk and early life stress on risk of depression investigated in a nationwide, Danish case-cohort study**
Nis Palm Suppli, Denmark
E. Agerbo, K. K. Andersen, V. Manikandan, M. E. Benros, W. Thompson, T. Munk-Olsen, M. Nordentoft, P. B. Mortensen, K. L. Musliner

**SA-01 INDUSTRY SPONSORED SATELLITE SYMPOSIUM**
13:15 – 14:45 Auditorium 12
Sunovion Satellite Symposium
Please see page 78

**T24: NEUROPATHOLOGY**

**TFS-02 WFSBP TASK FORCE SYMPOSIUM**
15:00 – 16:30 Congress Hall A 3
Post-mortem findings across psychiatric disorders and their association with cognitive symptoms
Chair: Andrea Schmitt, Germany
Co-Chair: Johann Steiner, Germany

001 **Alterations in hippocampal oligodendrocyte and neuron number in patients with schizophrenia, Bipolar Disorder (BP) and major depression**
Peter Falkai, Germany

002 **GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia**
Johann Steiner, Germany

003 **Presynaptic contributions to cognitive reserve**
William Honer, Canada

004 **Different changes in cortical muscarinic receptors in psychiatric and neurological disorders**
Andrew Gibbons, Australia
T32: PHARMACOGENETICS

TFW-01 WFSBP TASK FORCE WORKSHOP
15:00–16:30 Auditorium 12
Workshop of the WFSBP Task Force on genetics: Focus on pharmacogenomics
Chair: Dan Rujescu, Germany
Co-Chair: Jim Kennedy, Canada

001 Pharmacogenetics in schizophrenia
Rainald Mössner, Germany

002 Largest genome wide association study on agranulocytosis under Clozapine
Dan Rujescu, Germany

003 Whole exom sequencing reveals risk factors in treatment resistant depression
Alessandro Serretti, Italy

004 Pharmacogenetic discoveries and applications in psychiatric populations
Jim Kennedy, Canada

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-25 SYMPOSIUM
15:00–16:30 Auditorium 15
tDCS: From research to clinical practice
Chair: Jerome Brunelin, France

001 Translational research on tDCS: Data from a German multisite project
Frank Padberg, Germany

002 Combining tDCS with neuroimaging
Shirley Fecteau, Canada

003 Effects of tDCS on biological reactivity to stress and decision making
Jerome Brunelin, France

004 Improvement of cognitive control with anodal tDCS: Translational perspectives for the treatment of depression
Christian Plewnia, Germany

T33: PHARMACOLOGY

S-26 SYMPOSIUM
15:00–16:30 Auditorium 10
Into novel drugs for depression
Chair: Erich Seifritz, Switzerland

001 Conceptual strategies of Big Pharma into innovation in psychiatric therapies: Future leads
Siegfried Kasper, Austria

002 Personalizing psychiatry treatment
Florian Holsboer, Germany

003 Psychedelic drugs and clinical markers as innovation road to psychopharmacotherapy
Katrin Preller, Switzerland

004 Gamma-hydroxybutyrate: neuropharmacology and implications for depression treatment
Oliver G. Bosch, Switzerland

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-27 SYMPOSIUM
15:00–16:30 Auditorium 11
Beyond unitary models of psychosis: Confronting complex etiology and dimensionality
Chair: Mikhail Pletnikov, USA
Co-Chair: John Waddington, Ireland

001 Recognising the dimensionality of psychotic illness: Broadening the phenotype to the affective domain
Catherine Belzung, France

002 Addressing the translational challenge of etiological diversity: Complex gene-environment interactions in risk for psychosis
Mikhail Pletnikov, USA

003 Closing the translational gap between heritability and genetics: Complex gene-gene interactions in risk for psychosis
John Waddington, Ireland

004 Extending the strategy for translation: Human induced pluripotent stem cells
Kristen Brennand, USA

T11: DEPRESSION: BASIC / CLINICAL

S-28 SYMPOSIUM
15:00–16:30 B3 M3-M4
Wake and sleep electroencephalogram provide biomarkers of depression
Chair: Axel Steiger, Germany
Co-Chair: Thorsten Mikoteit, Switzerland

001 Central and autonomous nervous system activity in the prediction of antidepressant treatment
Sebastian Olbrich, Switzerland

002 The value of prefrontal theta cordance of resting EEG in the prediction of antidepressant response
Martin Brunovsky, Czech Republic

003 Novel REM-sleep derived biomarkers of depression
Thorsten Mikoteit, Switzerland
Scientific Programme / Monday, 19 June 2017

004 sLORETA derived from REM sleep EEG as biomarkers for treatment response in depression after antidepressant medication
Marcel Pawlowski, Germany

T11: DEPRESSION: BASIC / CLINICAL

WS-04 WORKSHOP
15:00–16:30 B3 M1-M2
Rethinking depression in the Century XXI: Where are we now in biological psychiatry?
Chair: Victoria Valdez, Ecuador
Co-Chair: Adriana Rivetti, Argentina

001 Genetics risk variants for major depressive disorder
Alejo Corrales, Argentina

002 Serotonergic hypothesis of depression: Is still up-to-date?
Adriana Rivetti, Argentina

T22: MOLECULAR NEUROBIOLOGY

TFS-03 WFSBP TASK FORCE SYMPOSIUM
17:00–18:30 Congress Hall A 3
Update biomarkers in psychiatry
Chair: Peter Riederer, Germany
Co-Chair: Peter Falkai, Germany

001 Biomarkers for schizophrenia
Florence Thibaut, France

002 Biological marker in alcoholism
Toshikazu Saito, Japan

003 Specificity of biomarkers for OCD/ADHD
Edna Grünblatt, Switzerland

004 Specificity of biomarkers for anxiety
Borwin Bandelow, Germany

T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

S-29 SYMPOSIUM
17:00–18:30 Auditorium 12
Autism spectrum disorders in adults – from the clinical phenotype to the underlying neurobiology – novel techincs such as phenotype-based genetic variants association studies, high field magnet resonance imaging and 3d brain organoids
Chair: Tanja Michel, Denmark
Co-Chair: Sophia Frangou, USA

001 On the outcome, time course and clinical presentation of autism in adults: A longitudinal study of clinical trajectories
Marlene Briciet Lauritsen, Denmark

002 Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes
Hannelore Ehrenreich, Germany

003 New insights from proteomics and nanotechnology- 3 D brain organoids: A promising new tool for an in vitro model for ASD
Tanja Michel, Denmark

004 The role of myelination in neurodevelopmental disorders
Sophia Frangou, USA

FC-04 FREE COMMUNICATION SESSION
17:00–18:30 B3 M1-M2
Neuroimaging 1
Chair: Glenda MacQueen, Canada
Co-Chair: Andreas J. Fallgatter, Germany

001 Cortical excitability in a healthy human cohort of mutation carriers in Plasticity Related Gene 1
Johann-Philipp Horstmann, Germany

002 Near-infrared Sprectoscopy (NIRS) neurofeedback in ADHD
Andreas J. Fallgatter, Germany
B. Barth, J. Hudak, A.-C. Ehls

003 Child maltreatment is associated with altered NAA/Cr concentration at the anterior cingulate gyrus in children and adolescents
Andrea Parolin Jackowski, Brazil
A. C. Milani, B. Foester, M. Feijó de Mello
004 Dynamic response to 12 week antidepressant treatment follows a sigmoid function and is negatively correlated with anterior cingulate and prefrontal activation in major depression
Christoph Kraus, Austria

002 Autoantibodies against NMDAR1: Pathogenic potential despite diversity
Bárbara Oliveira, Germany

003 Autoantibodies reacting with oxytocin are associated with antenatal depression
Frederico Garcia, Brazil
T. Castro e Couto, M. Brancaglion, R. Pereira, S. Caligionne, M. Neves, H. Corrêa

001 Resting state dynamics during systemic inflammation in healthy men: Neural correlates of state anxiety in the variability of low frequency oscillations
Franziska Labrenz, Germany
S. Benson, F. Ferri, M. Schedlowski, H. Engler, S. Eisenbruch, M. Costantini

004 Elevated levels of Insulin-like Growth Factor-1 (IGF-1) in drug-naïve patients with psychosis
Petros Petrikis, Greece
V. Boumba, A. Tsallas, P. Voulgari, P. Skapinakis, V. Mavreas

005 C-Reactive Protein as a marker of inflammation in acute psychosis and schizophrenia
Thomas Weickert, Australia
T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-30 SYMPOSIUM
08:30–10:00 Auditorium 15
Recent insights in schizophrenia physiopathology and treatments
Chair: Pierre-Michel Llorca, France
Co-Chair: Fabrice Berna, France

001 Bridging the gap between research and clinical practice: The development of a national network of schizophrenia expert centers
Fabrice Berna, France
G. Fond

002 Schizophrenia pathophysiology: Recent insights from neuroimaging on glutamatergic and neuroinflammatory mechanisms
Oliver Howes, United Kingdom

003 The influence of hormones on schizophrenia
Iris Sommer, The Netherlands

004 Novel adjunctive therapy approaches for inflammatory disturbances in psychiatric disorders
Michael Berk, Australia

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-32 SYMPOSIUM
08:30–10:00 Auditorium 12
New perspectives on transcranial magnetic stimulation in psychiatric disorders
Chair: Shinsuke Kito, Japan
Co-Chair: Motoaki Nakamura, Japan

001 Transcranial magnetic stimulation in the treatment of bipolar depression
Shinsuke Kito, Japan

002 Clinical application of Quadripulse Stimulation (QPS) to major depression
Motoaki Nakamura, Japan

003 Neurophysiological correlates of various transcranial magnetic stimulation paradigms in patients with psychiatric disorders: In search of novel biomarkers
Yoshihiro Noda, Japan

004 Combination of computerized cognitive remediation and transcranial magnetic stimulation
Akihiro Takamiya, Japan

T11: DEPRESSION: BASIC / CLINICAL

S-33 SYMPOSIUM
08:30–10:00 Auditorium 10
Epigenetic biomarkers for the diagnosis of mood disorders
Chair: Tetsuro Ohmori, Japan
Co-Chair: Lourdes Fañanás, Spain

001 DNA methylation profiles of the Brain-derived Neurotrophic Factor (BDNF) gene as a potent diagnostic biomarker in major depression
Manabu Fuchikami, Japan

002 Antenatal prediction of postpartum depression with blood DNA methylation biomarkers
Zachary Kaminsky, USA

003 Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles
Shusuke Numata, Japan

004 Differential methylation and variable methylation in depression: A genome-wide analysis of monozygotic twins
Aldo Cordova-Palomera, Spain
**T40: PSYCHOPATHOLOGY**

**S-34 SYMPOSIUM**

08:30–10:00 Auditorium 11

*Sex hormones and their wide-ranging effects on psychopathology*

*Chair:* Andrea Gogos, Australia  
*Co-Chair:* Mark Geyer, USA

001 *Estrogen, raloxifene and schizophrenia*  
Cyndi Shannon Weickert, Australia

002 *Cortical gene expression changes underlying estrogen’s effect in schizophrenia*  
Andrea Gogos, Australia

003 *17β-estradiol effects on psychosis-like attentional abnormalities in rats*  
Ina Weiner, Israel

004 *Sex differences in depression: The role of neuro-estrogens*  
Christina Dalla, Greece

**T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / CLINICAL**

**S-35 SYMPOSIUM**

08:30–10:00 B3 M3-M4

*New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid with schizophrenia and bipolar affective disorder*

*Chair:* E. Mohandas Warrier, India  
*Co-Chair:* Narayan R. Mutalik, India

001 *Neurobiology of obsessive compulsive disorder comorbid with schizophrenia*  
Narayan R. Mutalik, India

002 *Evidence based management of obsessive compulsive disorder comorbid with schizophrenia*  
Firoz Kazhunigil, India

003 *Neurobiology of obsessive compulsive disorder comorbid with bipolar disorder*  
Rajan Nishanth Jayarajan, Australia

004 *Recent updates in the management of obsessive compulsive disorder comorbid with Bipolar Disorder (BP)*  
Pawan Sharma, Nepal

**T43: SCHIZOPHRENIA: BASIC / CLINICAL**

**WS-05 WORKSHOP**

08:30–10:00 B3 M1-M2

*Gestures as window to psychosis pathobiology: From aberrant body experience to social interaction*

*Chair:* Sebastian Walther, Switzerland  
*Co-Chair:* Vijay Mittal, USA

001 *Schizophrenia in the flesh: Empirical studies of anomalous bodily self experiences*  
So-Hee Park, USA

002 *Impaired gesture performance in schizophrenia: Neurobiology and clinical consequences*  
Sebastian Walther, Switzerland

003 *The neural correlates of natural social-communcative perception processes in patients with schizophrenia: Understanding, recognition and interpretation of verbal and non-verbal information*  
Benjamin Straube, Germany

004 *What can gesture-speech mismatch tell us about pathophysiology underlying psychosis-risk syndromes?*  
Vijay Mittal, USA

**PL-02 PLENARY SESSION**

10:15–11:00 Auditorium 15

*Ketamine: Translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders*

*Chair:* Gregers Wegener, Denmark  
*Speaker:* Carlos Zarate, USA

**D-02 DEBATE**

11:15–12:45 Auditorium 15

*The Research Domain Criteria (RDoC) can create a new kind of taxonomy holding greater promise compared to the traditional Nosological Classification Systems in psychiatry*

*Chair:* Sabine Herpertz, Germany  
*Proponent:* Henrik Walter, Germany  
*Opponent:* Henning Saß, Germany
T45: SLEEP DISORDERS: BASIC / CLINICAL

TFS-04  WFSBP TASK FORCE SYMPOSIUM
11:15 – 12:45  Congress Hall A 3
Sleep in depression and cognition – from research to clinical practice
Chair: Edith Holsboer-Trachsler, Switzerland
Co-Chair: Birendra N. Mallick, India

001  Sleep as biomarker: Predictor of emotional regulation and depression
Martin Hatzinger, Switzerland

002  Sleep in dementia: A biomarker of cognition?
Dimitris Dikeos, Greece

003  Sleep and synaptic dysfunction in depression
Anne Eckert, Switzerland

004  REM sleep and prevention of neurodegeneration: Role of noradrenaline
Birendra N. Mallick, India

T9: COGNITIVE NEUROSCIENCE

S-36  SYMPOSIUM
11:15 – 12:45  Auditorium 12
The role of the nucleus accumbens in psychiatry
Chair: Jens Kuhn, Germany
Co-Chair: Leonhard Schilbach, Germany

001  The anatomy of the nucleus accumbens
Ioannis Mavridis, Greece

002  The role of nucleus accumbens in social cognition
Leonhard Schilbach, Germany

004  Deep brain stimulation of the nucleus accumbens
Sina Kohl, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-37  SYMPOSIUM
11:15 – 12:45  Auditorium 10
Neurobiologic imaging studies of mood disorders, neurogenetics and antidepressant action with positron emission tomography
Chair: J. John Mann, USA
Co-Chair: Gitte Moos Knudsen, Denmark

001  Familial transmission of 5-HT1A autoreceptor up-regulation: An impaired serotonergic endophenotype in mood disorders
J. John Mann, USA

002  Molecular neuroimaging and genetics
Gitte Moos Knudsen, Denmark

003  Predictiveness of clinical and peripheral markers for PET measurement of monoamine oxidase A: Implications for biomarker development in major depressive disorder and prevention of postpartum depression
Jeffrey Meyer, Canada

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-38  SYMPOSIUM
11:15 – 12:45  Auditorium 11
Treatment resistant schizophrenia: Definitions, psychobiology and clinical treatment
Chair: John Kane, USA
Co-Chair: Ofer Agid, Canada

001  Methodological issues in clinical trial designs for TRS
John Kane, USA

002  A longitudinal perspective on the evolution of treatment resistance
Ofer Agid, Canada

003  The biology of treatment resistance
Oliver Howes, United Kingdom

004  Definitions and epidemiology of treatment resistance
Christoph U. Correll, USA

T49: SUICIDE: BASIC / CLINICAL

WS-06  WORKSHOP
11:15 – 12:45  B3 M1-M2
Neurobiology of suicidal behaviour
Chair: Leo Sher, USA
Co-Chair: Zoltan Rihmer, Hungary

001  Testosterone and suicidal behavior in men and women
Leo Sher, USA

002  Suicide in men: Clinical and biological correlates
Zoltan Rihmer, Hungary

003  Neuroinflammatory biomarkers of suicidal behavior
Jussi Jokinen, Sweden

004  Endophenotypes of suicidal behavior for genetic research
Xenia Gonda, Hungary
T51: MISCELLANEOUS

WS-08 WORKSHOP
11:15–12:45 B3 M3-M4
Functional neuroanatomy of hallucinations
Chair: Rajesh Nagpal, India
Co-Chair: Harishchandra Gambheera, Sri Lanka

001 Functional neuroanatomy of auditory hallucinations
E. Mohandas Warrier, India

002 Neural signature of visual hallucinations
Venu Gopal Jhanwar, India

003 Neural mechanisms of somatic, musical and extracampine hallucinations
Anukant Mital, India

004 The neural signature overlap between delusions and hallucinations
Debashis Ray, India

P-06 POSTER TOUR
13:00–14:30 Congress Hall A 1
Depression 2
Chair: Poul Videbech, Denmark

003 Early Serum-BDNF-Increase is facilitated by aerobic exercise and associated with lower insomnia severity after 6 weeks of inpatient treatment for depression
Christian Imboden, Switzerland

005 Effects of the adenosine A(1) receptor neurotransmission on hyper-emotionality of olfactory bulbectomized rat
Yuma Ogushi, Japan
L. Gotoh, K. Kira, T. Kawaguchi, A. Hatanaka, H. Kawasaki

007 Risk markers for recurrence in major depression
Marcus Ising, Germany
P. Belcredi, S. Scheuer, M. Wierzyk, M. Uhr, S. Lucae, F. Holsboer

008 Attenuation of deficits in behaviour and microglia population in male high anxiety-related behaviour rats by minocycline
Anna-Kristina Schmidtner, Germany
V. Malik, B. Di Benedetto, D. Slattery, I. Neumann

009 Hippocampal protein turnover alterations in response to paroxetine treatment
Michaela Filiou, Germany
C. Webhofer, C. Guillermier, C. Poczatek, A. Chen, C. Turk, C. Lechene

010 Positron emission tomography assessment of Ketamine binding on the Serotonin transporter in humans
Marie Spies, Austria
G. James, N. Berroterán Infante, H. Ibeschitz, J. Unterholzner, M. G. Godbersen, J. Jungwirth, M. Mitterhauser, W. Wadsak, S. Kasper, R. Lanzenberger

011 A pharmacogenetic marker in DISP1 is not associated with antidepressant response in obsessive-compulsive disorder
Gwyneth Zai, Canada
A. Lisoway, K. Wigg, D. Zhang, N. Freeman, D. Mueller, J. Kennedy, M. Richter

012 Vortioxetine for the treatment of depression: A systematic review and meta-analysis
Chi-Un Pae, Republic of Korea

013 Correlations between middle-term outcome of major depressive disorder and metabolic syndrome
Tudor Udristoiu, Romania
A. L. Chirita, F. Militaru, I. Udristoiu, S. Ristea

014 Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450 mediated metabolism of Venlafaxine
Michael Paulzen, Germany
M. Kuzin, E. Haen, C. Hiemke, G. Gründer, G. Schoretsanitis

015 Measures of daily mood, stress and reward responses in offspring of depressed parents
Matthias Guillod, Switzerland
C. Gaillard, R. Recabarren, D. Schoebi, M. Merlo, G. Hasler, C. Martin-Soelch

016 Does cortisol awakening response indicate the impact of poor sleep on next day's negative affect?: An event sampling study on major depression and controls
Thorsten Mikoteit, Switzerland
C. Imboden, F. Maier, M. Hatzinger, E. Holsboer-Trachsler, R. Lieb, A. Gloster

017 Evaluation of affective temperaments, depression and anxiety in different hypertensive conditions
Xénia Gonda, Hungary
018 Exp-ECT: The impact of patients' expectation on effectiveness and tolerability of electroconvulsive therapy
David Zilles, Germany
M. Belz, M. Besse, L. Krech, I. Methiessle, D. Wedekind

019 Anxiety attacks with or without life threatening situations, major depressive disorder, and suicide attempt: A nationwide community sample of Korean adults
Hye-Won Kim, Republic of Korea
K.-W. Kim, K.-W. Choi, H.-J. Jeon

021 Prevalence and use of mental health services among subjects with comorbid mood and anxiety disorders among Brazilians
Sergio Blay, Brazil
G. Fillenbaum, M. Mello, M. Quintana, J. Mari, R. Bressan, S. Andreoli

022 Cholecalciferol treatment reverses depression-like behavior and corticosterone levels in female rats with experimental model of menopause
Julia Fedotova, Russia
S. Pivina, A. Sushko

001 Dyslipidemia in adolescents with early onset psychosis
Kirsten Wedervang-Resell, Norway
V. Lonning, R. Smelror, S. Ulven, I. Agartz, A. Myhre

002 A randomized controlled trial of mindfulness-based cognitive therapy for youth living with Inflammatory Bowel Disease (IBD) and depression
Tatjana Ewais, Australia
J. Begun

003 Retinoic acid signaling in anti-inflammatory effects of minocycline
Vera Clemens, Germany
F. Regen, I. Heuser, J. Hellmann-Regen

004 Immune system dysregulation in the pathogenesis of first-onset postpartum psychosis: Clues from peripheral markers
Gopinath Sathyanarayanan, India
H. Thippeswamy, R. Mani, M. Venkataswamy, M. Kumar, M. Philip, P. S. Chandra

005 C-reactive protein and white blood cell levels in schizophrenia, Bipolar Disorders (BP) and depression and associations with mortality and psychiatric outcomes: A Danish population-based study
Henriette Thisted Horsdal, Denmark
O. Köhler, M. Eriksen Benos, C. Gasse

006 C-reactive protein levels and associations with treatment resistance in schizophrenia: A Danish population-based study
Henriette Thisted Horsdal, Denmark
T. Wimberley, M. Eriksen Benos, C. Gasse

007 A case report of comorbid schizophrenia and psoriasis that illustrates the potential relationship between response to antipsychotics and immunity
Guillermo Joaquin Hönig, Argentina
S. Wikinski

008 Serum inflammatory biomarkers are adjunct diagnostic tools for schizophrenia in clinical practice
Shohei Nishimon, Japan

011 Serum high-sensitivity C-reactive protein, risk of cardiovascular disease, and disease stages in patients with schizophrenia
Jeffrey Yao, USA
R. Reddy, J. Gurklis, A. Sonel, E. Sonel, B. Kisslinger, R. Chengappa, M. Keshavan, G. Haas

012 Peripheral levels of a pro-inflammatory metabolite in the arachidonic acid cascade differentiate pharmacotherapy resistant from pharmacotherapy responding major depressive disorder patients
Fotini Boufidou, Greece
M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli, C. Nikolaou

001 Brain-behavior correlation in a high risk for psychiatric disorders Brazilian cohort: A replication study
Andrea Jackowski, Brazil
A. Zugman, E. Trejos-Castillo, A. Mastergeorge

002 Correlation between hypothalamus and third ventricle of patients with affective disorders
Marie Stroske, Germany
S. Schindler, M. Storch, S. Geyer, P. Schönknecht
003  Color up your MRI! – Performance of intensity standardisation techniques with 7T high-resolution MRIs
Stephanie Schindler, Germany
J. Schreiber, P.-L. Bazin, R. Trampel, A. Anwander, S. Geyer, P. Schönknecht

004  Hypothalamic enlargement in mood disorders – high-resolution in-vivo evidence
Stephanie Schindler, Germany

006  Higher daily cortisol concentration predicts enhanced functional connectivity between amygdala and hippocampus during emotional processing
Yuko Hakamata, Japan

007  Amygdala reactivity to fearful faces correlates positively with impulsive aggression
Sofi Da Cunha-Bang, Denmark
P. Fisher, L. Vadskaer Hjordt, K. Holst, G. Knudsen

008  Severity of past aggression coupled to higher baseline oxygenated hemoglobin in right dorsolateral prefrontal cortex in schizophrenia
Anette Johansson, Sweden
A.-N. Hellsing, L. Harmat, M. Kristiansson, H. Fischer, L. Högman

009  Increases in dopamine transporter binding potential in amygdala in social anxiety disorder: A case-control study using positron emission tomography
Olof Hjorth, Sweden

010  Mindfulness effects on high and low trait-anxiety: A neuroimaging study
Guido Bondolfi, Switzerland
Y. Cojan, M. Desseilles, F. Jermann, B. Weber, S. Schwartz, P. Vuilleumier

011  Interoceptive processing as a white matter correlates of anxiety sensitivity in panic disorder
Sang-Hyuk Lee, Republic of Korea
M.-K. Kim, B. Kim, T.-K. Choi

012  Brain volumetric abnormalities in recent first episode manic patients with Bipolar I Disorder (BD)
Trisha Chakrabarty, Canada
S. S. Arumugham, I. Torres, D. J. Lang, W. Su, W. Honer, R. Lam, L. Yatham

014  Brain areas processing chronic pain in patients with fibromyalgia: A case-control study using resting state arterial spin labelling
Monika Mueller, Switzerland
F. Wuethrich, A. Federspiel, R. Wiest, M. Curatolo, S. Walther

015  Role of neuroimaging in depression with incomplete response and cognitive and social dysfunction
Tudor Udristoiu, Romania
I. Marinescu, F. Militaru, I. Udristoiu, D. Marinescu

016  Regulation of neural responses to emotion perception by mobile-based self-help therapy for major depressive disorder
Bo-Ram Kim, Republic of Korea

017  Effectiveness verification of CBT program based on mobile application for depression
Da-Som Park, Republic of Korea

018  Brain tumor-associated first episode psychosis with severe self-mutilation and extensive religious determination: A case report
Lars Dutschke, Switzerland
S. Steinau, R. Wiest, S. Walther

019  Multivariate classification of schizophrenia by local activity features of resting-state fMRI
Kyoung-Uk Lee, Republic of Korea

020  Primary auditory cortex relative surface area alteration and its correlation with hallucination and disease severity in schizophrenia
Kyoung-Uk Lee, Republic of Korea
J.-H. Oh, K.-C. Paik

021  Sexual-dimorphism of the planum temporale in schizophrenia: An MRI study
Alessandro Pigoni, Italy
G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri, A. C. Altamura, M. Bellani, P. Brambilla

022  White matter maturation and the association with cognitive domains in children at genetic risk for schizophrenia
Amanda Lyall, USA
Z. Fitzgerald, O. Pasternak, N. Somes, E. Molokotos, R. Meshofam-Gately, H. Themenos, S. Whitfield-Gabrieli, J. Gabrieli, M. Keshavan, M. Kubicki, L. Seidman

023  Connectivity within and between brain areas of the mirror neuron system in schizophrenia
Yuliya Zaytseva, Czech Republic
M. Bendova, F. Spaniel, J. Horacek
The normalization of brain F-18-FDG hypometabolism following electroconvulsive therapy in a woman with treatment-resistant depression: Case report
Se-Hoon Shim, Republic of Korea
J.-S. Kim

Effects of Neurexan® on emotional brain response
Luisa Fensky, Germany
A. Kühnel, V. Teckentrup, M. Schultz, Y. Fan, M. Walter

Neurexan® influences stress-induced activity of the anterior cingulate cortex and associated brain regions
Anne Kuehnel, Germany
Y. Fan, L. Fensky, V. Teckentrup, M. Schultz, M. Walter

Probable postpartum hypomania and depression in a South African cohort
Leigh van den Heuvel, South Africa
J. Pingo, B. Vythilingum, S. Seedat

Garcinia mangostana linn (mangosteen) pericarp as an add-on treatment for bipolar depression
Melanie Ashton, Australia
M. Berk, C. Ng, M. Hopwood, O. Dean

Neurocognitive profile, personality, temperament and creativity in euthymic patients with Bipolar Disorder (BP) and major depressive disorder
Nam-Woo Kim, Republic of Korea
E.-Y. Kim, S.-H. Kim, H.-J. Lee, Y.-M. Ahn

Obvious impairment of attention and processing speed in patients with schizoaffective disorder
Chih-Ken Chen, Taiwan
L.-J. Wang

Bipolar Disorder (BP) and pregnancy desire
Isaac Gonzalez Gonzalez, Spain
A. Hernández Dorta

Eating disorders in Bipolar Disorder I (BP)
Nuria Corominas, Spain
D. Alberca, S. Alberca

Modeling mitochondrial damage in human neuronal cells by various concentrations of two mitochondrial complex inhibitors
Nofar Shemesh, Israel
O. Damri, T. Bar-Yosef, G. Las, G. Agam

Cognitive Subgroups in First Episode Bipolar I Disorder: Relation to Clinical and Brain Volumetric Variables
Trisha Chakrabarty, Canada
I. Torres, L. Yatham

High consumption of caffeine and manic episode
Alejandro Hernández Dorta, Spain
I. Gonzalez Gonzalez

Effects of cognitive remediation for bipolar disorders on neurocognition and psychosocial functioning: results of a randomized controlled study
Clemence Isaac, France
M.-C. Castillo, F. Durand, O. Bolloré, S. Braha-Zeitoun, V. Moulier, D. Januel

The association between school achievement and subsequent development of Bipolar Disorder (BP)
Steffie Damgaard Pedersen, Denmark
L. Petersen, O. Mors, S. Dinesen Østergaard

Drugs used to treat Bipolar Disorder (BP) act via microRNAs to regulate expression of genes involved in neurogenesis and neurite outgrowth
Srisaiyini Kidnapillai, Australia

Can a gene expression signature be used to identify drugs that may be repurposed for Bipolar Disorder (BP)?
Chiara Bortolasci, Australia

Volumetric integrity of the pituitary gland in Bipolar Disorder (BP)
Gian Mario Mandolini, Italy
G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri, A. C. Altamura, M. Bellani, P. Brambilla

BDNF and COMT polymorphism with lithium response in bipolar disorder: a pharmacogenetic association study
Pradip Paul, India
019  Structural and functional correlates of serum Soluble IL-6 receptor level in patients with Bipolar Disorder (BP)
Ya-Mei Bai, Taiwan
P.-C. Tu, C.-T. Li, T.-P. Su

020  Does N-acetylcysteine decrease oxidative stress biomarkers in urine among patients suffering from Bipolar Disorder (BP)?
Pernille Kempel Ellegaard, Denmark
R. W. Licht, H. E. Poulsen, C. T. Nielsen

P-10  POSTER TOUR
13:00–14:30  Congress Hall A1
Schizophrenia 1
Chair: Oliver Howes, United Kingdom

001  Schizotypy in ultra-high risk for psychosis: Its relations with basic symptoms
Suk-Kyoon An, Republic of Korea
M.-J. Bang

002  Low level of paraoxonase 1 activity and increased proinflammatory and anti-inflammatory cytokines are associated in drug naive first episode psychosis
Chiara Bortolasci, Australia
K. Landucci, F. Brinholi, C. de Farias, L. Higachi, E. Moreira, C. Noto, M. Maes, D. Barbosa

003  Amisulpride switching in schizophrenic patients who showed suboptimal effect and/or tolerability to current antipsychotics in a naturalistic setting: An explorative study
Jung-Jin Kim, Republic of Korea

004  Clinical assessment interview for negative symptoms: Validation of the Czech version
Ladislav Hosák, Czech Republic
K. Hosakova, I. Viktorova, M. Leclibach

005  Gesture performance as a possible trait marker in schizophrenia: Test-retest reliability of gesture performance in schizophrenia patients, unaffected relatives and healthy controls
Sarah Eisenhardt, Switzerland
K. Stegmayer, J. Moor, T. Vanbellingen, S. Bohlhalter, S. Walther

006  Relationship between symptom severity and vitamin D deficiency in first-episode psychosis
Ricardo Coentre, Portugal
C. Gois, M. L. Figueira, M. Talina

007  Differences in social functioning among patients with major psychiatric disorders: Interpersonal communication is impaired in patients with schizophrenia and correlates with an increase in schizotypal traits
Takamitsu Shimada, Japan
K. Ohi, T. Yasuyama, T. Uehara, Y. Kawasaki

008  First episode of schizophrenia is followed by changes in activity of blood amine oxidases
Marat Uzbekov, Russia
V. Brilliantova, S. Shikhov, E. Skokina

009  Validation of the Comprehensive ICF Core Set for schizophrenia from the perspective of psychiatrists
Laura Nuño Gómez, Spain
M. Barrios, E. Rojo, J. Gómez Benito, C. Guílerra

011  Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, double-blind, placebo-controlled, maintenance study
Emmanuelle Weiller, Denmark
M. Hobart, S. Pfister, A. Forbes, J. Ouyang, C. Weiss

013  Clozapine use rate influenced by seasonal birth and onset age: Big data analysis of Korean patients with schizophrenia
Seung-Hwan Lee, Republic of Korea
J.-S. Kim, S.-W. Hahn, W.-Y. Jung, Y.-M. Jae

014  Relevant areas of functioning in schizophrenia: From what perspective?
Oscar Pino López, Spain
M. Barrios, G. Guílerra, E. Rojo, J. Gómez

015  Short-term and long-term efficacy of brexpiprazole in adults with schizophrenia: Effect across Marder factors
Catherine Weiss, USA
A. Forbes, M. Hobart, S. Pfister, J. Ouyang, E. Weiller

016  Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: The REAP-AP4 study
Shih-Ku Lin, Taiwan

017  Factors affecting quality of life and family burden among the families of patients with schizophrenia
Chul-Eung Kim, Republic of Korea

019  Negative symptoms of schizophrenia: there will be a potential role for antidepressants? – a case report
Raquel Serrano, Portugal
H. Medeiros, J. Ramos, T. Maia
T13: EMERGENCY PSYCHIATRY

TFW-02 WFSBP TASK FORCE WORKSHOP
15:00–16:30 Auditorium 12
WFSBP Consensus on the management of agitation in psychiatry
Chair: Siegfried Kasper, Austria
Co-Chair: Eduard Vieta, Spain

001 Agitation: Causes and differential diagnosis
Marina Garriga, Spain

002 Agitation in schizophrenia
Dieter Naber, Germany

003 Agitation in Bipolar Disorder (BP)
Lakshmi Yatham, Canada

004 WFSBP Consensus on agitation in psychiatry
Eduard Vieta, Spain

T1: ADDICTIVE DISORDERS

S-39 SYMPOSIUM
15:00–16:30 Auditorium 10
Current research on the use of cannabinoids
Chair: Aviv Weinstein, Israel
Co-Chair: Amine Benyamina, France

001 Cannabis use disorder and its effects on cognitive function
Valerie Curran, United Kingdom

002 The relationship between cannabis and psychosis
Deepak Cyril D’Souza, USA

003 The genetics of cannabis use disorder
Amine Benyamina, France

004 The effects of chronic use of synthetic cannabinoids on executive brain function
Aviv Weinstein, Israel

T10: DEMENTIA: BASIC / CLINICAL

S-40 SYMPOSIUM
15:00–16:30 Auditorium 11
Alzheimer's Disease (AD) pathophysiology, prevention and treatment strategies: Where we stand and where we go?
Chair: Jerzy Leszek, Poland
Co-Chair: Ramón Cacabelos, Spain

001 Pharmacogenetics of cerebrovascular phenotypes of risk in dementia
Ramón Cacabelos, Spain
002 Insulin resistance in neurodegeneration: The role of p53/miRNA/SIRT1 axis
Kazimierz Gasiorowski, Poland

003 Alzheimer drug discovery: Targeting synaptic glutamate signaling
Markku Kurkinen, USA

004 Nanotechnology for early detection and treatment of Alzheimer's Disease (AD): Where we stand and where we go?
Jerzy Leszek, Poland

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-41 SYMPOSIUM
15:00–16:30 B3 M3-M4
Electroconvulsive therapy for depression – optimising treatment and maintaining recovery
Chair: Declan McLoughlin, Ireland
Co-Chair: Pascal Sienaert, Belgium

001 The KEEP-WELL Trial: Ketamine for depression relapse prevention following ECT (NCT02414932)
Declan McLoughlin, Ireland

002 Immediate and long-term outcomes for Brief-pulse (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The ResPECT trials' experience
Pascal Sienaert, Belgium
H.-P. Spaans, E. Verwijk, F. Bouckaert

003 Pre- and post-ECT cognitive performance as predictors for outcome and relapse in depression (NTR1304)
Esmée Verwijk, The Netherlands

004 The PRIDE Trial – Prolonging remission in depressed elderly (NCT01028508): Results from the randomised phase
Charles Kellner, USA

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

TFS-06 WFSBP TASK FORCE SYMPOSIUM
17:00–18:30 Auditorium 12
Electroconvulsive therapy: Beyond depression
Chair: Georgios Petrides, USA
Co-Chair: William McDonald, USA

001 ECT for the treatment of catatonia
Tom Bolwig, Denmark

002 ECT in autism spectrum disorders: Catatonia and beyond
Lee Wachtel, USA

003 ECT for agitation in elderly patients with dementia
Adriana Hermida, USA

004 ECT-related mortality rates
Søren Dinesen Østergaard, Denmark

T22: MOLECULAR NEUROBIOLOGY

S-42 SYMPOSIUM
17:00–18:30 Congress Hall A 3
Neuroepigenetic approaches to assess disease risk, mechanism and treatment
Chair: Alfonso Bull, Denmark
Co-Chair: Jonathan Mill, United Kingdom

001 CACNA1C hypermethylation associated with Bipolar Disorder (BD)
Anna Starnawska, Denmark

002 Epigenomic trajectories across human brain development: Relevance for schizophrenia and other neurodevelopmental disorders
Jonathan Mill, United Kingdom
003 Neonatal epigenetic profiling in Danish twins discordant for psychiatric disorder
Shantel Weinsheimer, Denmark

004 Epigenetics in schizophrenia and association with antipsychotic response to clozapine
Marta Bosia, Italy

T33: PHARMACOLOGY

S-66 SYMPOSIUM
17:00–18:30 Auditorium 15

NMDA receptor antagonists in psychiatry
Chair: Peter Gass, Germany
Co-Chair: Gerard Sanacora, USA

001 Glutamatergic mechanisms in schizophrenia: Focus on genetics
Dan Rujescu, Germany

002 Insight into Ketamine's effect via cross-species translational neuroimaging
Oliver Grimm, Germany

003 Molecular and cellular determinants of the pleiotropic effects of NMDA receptor antagonists
Dragos Inta, Germany

004 Antidepressant effects of NMDA receptor targeting drugs
Gerard Sanacora, USA

FC-06 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 10

Antipsychotics 1
Chair: Jimmi Nielsen, Denmark
Co-Chair: Hsien-Yuan Lane, Taiwan

001 Would I take antipsychotics, if I had psychotic symptoms? Examining social determinants of the decision to take antipsychotics
Fabrice Berna, France
A. S. Göritz, P.-M. Llorca, P. Vidailhet, G. Fond, S. Moritz

002 Relative NMS risk in older men
Ronald Gurerra, USA

003 Sodium benzoate, a D-amino Acid Oxidase Inhibitor, added to Clozapine for the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial
Hsien-Yuan Lane, Taiwan
C.-H. Lin

004 Lessons learned from a risperidone therapeutic drug monitoring database
Georgios Schoretsanitis, Switzerland

005 Revisiting the increased prevalence of Clozapine induced cardiotoxicity in Australasia and proposal for a universal monitoring guideline
Guna Kanniah, New Zealand
S. Kumar
001 Therapeutic Drug Monitoring (TDM) in maternal serum, amniotic fluid and umbilical cord blood during pregnancy and delivery
Michael Paulzen, Germany
S. E. Lammertz, T. Veselinovic, T. W. Goecke, G. Gründer, G. Schoretsanitis

002 Melatonin and subjective measures of biological rhythms in women at risk for postpartum depression: Preliminary results
Benicio Frey, Canada
A. Slyepchenko

003 Depressed multiple suicide attempters: A high risk patient group
Leo Sher, USA
M. Grunebaum, A. Burke, S. Chaudhury, J. J. Mann, M. Oquendo

004 Rumination as a mediator between childhood trauma and adulthood depression and anxiety in non-clinical samples
Seung-Hwan Lee, Republic of Korea
J.-S. Kim, M.-J. Jin, S.-W. Hahn, Y. Jae, Y.-M. Jae

005 The Wistar Kyoto rat as a preclinical model of depression: Identification of a clinically relevant plasma biomarker
Jack Prenderville, Ireland
### T2: ANTIDEPRESSANTS: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-43</td>
<td>Novel approaches in mechanisms of action of antidepressant treatment</td>
<td>08:30–10:00</td>
<td>Auditorium 15</td>
<td>Rainer Rupprecht, Germany; Mark Rasenick, USA</td>
</tr>
<tr>
<td></td>
<td><strong>001</strong> Signal transduction in membranes as mechanism of action of antidepressants</td>
<td></td>
<td></td>
<td>Mark Rasenick, USA</td>
</tr>
<tr>
<td></td>
<td><strong>002</strong> Cytoskeleton as target for antidepressants</td>
<td></td>
<td></td>
<td>Massimiliano Bianchi, Ireland</td>
</tr>
<tr>
<td></td>
<td><strong>003</strong> Biomarkers during antidepressant treatment</td>
<td></td>
<td></td>
<td>Thomas Baghai, Germany</td>
</tr>
<tr>
<td></td>
<td><strong>004</strong> Antidepressants may affect signaling independently from monoamine reuptake</td>
<td></td>
<td></td>
<td>Rainer Rupprecht, Germany</td>
</tr>
</tbody>
</table>

### T1: ADDICTIVE DISORDERS

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-45</td>
<td>Behavioral addictions: Diagnosis, co-morbidity and neurobiology</td>
<td>08:30–10:00</td>
<td>Auditorium 10</td>
<td>Michel Lejoyeux, France; Aviv Weinstein, Israel</td>
</tr>
<tr>
<td></td>
<td><strong>001</strong> Internet gaming disorder - addiction, co-morbidity and the brain</td>
<td></td>
<td></td>
<td>Aviv Weinstein, Israel</td>
</tr>
<tr>
<td></td>
<td><strong>002</strong> Neuroimaging evidence for considering hypersexuality as an addiction</td>
<td></td>
<td></td>
<td>Florence Thibaut, France</td>
</tr>
<tr>
<td></td>
<td><strong>003</strong> New data on phenomenology and psychiatric comorbidity of compulsive buying</td>
<td></td>
<td></td>
<td>Michel Lejoyeux, France</td>
</tr>
<tr>
<td></td>
<td><strong>004</strong> The genetic background of gambling behavior</td>
<td></td>
<td></td>
<td>Csaba Barta, Hungary; Z. Demetrovics, E. Kötyuk, A. Verezckei, R. Urbán, A. Eisinger, A. Magi, G. K Köönya, A. Veres-Székhely, Á. Gyollai, K. Blum, M. Ssvári-Székely</td>
</tr>
</tbody>
</table>

### T17: GENETICS

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-44</td>
<td>Cannabinoid Receptor (CBR) gene variations in neuropsychiatric disorders</td>
<td>08:30–10:00</td>
<td>Congress Hall A 3</td>
<td>Hiroki Ishiguro, Japan; Emmanuel Onaivi, USA</td>
</tr>
<tr>
<td></td>
<td><strong>001</strong> Environmental stressors induce psychosis based on genetic variation of CB2Rs</td>
<td></td>
<td></td>
<td>Hiroki Ishiguro, Japan</td>
</tr>
<tr>
<td></td>
<td><strong>002</strong> ECB system alteration in an animal model of autism spectrum disorders</td>
<td></td>
<td></td>
<td>Eugene Dennis, USA</td>
</tr>
<tr>
<td></td>
<td><strong>003</strong> CBR genetics: From mice to human subjects</td>
<td></td>
<td></td>
<td>Emmanuel Onaivi, USA</td>
</tr>
<tr>
<td></td>
<td><strong>004</strong> Species differences in CBR genes</td>
<td></td>
<td></td>
<td>Emmanuel Onaivi, USA</td>
</tr>
</tbody>
</table>

### T50: VIOLENCE: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-46</td>
<td>Neurobiology and psychopharmacology of aggressive behaviour: Where are we?</td>
<td>08:30–10:00</td>
<td>Auditorium 11</td>
<td>Stefano Comai, Italy; Gabriella Gobbi, Canada</td>
</tr>
<tr>
<td></td>
<td><strong>001</strong> Neurobiology and biomarkers of aggression</td>
<td></td>
<td></td>
<td>Stefano Comai, Italy</td>
</tr>
<tr>
<td></td>
<td><strong>002</strong> Clinical management of aggression in childhood and adolescence</td>
<td></td>
<td></td>
<td>Pradeep Rao, Australia</td>
</tr>
<tr>
<td></td>
<td><strong>003</strong> Substance use disorders and aggressive behaviour</td>
<td></td>
<td></td>
<td>Gabriella Gobbi, Canada</td>
</tr>
<tr>
<td></td>
<td><strong>004</strong> Epilepsy, antiepileptic drugs and aggression</td>
<td></td>
<td></td>
<td>Martin J. Brodie, United Kingdom</td>
</tr>
</tbody>
</table>
### Wednesday, 21 June 2017 / Scientific Programme

#### T11: DEPRESSION: BASIC / CLINICAL

**S-47** SYMPOSIUM

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Co-Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–10:00</td>
<td>B3 M1-M2</td>
<td><strong>Catecolamines, anhedonia and depression</strong></td>
<td>Jose Luis Ayuso Gutierrez, Spain</td>
<td>Victoria Valdez, Ecuador</td>
</tr>
</tbody>
</table>

001  **Catecholamines, reward circuits and depression**
Gregor Hasler, Switzerland

002  **Positive affects and depression**
Jorge Tellez-Vargas, Colombia

003  **Anhedonia and suicide behavior**
Maurizio Pompili, Italy

004  **Exploring the role of proinflammatory cytokines in anhedonia**
Ruby Castilla-Puentes, USA

#### FC-09 FREE COMMUNICATION SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–10:00</td>
<td>Auditorium 12</td>
<td><strong>Depression 1</strong></td>
<td>Lars Vedel Kessing, Denmark</td>
</tr>
</tbody>
</table>

001  **Blood biomarkers to predict suicidal behavior**
Bérengère Vire, France
D. Weissmann, N. Salvetat, S. Pointet, Y. Lannay, G. Marcellin, S. van der Laan, F. Molina, P. Courtet, P. A. Saiz

002  **Transcranial direct current stimulation for treatment-resistant depression: An open-label study for 8 weeks**
Galen Hung, Taiwan
M.-S. Li

003  **Season-independent cognitive deficits in seasonal affective disorder and their relation to depressive symptoms**
Liv Vadskaer Hjordt, Denmark
D. S. Stenbaek, B. Ozenne, B. Mc Mahon, I. Hageman, S. G. Hasselbalch, G. M. Knudsen

004  **Functional network-based statistics in depression: theory of mind subnetwork and importance of parietal region**
Chien-Han Lai, Taiwan
Y.-T. Wu

005  **Gene expression profiles within a pharmacologically induced depression model: The role of estrogen in perinatal depression**
Vibe G. Frokjaer, Denmark
D. Mehta, M. Rex-Hafiner, A. Pinborg, E. Binder, V. G. Frokjaer

#### FC-10 FREE COMMUNICATION SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30–10:00</td>
<td>B3 M3-M4</td>
<td><strong>Antipsychotics 2</strong></td>
<td>Kohji Fukunaga, Japan</td>
</tr>
</tbody>
</table>

002  **Importance of early changes of blood lipid levels to predict long-term dyslipidemia during psychotropic drug treatment**
Aurélie Delacrétau, Switzerland

003  **Association of body mass index with socioeconomic factors in Swiss psychiatric cohorts**
Axel Levier, Switzerland

004  **Discovery of a novel intracellular dopamine D2 receptor function**
Kohji Fukunaga, Japan
N. Shioda

005  **Altered cerebral concentration of major inhibitory neurotransmitter in the medicated UHR subjects: 1H MRS study**
Petr Menshchikov, Russia
N. Semenova, T. Akhadov

#### PL-03 PLENARY SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15–11:00</td>
<td>Auditorium 15</td>
<td><strong>Epigenetic consequences of early adversity: Implications for psychiatric disorders</strong></td>
<td>Constantin Soldatos, Greece</td>
<td>Elisabeth Binder, Germany</td>
</tr>
</tbody>
</table>

#### D-03 DEBATE

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair</th>
<th>Proponent</th>
<th>Opponent</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15–12:45</td>
<td>Auditorium 15</td>
<td><strong>Deep brain stimulation is a worthwhile treatment method in psychiatry</strong></td>
<td>Gregers Wegener, Denmark</td>
<td>Thomas Schläpler, Germany</td>
<td>Marwan Hariz, United Kingdom</td>
</tr>
</tbody>
</table>
T20: LIAISON PSYCHIATRY

TFS-07 WFSBP TASK FORCE SYMPOSIUM
11:15 – 12:45 Congress Hall A 3
Enhancing the role of primary care in looking after people with mental health problems: A new position paper from the Collaborative Care Task Force of the WFSBP
Chair: Nick Kates, Canada

001 Improving primary mental health care – Definitions, models, principles and challenges
Nick Kates, Canada

002 Integrating mental health services within primary care settings
Henrikje Klasen, The Netherlands

003 The role of the family physician in delivering mental health care
Torleif Ruud, Norway

004 Capacity building, training and adapting the approach for different countries
Nick Kates, Canada

T32: PHARMACOGENETICS

S-48 SYMPOSIUM
11:15 – 12:45 Auditorium 12
Pharmacogenetics of drug defense and neuroprotection: From the Neandertal to the modern humans
Chair: Julia Stingl, Germany
Co-Chair: Magnus Ingelman-Sundberg, Sweden

001 The evolutionary aspect of trait biomarkers in drug metabolism and neuroprotection
Magnus Ingelman-Sundberg, Sweden

002 Pharmacogenetic polymorphisms on behavioral and structural brain phenotypes uncovered by neuroimaging data
Roberto Viviani, Germany

003 Prevention of drug toxicity to the brain: The vulnerable brain and ADRs of nervous system disorders
Julia Stingl, Germany

004 Serotonin Transporter Expression Variability: Role in Neurogenesis and Pharmacological Modulation
Abdul Karim Barakat, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-49 SYMPOSIUM
11:15 – 12:45 Auditorium 10
Evidence-based guidelines for treatment of major depressive disorder: Contrasting views across the world
Chair: Roumen Milev, Canada
Co-Chair: Allan Young, United Kingdom

001 Evolution of WFSBP depression guidelines
Michael Bauer, Germany

002 The evolution of the CANMAT guidelines
Raymond Lam, Canada

003 The view from the UK: BAP guidelines for Mood Disorders (MD)
Allan Young, United Kingdom

004 Even the best guidelines don’t work unless they are implemented
Sagar Parikh, USA

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-50 SYMPOSIUM
11:15 – 12:45 Auditorium 11
Real time assessment of psychopathology and behavior in Bipolar Disorder (BP) using e-mental health technologies
Chair: Lars Kessing, Denmark
Co-Chair: Michael Bauer, Germany

001 Mood instability and Bipolar Disorder (BD): Deriving useful biosignatures from multidimensional, time stamped, streamed data
John Geddes, United Kingdom

002 Smartphones as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)
Lars Kessing, Denmark

003 Voice recognition as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP)
Maria Fauerholt-Jepsen, Denmark

004 Smartphone based ambulatory assessment of early warning signs in Bipolar Disorder (BP)
Michael Bauer, Germany
### Schizophrenia Research in Chile

**Chair:** Hernan Silva, Chile  
**Co-Chair:** Veronica Larach, Chile

<table>
<thead>
<tr>
<th>Workshop</th>
<th>Title</th>
<th>Presenter, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS-09</td>
<td><strong>BDNF as a biomarker of cognitive function in schizophrenia:</strong> A study in Chilean population</td>
<td>Hernan Silva, Chile</td>
</tr>
<tr>
<td></td>
<td><strong>Pragmatic and linguistic disorders in schizophrenia since the first episode</strong></td>
<td>Eduardo Duran, Chile</td>
</tr>
<tr>
<td></td>
<td><strong>Atypical antipsychotics and psychosis spectrum:</strong> Chilean experience</td>
<td>Eugenio Olea, Chile</td>
</tr>
<tr>
<td></td>
<td><strong>Universal coverage for schizophrenia: The GES program in Chile</strong></td>
<td>Veronica Larach, Chile</td>
</tr>
</tbody>
</table>

---

### General Assembly

**13:00 – 15:00**  
**Auditorium 11**  
**WFSBP General Assembly**
002 A meta-analysis of lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis
Blazej Misiak, Poland
B. Stanczykiewicz, Ł. Łaczmanski, D. Frydecka

003 Elevated levels of Asymmetric Dimethylarginine (ADMA) in first-episode schizophrenia patients: A cross-sectional study with meta-analysis
Blazej Misiak, Poland
M. Fleszar, J. Wisniewski, D. Frydecka

004 Impact of val-allele of Catechol-O-Methyl transferase on frontal executive functions in schizophrenia using novel MBIAL computerised battery: A case-control study
Narayan R. Mutalik, India
J. P. John, H. HN, S. Jain

005 Altered age-related subcortical trajectories in familial high-risk of schizophrenia with transition to psychosis
Synthia Guimond, USA
S. Sarvode, C. Makowski, M. Chakravarty, M. Keshavan

006 Collapsin-response mediator Protein-5 gene RS13017554 polymorphism and schizophrenia
Sofi Atshemyan, Armenia
R. Zakhrany, A. Arakelyan

007 The role of complexin family single nucleotide polymorphisms in schizophrenia
Sofi Atshemyan, Armenia
R. Zakhrany, A. Arakelyan

009 Symptomatic differences between remitted schizophrenia and non-remitted schizophrenia
Yeon-Ho Joo, Republic of Korea
S.-Y. Park, J.-S. Lee

011 Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma
David Misdrahi, France
A. Tessier, L. Boyer, F. Baylé, M. Husky, P.-M. Llorca

012 Exploring adherence profile to antipsychotics in patients with schizophrenia in a 6 month MEMS device follow-up post discharged study
David Misdrahi, France
A. Tessier, M. Husky, A. C. Lange, B. Vrijens, P.-M. Llorca, F. Baylé

014 Hallucinations and delusions differ in response to antipsychotic medication
Jill Bjørke, Norway

015 Cannabidiol attenuates the behavioral changes induced by repeated administration of a NMDA receptor antagonist through a 5HT1A receptor-dependent mechanism
Francisco Guimaraes, Brazil
N. Rodrigues, N. R. Silva, F. V. Gomes

016 Factors predicting personal and social performance in schizophrenia patients
Seung-Hyun Kim, Republic of Korea

017 Evidence on the use of antipsychotics for people at ultra-high risk of psychosis
Adriana Carapucinha, Portugal
R. Trindade, R. Catarino

018 Neurocognition and social cognition in parents with schizophrenia or Bipolar Disorder
Aja Neergaard Greve, Denmark

019 Neurocognitive deficits in patients with early-onset schizophrenia, and their nonpsychotic siblings
Nora S. Vyas, United Kingdom
L. Burke, M. Sirota, S. Netherwood, P. Caviston, M. Simic, K. J. Aitchison

020 “No gain, more pain”: Impact of reward on pain threshold and tolerance to experimental pain (Cold pressor task) in healthy subjects and patients with schizophrenia
Noomane Bouaziz, France
V. Moulier, S. Regat, D. Januel, R. Benadhira

021 Niacin response abnormality in patients with first-episode psychosis: A potential schizophrenia endophenotype
Fotini Boufidou, Greece
M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli, C. Nikolaou
Wednesday, 21 June 2017 / Scientific Programme

P-12 POSTER TOUR
13:00–14:30 Congress Hall A 1
Cognitive neuroscience
Chair: NN

003 Spatial attention modulates conscious somatosensory perception
Deniz Doruk Camsari, USA
L. Chanes, A. Malavera, L. Merabet, A. Valero-Cabre, F. Fregni

006 Mental fatigue effects cognitive functioning after acute cardiac events
Julius Burkauskas, Lithuania
A. Benevicius, J. Brozaitiene, N. A. Fineberg, D. Wellsted, N. Mickuviene, R. Benevicius

008 Computer-assisted cognitive remediation in schizophrenia and Bipolar Disorder BP: A prospective, randomized, double-blind, sham-controlled study
Chih-Ming Cheng, Taiwan
M.-H. Chen, T.-P. Su, C.-T. Li

009 The effects of varenicline in a ketamine-based rat model of cognitive dysfunction
Agnieszka Nikiforuk, Poland
A. Potasiewicz, P. Popik

P-13 POSTER TOUR
13:00–14:30 Congress Hall A 1
Sleep & eating disorders
Chair: Elisabeth Binder, Germany

001 Saccadic control in anorexia nervosa: Implications for the potential neurobiological underpinnings of anorexia nervosa
David Castle, Australia
A. Phillipou, S. Rossell, C. Gurvich, L. Abel

002 Eating disorders and psychiatric comorbidity in ambulatory care: A case series
María Marta Jalon Urbina, Spain
A. González Fernández, L. Gómez de Segura Iriarte, P. González García

004 Physical activity in depressed and non-depressed patients with obesity
Hubertus Himmerich, United Kingdom

005 Kynurenine-pathway and microbial diversity in anorexia nervosa: Relationship or independency?
Preliminary data
Sabrina Mörl, Austria
A. Meinitzer, S. Lackner, C. Blesl, A. Painold, G. Gorkiewicz, K. Kashofer, S. Holasek

P-14 POSTER TOUR
13:00–14:30 Congress Hall A 1
Neurostimulation
Chair: NN

001 Psychiatric deep brain stimulation: Recurrent and neglected ethical issues
Laura Cabrera, USA
R. McKenzie, R. Bluhm

002 Invasiveness of deep brain stimulation for obsessive-compulsive disorder: patient perspective
Simon Raymaekers, Belgium
K. Demyttenaere, L. Luyten, B. Nuttin, L. Gabriels, C. Bervoets

003 ECT-related anxiety: What have we (not) learned?
Jasmien Oubbels, Belgium
E. Verwijk, F. Bouckaert, P. Sienaert

004 Attitudes towards ECT: A survey of Polish mental health professionals
Anna Antosik-Wójcińska, Poland
G. Gazdag, L. Świecicki, J. Rybakowski, B. Majtczak, A. Wichniak
Electroconvulsive therapy for treatment of parkinsonism with on-off phenomenon with dementia: a case series
Tak Youn, Republic of Korea
I.-W. Chung, Y.-S. Kim

Electroconvulsive stimulation transiently enhances the permeability of the rat blood-brain barrier and induces astrocytic changes
Masanobu Ito, Japan

Transcranial magnetic stimulation for the treatment of major depression during pregnancy: Efficacy and safety of a novel therapeutic strategy
Ygor Ferrão, Brazil
R. Felipe, R. Lieberknecht

Electroconvulsive therapy for treatment resistant psychosis
Tak Youn, Republic of Korea
I.-W. Chung, Y.-S. Kim, Y.-W. Jeong

Impact of Theta Burst Transcranial Stimulation (TBS) on auditory hallucinations in schizophrenia
Noomane Bouaziz, France
V. Moulier, S. Braha, F. Thomas, R. Benadhira, D. Januel

Protocol for the management of psychiatric patients with psychomotor agitation
Eduard Vieta, Spain
M. Garriga, L. Cardete, M. Bernardo, M. Lombrana, J. Blanch, R. Catalán, M. Vázquez, V. Soler, N. Ortuño, A. Martínez Arán

The relationship between depression, anxiety, somatization, personality and symptoms of lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Chi-Un Pae, Republic of Korea

Gender differences in psychological vulnerability in donors and recipients for kidney transplantation
Young-Myo Jae, Republic of Korea

Psychotic-like experiences in individuals with rheumatic disease: Preliminary results
Juan L. Prados, Spain
A. Escudero, R. Luque, J. A. Alcalá, E. Collantes

Huntington's disease with psychiatric presentation – a case report
Raquel Serrano, Portugal
H. Medeiros, M. Nascimento, T. Maia

DESA study: An 8-year retrospective analysis of mechanical restraint application in an acute mental health unit, clinical and organizational factors
Jose Maria Villagran Moreno, Spain
R. Guerrero Vida, J. I. Pérez Revuelta, F. González Sáiz

Psychopathy and twins
Alejandro Hernández Dorta, Spain
I. Gonzalez Gonzalez

The Chemo brain: Severe cognitive decline following chemotherapy of breast cancer
Wolfgang Kaschka, Germany
J. Steyer, M. Jandl, I. Kaschka, S. Hodgkinson

Delirious Mania
Isaac Gonzalez Gonzalez, Spain
A. Hernández Dorta

Gender differences of occupational stress associated with suicide ideation among South Korean employees
Sun-Young Kim, Republic of Korea

Overlapping effect of the components of occupational stress associated with depressive symptoms and suicidal idea among Korean employees
Sun-Young Kim, Republic of Korea

What kind of stress associated with depression, anxiety and suicidal ideation in Korean employees?
Da-Eun Lee, Republic of Korea
S.-Y. Kim, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh

The brain-heart connection in TakoTsubo cardiomyopathy: A case report
João Fonseca, Portugal
R. Rodrigues

Effects of a prevention program on perceived stress and cortisol level using an ambulatory assessment approach among university students in Switzerland
Romina Recabarren, Switzerland
C. Gaillard, M. Guillod, C. Martin-Sölch
P-16  POSTER TOUR
13:00–14:30  Congress Hall A 1
Suicide
Chair:  Lars Vedel Kessing, Denmark

001  The identification of two subgroups in Korean suicide attempters using cluster analysis
Hye-Young Kim, Republic of Korea
B. Kim, K. Ha, J-W. Lee, Y-M. Ahn

002  Comparison of suicidal behavior between a hospital-based cohort and a community-based cohort: Korean cohort for the model predicting a suicide and suicidal behavior (K-COMPASS)
Christopher Hyung Keun Park, Republic of Korea
J-W. Lee, H-Y. Kim, Y-M. Ahn

003  Serum lipids as state and trait marker of aggression in recent suicide attempters
Marie Asp, Sweden
Å. Westrin, L. Träskman Bendz, L. Ambrus

004  Measuring quality of life through the Seville Questionnaire in patients with suicidal attempts at a psychiatry emergency hospital
Eduardo Rubio, Argentina
B. López

005  Is parity a protective factor against suicide attempts in women who have suffered sexual violence?
Victoria Valdez, Ecuador
P. Dueñas, J. Jimenez

006  Association between altered lipid profile and suicide attempt among Tunisian patients with schizophrenia
Ahmed Mhalla, Tunisia
R. Mensi, A. Messaoud, B. Amamou, A. Mrad, W. Douki, L. Gaha

007  Alcohol-induced disinhibition is associated with impulsivity, depression, and suicide attempt: A nationwide community sample of Korean adults
Kwan-Woo Choi, Republic of Korea
K-W. Kim, E-J. Na, H-J. Jeon

008  Tryptophan metabolism via Serotonin and Kynurenine biomarkers in major depression patients with suicide attempts
Stefano Comai, Italy
A. Messaoud, M. Rym, D. Wahiba, L. Gaha, G. Gobbi, F. Valtorta

009  Clinical factors of the index suicide attempt predicting later death by suicide
Kyoung-Uk Lee, Republic of Korea
M-S. Kim, K-C. Paik

010  Factors affecting suicide method lethality among suicide attempters in the Korea National Suicide Survey
Tae-Sung Yeum, Republic of Korea
B. Kim, E-Y. Kim, S-H. Kim, K. Ha, Y-M. Ahn

011  Risk factors in demographic variables to depressive symptoms and suicidality of elderly who live alone in South Korea
Kyung-Young Lee, Germany
H-S. Park

012  Suicidal behavior in monozygotic twins, Lima, Peru
Freddy Vasquez, Peru
Y. Nicolas, S. Falconi

013  Similarities between platelet proteome and cerebrospinal fluid proteome: In search of potential biomarker candidates for suicide with proteomics (Preliminary results)
Erika Semancikova, Slovakia
S. Tkacikova, J. Simonova, J. Talian, M. Benckova, J. Firment, E. Palova, J. Sabo

015  Suicide attempt and completed suicide by jumping in patients with electroencephalographic (EEG) abnormalities
Freddy Vasquez, Peru
Y. Nicolas, S. Falconi

P-17  POSTER TOUR
13:00–14:30  Congress Hall A 1
Anxiety, OCD & PTSD
Chair:  Ulrike Schmidt, Germany

001  Clinical utility of heart rate variability during head-up tilt test in subjects with chronic Post-traumatic Stress Disorder (PTSD)
Moon-Yong Chung, Republic of Korea
S-H. Kang, K-C. Paik, J-E. Park

002  Heart rate variability of chronic Post-traumatic Stress Disorder (PTSD) in the Korean veterans
Joo-Eon Park, Republic of Korea

004  7.8 earthquake in Ecuador: Comparing Post Traumatic Stress Disorder between urban and rural premedical students
Victoria Valdez, Ecuador
J. Jimenez, P. Dueñas

005  Combination of an epigenetic modulator and a regulator of a differentially methylated pathway reverses PTSD in a Rat model: A novel approach to PTSD treatment
Gal Warhaftig, Israel
N. Zilman, C-M. Sokolig, R. Massart, O. Gabay, V. Farida, M. Szyf, G. Yadid
007 Investigating differential expression in PTSD patients versus controls: An RNA-Seq study
Sian Hemmings, South Africa
L. Dicks, M. Jalali, J. Camielddien, S. Seead, L. van den Heuvel

008 Cho/Cr ratios in Anterior Cingulate Gyrus in a prospective study in pediatric sample exposed to multiple types of violence
Andrea Parolin Jackowski, Brazil
A. C. Milani, B. Foester, M. Feijó de Mello

010 Tumor necrosis factor-alpha and Post-Traumatic Stress Disorder (PTSD)
Serkan Hussein, United Kingdom
H. Himmerich, B. Dalton

011 Inflammatory markers in adult women with Post-traumatic Stress Disorder (PTSD)
Hiroaki Hori, Japan

012 Fornix integrity associated with early trauma in panic disorder
Sang-Hyuk Lee, Republic of Korea
S.-T. Yu

013 Reduced cortical thickness in paralimbic regions and inferior frontal gyrus of patients with panic disorder
Sang-Hyuk Lee, Republic of Korea

014 Relationship between monoaminergic and hormonal systems and endogenous intoxication in anxious depression
Marat Uzbekov, Russia
N. Maximova

017 Application of mobile app and paper survey of PTSD checklist in the elderly Korean veterans of the Vietnam war
Tae-Yong Kim, Republic of Korea

018 Characterization of a rare Slitrk1 frame-shift mutation in mice
Dorothy Grice, USA
Y. Kajiwara, J. D. Buxbaum

019 Cerebral activation associated with the influences of symptom provocation during memory retrieval in patients with obsessive-compulsive disorder
Jong-Chul Yang, Republic of Korea
K.-C. Paik

020 Descriptive phenomenology of depressive and anxious symptoms in patients with obsessive-compulsive disorder
Ygor Ferrão, Brazil
M. Damion, N. Morais, M. A. de Mathis

021 A pilot study of novel bilateral thermal capsulotomy with focused ultrasound for treatment-refractory obsessive-compulsive disorder: 2-Year follow-up
Chan-Hyung Kim, Republic of Korea
S.-J. Kim, H.-H. Jung, J.-W. Chang

024 Direct exposure to oxytocin results in increased social behavior and mobility performances in a zebrafish animal model
Ioana-Miruna Balmus, Romania
S.-A. Strungaru, G. Plavan, M. Nicoara, A. Ciobica

T51: MISCELLANEOUS

TFS-08 WFSBP TASK FORCE SYMPOSIUM
15:00 – 16:30 Congress Hall A 3

Men's mental health: Contemporary aspects
Chair: Leo Sher, USA
Co-Chair: Timothy Rice, USA

001 Future research and clinical directions in the field of men's mental health
Leo Sher, USA

002 Towards a neuropsychiatric model of disruptive behavior disorders in boys and young men: Developmental deficits in the emotion regulation system, their origin, and their therapeutic address
Timothy Rice, USA

003 Sex differences in addictive disorder and its clinical connotation
Shih-Ku Lin, Taiwan

004 Sex differences in early predictors of adult personality and intelligence
Trine Flensborg-Madsen, Denmark

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

TFW-03 WFSBP TASK FORCE WORKSHOP
15:00 – 16:30 Auditorium 12

WFSP Treatment Guideline Session: Do bipolar mixed states merit a treatment guideline on its own?
Chair: Siegfried Kasper, Austria
Co-Chair: Heinz Grunze, United Kingdom

001 Clinical manifestations of bipolar mixed states—epidemiological and clinical research
Jean-Michel Azorin, France

002 The changing concept of mixed states over time: DSM5 broadening and downgrading at the same time
Eduard Vieta, Spain
003 The WFSBP Treatment guideline for mixed states—evidence and recommendations
Heinz Grunze, United Kingdom

004 What the CINP guideline recommends in mixed states
Konstantinos Fountoulakis, Greece

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-51 SYMPOSIUM
15:00–16:30 Auditorium 15
Advances in biomarker development for neurostimulation
Chair: Paul Croarkin, USA
Co-Chair: Motoaki Nakamura, Japan

001 Stimulation-induced neuroplasticity of prefrontal cortex in adult autism spectrum disorder
Motoaki Nakamura, Japan

002 Glutamatergic biomarker development for repetitive transcranial magnetic stimulation
Paul Croarkin, USA

003 Neurocognitive effects of major depressive disorder and neurostimulation therapies
Shawn McClintock, USA

004 Predicting remission of suicidal ideation following Magnetic Seizure Therapy (MST) in patients with treatment-resistant depression
Zafiris J. Daskalakis, Canada

T3: ANTIPSYCHOTICS: BASIC / CLINICAL

S-52 SYMPOSIUM
15:00–16:30 Auditorium 10
The G protein coupled receptors as a target for psychotropic drugs
Chair: Andrzej Pilc, Poland
Co-Chair: Jeffrey P. Conn, USA

001 Positive allosteric modulators of GPCRs as a novel treatment for schizophrenia
Jeffrey P. Conn, USA

002 The mGlu5 receptor imaging in schizophrenia and depression
Gregor Hasler, Switzerland

003 The mGlu2/3 receptor as a novel therapeutic target for treatment-resistant depression
Shigeyuki Chaki, Japan

004 The allosteric modulation of group III mGlu receptors as target for antipsychotic or antidepressant drugs
Andrzej Pilc, Poland

T49: SUICIDE: BASIC / CLINICAL

S-53 SYMPOSIUM
15:00–16:30 B3 M3-M4
Suicidal behavior: Neurobiological and genetic determinants
Chair: Yogesh Dwivedi, USA

001 Epigenetic modifications in brain of suicide individuals: Focus on global and site-specific changes in 5-hydroxymethylcytosine
Gustavo Turecki, Canada

002 Genetics of intermediate phenotypes for suicidal behavior: Focus on impulsivity and aggression
Dan Rujescu, Germany

003 Toxoplasma gondii seropositivity and suicidal behavior
Teodor Postalache, USA

004 Non-coding RNAs: Novel epigenetic regulators in suicidal behavior
Yogesh Dwivedi, USA

T23: MOOD STABILISERS: BASIC / CLINICAL

S-55 SYMPOSIUM
15:00–16:30 Auditorium 11
Rediscovering Lithium
Chair: David Taylor, United Kingdom
Co-Chair: Jonathan Meyer, USA

001 The evidence for Lithium’s antisuicide properties and impact on mortality
Jimmi Nielsen, Denmark

002 The evidence for Lithium’s neuroprotective properties
Barrat Luft, United Kingdom

003 What is the risk for end stage renal disease with Lithium: A sophisticated review
Ursula Werneke, Sweden
M. Ott, E. Salander Renberg, B. Stegmayr

004 An update on assessing and managing Lithium’s renal effects
Jonathan Meyer, USA
T43: SCHIZOPHRENIA: BASIC / CLINICAL

**WS-10**

**WORKSHOP**

15:00–16:30 B3 M1-M2

Evidence for brain stimulation methods in schizophrenia

Chair: Joachim Cordes, Germany

Co-Chair: Christian Plewnia, Germany

**001** Effects of transcranial direct current stimulation (tDCS) on executive functions

Christian Plewnia, Germany

**002** rTMS for the treatment of negative symptoms in residual schizophrenia

Joachim Cordes, Germany

**003** The treatment of hallucinations in schizophrenia spectrum disorders

Iris Sommer, The Netherlands

**004** Predictors of response to ECT in treatment-resistant schizophrenia

Tomasz Pawelczyk, Poland

T50: VIOLENCE: BASIC / CLINICAL

**TFS-09**

**WFSBP TASK FORCE SYMPOSIUM**

17:00–18:30 Congress Hall A 3

Providing acute inpatient care for children, adolescents and young adults from a men's mental health perspective: Focus on violence reduction

Chair: M. Pilar Trelles, USA

Co-Chair: Lesha Shah, USA

**001** Brain development: A focus on normal male development and psychopathology

M. Pilar Trelles, USA

**002** Asking for the IM: What to do when the disruptive male child appears to seek punishment

Timothy Rice, USA

**003** Agression in adolescence

Lesha Shah, USA

**004** Violent and suicidal behavior among young male veterans on an inpatient psychiatric unit

Leo Sher, USA

T51: MISCELLANEOUS

**S-54**

**SYMPOSIUM**

17:00–18:30 Auditorium 12

Lithium as a neuroprotective agent: When and how?

Chair: Galila Agam, Israel

Co-Chair: Changlian Zhu, People’s Republic of China

**001** In vivo lithium-induced augments mitochondrial function, reduced neuroinflammation and increased autophagy

Galila Agam, Israel

**002** Lithium as a novel approach to treat developing brain injury

Changlian Zhu, People’s Republic of China

**003** GSK3beta inhibition-independent lithium-induced neuroprotection in stroke: The involvement of increased miR-124 expression, reduced RE1-silencing transcription factor abundance and decreased protein deubiquitination

Thorsten Doeppner, Germany

**004** A fully integrated new model for lithium's mode of action: Lithium utilizes hidden cellular fail-safe-mechanisms

Ernie van Woerkom, United Kingdom

**FC-08**

**FREE COMMUNICATION SESSION**

17:00–18:30 B3 M3-M4

Addictive disorders

Chair: Fabricio Moreira, Brazil

Co-Chair: Philippe Jaury, France

**001** New UK Government recommended guidelines on the “safe limits” of alcohol for adult males and its impact upon everyday prospective memory function

Thomas Heffernan, United Kingdom

A.-M. Marshall

**002** Bacloville: A clinical efficacy study of high dose baclofen in reducing alcohol consumption in high risk drinkers

Philippe Jaury, France

**003** Is there a role for cannabidiol in psychiatry?

Frederico Garcia, Brazil

J. Khoury, M. Neves, M. Roque, D. Queiroz, A. Freitas, Á. de Fátima, F. Moreira

**004** The electronic cigarette: A tool of withdrawal or a new addiction?

Samia Ben Saadi, Tunisia

O. Moula, O. Zerria, R. Triki, R. Ghachem
005 Clock genes SNP array identifies a key role of the PER1/HES7 gene in the risk of cannabis addiction and psychiatric comorbidities
Geneviève Lafaye, France
A. Benyamina

006 Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction
Malgorzata Filip, Poland
K. Wydra, A. Suder, E. Przegalinski, K. Fuxe

007 Predictors of online-gambling in a population of English students
Tuba Mazhari, United Kingdom
G. Ofori-Attah, N. Knights, A. Lineham

002 A review article: An overview of the role of celecoxib in treatment of psychiatric disorders
Mohammadreza Shalbafan, Iran
S. Donboli, F. Malekpour, E. Shirazi

003 Differential cytokine levels between early withdrawal and remission states in patients with alcohol dependence
San-Yuan Huang, Taiwan
M.-C. Shih

004 Parental infections during pregnancy as risk factors for mental disorders in childhood and adolescence: A nationwide Danish study
Cecilie Lydholm, Denmark
O. Köhler-Forsberg, M. Nordentoft, R. Yolkens, L. Petersen, M. E. Benrös

005 Vitamin D deficit in patients with schizophrenia or depression
Jose Maria Pelayo Teran, Spain
Y. Zapico Merayo, N. Martín Navarro, M. A. Reguero Palacio, M. M. Martínez Perez, L. García Menendez, A. Diez Hernandez

FC-11 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 11
Inflammation
Chair: Michael Maes, Thailand
Co-Chair: Jose Maria Pelayo Teran, Spain

002 Motion analysis in schizophrenia: Impaired gestures are linked to increased movement and prolonged motor planning and execution
Lars Dutschke, Switzerland
K. Stegmayer, F. Ramseyer, S. Bohlhalter, T. Vanbellingen, W. K. Strik, S. Walthier

002 A typology of homeless persons with mental health issues: Effects of mental and physical illness on rehabilitation
Jean-Pierre Bonin, Canada
C. Larue, J.-F. Pelletier, H. Racine

004 Environment and vulnerability to schizophrenia: A case-control study of warly parental loss in schizophrenia
Ofer Agid, Canada

005 Levels of glutamate and GABA are associated with cognitive deficits in antipsychotic-naïve patients with schizophrenia
Kirsten Borup Bojesen, Denmark
B. Fagerlund, M. Jensen, K. Jessen, A. Sigvard, G. Saltoft Andersen, E. Rostrup, B. V. Broberg, B. Glenthøj

FC-12 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 15
Schizophrenia
Chair: Oliver Howes, United Kingdom
Co-Chair: Rakesh Karmacharya, USA

001 Motion analysis in schizophrenia: Impaired gestures are linked to increased movement and prolonged motor planning and execution
Lars Dutschke, Switzerland
K. Stegmayer, F. Ramseyer, S. Bohlhalter, T. Vanbellingen, W. K. Strik, S. Walthier

002 A typology of homeless persons with mental health issues: Effects of mental and physical illness on rehabilitation
Jean-Pierre Bonin, Canada
C. Larue, J.-F. Pelletier, H. Racine

004 Environment and vulnerability to schizophrenia: A case-control study of warly parental loss in schizophrenia
Ofer Agid, Canada

005 Levels of glutamate and GABA are associated with cognitive deficits in antipsychotic-naïve patients with schizophrenia
Kirsten Borup Bojesen, Denmark
B. Fagerlund, M. Jensen, K. Jessen, A. Sigvard, G. Saltoft Andersen, E. Rostrup, B. V. Broberg, B. Glenthøj

FC-13 FREE COMMUNICATION SESSION
17:00–18:30 Auditorium 10
Genetics
Chair: Thomas Werge, Denmark
Co-Chair: Hannelore Ehrenreich, Germany

001 Risk of psychiatric disorders among individuals with the 22q11.2 deletion or duplication: A Danish nation-wide register based study
Louise Hoeftiding, Denmark

002 Identification of differentially methylated loci associated with late-life depression
Ruby Tsang, Australia
003 Polygenic risk score analysis of suicidal behaviour severity in Bipolar Disorder (BP)
Clement Zai, Canada
A. Tiwari, V. de Luca, J. Kennedy

005 OTTO: A new strategy to extract mental disease-relevant combinations of GWAS hits from individuals
Hannelore Ehrenreich, Germany
M. Mitjans, B. Oliveira, S. van der Auwera, T. P. Centeno, M. Begemann, H. J. Grabe, S. Bonn, K.-A. Nave

001 Behavioral, neurotransmitter and metabolic changes following selective activation of the nigrostriatal dopaminergic pathway
Mikael Palner, Denmark

002 18F-Fallypride binding potential correlates differently with executive function in medication-naïve schizophrenia patients and healthy volunteers
Nora S. Vyas, United Kingdom
D. S. Lehrer, B. Merrill, A. DeCastro, N. A. Doninger, B. T. Christian, J. Mukherjee, M. S. Buchsbaum

003 Dopamine transporter and hippocampal volume in schizophrenia
Yuan-Hwa Chou, Taiwan

004 Improving prognostic accuracy in subjects at clinical high risk for psychosis: Systematic review of predictive models and meta-analytical sequential testing simulation
André Schmidt, Switzerland

005 Neural correlates of childhood trauma with cognitive impairment in young healthy adults: A resting-state fMRI study
Shaojia Lu, People’s Republic of China
F. Pan, W. Gao, M. Huang, S. Hu, Y. Xu, L. Li
Thursday, 22 June 2017

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-56 SYMPOSIUM
08:30 – 10:00 Auditorium 15
Clinical effects and neural mechanisms of electroconvulsive therapy in major depression and schizophrenia
Chair: Robert Christian Wolf, Germany
Co-Chair: Philipp Thomann, Germany

001 ECT in major depression and schizophrenia: Indications and clinical effects
Dusan Hirjak, Germany

002 Effects of ECT on brain structure and function: Lessons from major depressive disorder
Robert Christian Wolf, Germany

003 ECT-related effects on regional brain volume and structural networks in patients with schizophrenia and major depressive disorder
Philipp Thomann, Germany

004 Modulation of intrinsic network connectivity by ECT in patients with schizophrenia and major depressive disorder
Fabio Sambataro, Italy

T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-57 SYMPOSIUM
08:30 – 10:00 Congress Hall A 3
Causes and consequences of inflammation in Bipolar Disorder (BP)
Chair: Lars Kessing, Denmark
Co-Chair: Flavio Kapczinski, Brazil

001 Peripheral inflammation in Bipolar Disorder (BP): Trait and state related alterations
Klaus Munkholm, Denmark

002 Targeting mitochondrial inflammation in Bipolar Disorder (BP)
Ana Andreazza, Canada

003 Relationships between inflammation, elevated body mass index, and depressive relapse in Bipolar Disorder (BP)
David Bond, USA

004 Genetic and central nervous system aspects of immune dysregulation in Bipolar Disorder (BP)
Bartholomeus Haarman, The Netherlands

T51: MISCELLANEOUS

S-58 SYMPOSIUM
08:30 – 10:00 Auditorium 12
Novel therapeutics for neurodegenerative disorders
Chair: Ramón Cacabelos, Spain

001 ASS234, as a new multi-target directed propargylamine for Alzheimer’s Disease (AD) therapy
José Marco-Contelles, Spain

002 EB101 immunotherapy against amyloid: A promising strategy for treating Alzheimer’s Disease (AD)
Iván Carrera, Spain

003 The Intelligent Pharmacogenetic Card (PGx-iCard) for neuropsychiatric disorders
Juan C. Carril, Spain

004 Neuroprotective effects of Atremorine in Cerebral Ischemia and Parkinson disease-related models
Javier Egea, Spain

005 Basic and clinical studies with E-PodoFavalin-15999 (Atremorine®) in Parkinson’s Disease: Selective dopaminergic neuroprotection and pharmacogenetics
Ramón Cacabelos, Spain

T22: MOLECULAR NEUROBIOLOGY

S-59 SYMPOSIUM
08:30 – 10:00 Auditorium 10
The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Converging insights from mouse genetics, physiology, and human studies
Chair: Peter Falkai, Germany
Co-Chair: Moritz Rossner, Germany

001 The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Insights from human studies
Cyndi Shannon Weickert, Australia

002 Neuregulin1-ErbB4 signaling: Integration at the network level
Beatriz Rico, United Kingdom

003 The relevance of Neuregulin1-ErbB4: Insights from mouse physiological analyses
Andrés Buonanno, USA

004 Neuregulin1-ErbB4 signaling: Insights from mouse genetics
Markus Schwab, Germany
### T22: MOLECULAR NEUROBIOLOGY

**S-60 SYMPOSIUM**

**08:30–10:00**

**Auditorium 11**

**Multi-omics and psychiatry: The missing molecular link**

*Chair:* Michaela Filiou, Germany  
*Co-Chair:* Anthony Zannas, Germany

---

001 **Stress-related phenotypes and epigenetic aging**  
Anthony Zannas, Germany

002 **From proteomics to biological mechanisms involved in schizophrenia**  
Daniel Martins de Souza, Brazil

003 **Multi-omics driven discovery of pharmacological targets for stress-related disorders**  
Michaela Filiou, Germany

004 **Role of CYP2C19 in major depressive disorder? Translational study**  
Marin Jukic, Sweden

---

### T49: SUICIDE: BASIC / CLINICAL

**S-61 SYMPOSIUM**

**08:30–10:00**

**B3 M1-M2**

**Suicide: Aspects that burn**

*Chair:* Konstantinos Fountoulakis, Greece  
*Co-Chair:* Dina Popovic, Israel

---

001 **Genetic basis of suicidal behaviour**  
Alessandro Serretti, Italy

002 **Mixed features and suicidality: Is DSM 5 wrong?**  
Dina Popovic, Israel

003 **How does clinical prediction of suicidality affect our daily clinical practice?**  
Mark Weiser, Israel  
M. Davidson

004 **Suicidality and overlapping geographical maps: Spurious correlations or cues for an underlying biological substrate?**  
Konstantinos Fountoulakis, Greece

---

### PL-04 PLENARY SESSION

**10:15–11:00**

**Auditorium 15**

**Lithium in mood disorders including a homage to Danish contribution**

*Chair:* Tudor Udristoiu, Romania  
*Speaker:* Janusz Rybakowski, Poland

---

### T49: SUICIDE: BASIC / CLINICAL

**S-62 SYMPOSIUM**

**11:00–12:30**

**Auditorium 15**

**Innovative approaches in suicide research**

*Chair:* Philippe Courtet, France  
*Co-Chair:* Sidney Kennedy, Canada

---

001 **Initiative for research network**  
Sidney Kennedy, Canada

002 **Neurosciences based phenomenology of suicidal behaviour**  
Philippe Courtet, France

003 **MeMind project: Ambulatory assessment in suicide behaviour. Do different things to expect different results?**  
Enrique Baca Garcia, Spain

004 **The use of machine learning and big data to predict suicide**  
Michael Berk, Australia

---

### T33: PHARMACOLOGY

**S-63 SYMPOSIUM**

**11:00–12:30**

**Congress Hall A 3**

**Atypical neurotransmitters in psychiatry: Relevance for future therapeutics**

*Chair:* Gregers Wegener, Denmark  
*Co-Chair:* Sâmia Joca, Brazil

---

001 **Nitric oxide signalling in psychiatric disorders: Evidence from Gene x Environment x Development (GxExD) studies**  
Gregers Wegener, Denmark
002 ATP and NO interaction in stress models of depression  
Sâmia Joca, Brazil

003 The endocannabinoid and endovanilloid system in stress-coping responses  
Fabricio Moreira, Brazil

004 Neurotrophins and psychiatric disorders  
Eero Castrén, Finland

T43: SCHIZOPHRENIA: BASIC / CLINICAL

S-64 SYMPOSIUM
11:00–12:30 Auditorium 12

Operationalizing the dysconnection syndrome: Translational approaches reveal brain network dysfunction in schizophrenia  
Chair: Bernat Kocsis, USA  
Co-Chair: Vaibhav Diwadkar, USA

001 Dysconnection in rodent models of schizophrenia: Directed connectivity analyses of frequency-tagged oscillatory coupling of frontal-hippocampal signals  
Bernat Kocsis, USA

002 Ketamine disrupts the functional state of corticothalamic systems: A mechanistic model for prodromal schizophrenia  
Didier Pinault, France

003 Structural and functional brain dysconnectivity predating the onset of psychosis  
Stefan Borgwardt, Switzerland

004 The dynamics of the functional “dysconnectome” in schizophrenia: Network modeling of in vivo fMRI signals  
Vaibhav Diwadkar, USA

T24: NEUROPATHOLOGY

S-65 SYMPOSIUM
11:00–12:30 Auditorium 10

Cell-type specific epigenetic, proteomic and gene expression signatures in schizophrenia: New findings from post-mortem investigations  
Chair: Peter Falkai, Germany  
Co-Chair: Andrea Schmitt, Germany

001 Alteration of genome-wide gene expression in hippocampal CA4 pyramidal neurons in schizophrenia  
Andrea Schmitt, Germany

002 Is the energy dysfunction observed in schizophrenia brains being originated in oligodendrocytes?  
Daniel Martins de Souza, Brazil

003 Integrated analysis of cell-type specific epigenome-wide methylation changes in schizophrenia brains  
Theo Kraus, Germany  
A. Schmitt, J. Spanner, P. Falkai, A. Giese

004 Epigenetic signatures in the brain of schizophrenia patients  
Andre Fischer, Germany

T11: DEPRESSION: BASIC / CLINICAL

S-67 SYMPOSIUM
11:00–12:30 B3 M1-M2

Spectrum of Mood Disorders (MD): Where is the place for mixed states?  
Chair: Trisha Suppes, USA

002 Bipolar mixed states: Review of clinical presentation, treatment and outcomes  
Mark Frye, USA

003 Major depressive disorder with mixed features: Epidemiology, clinical characteristics and prognosis  
Allan Young, United Kingdom

004 Major depressive disorder with mixed features: Review of current treatment options  
Trisha Suppes, USA

P-18 POSTER TOUR
13:00–14:30 Congress Hall A 1

Pharmacology & pharmacogenetics  
Chair: Dan Rujescu, Germany

001 In vitro inhibition of human cytochrome P450 isoenzymes by the novel atypical atipsychotic drug iloperidone  
Jacek Wójcikowski, Poland  
P. Danek, W. A. Daniel

002 The stimulating effect of 5-HT2 receptor activation in the hypothalamic arcuate nuclei (ARC) on cytochrome P450 activity in rat liver  
Marta Rysz, Poland  
E. Bromek, A. Haduch, W. A. Daniel

003 Activation of 5-HT1A receptors in the hypothalamic Paraventricular Nuclei (PVN) negatively regulates cytochrome P450 expression in rat liver  
Anna Haduch, Poland  
E. Bromek, M. Rysz, J. Wójcikowski, W. A. Daniel
004 Gender related differences in reporting side-effects in Glasgow Antipsychotic Side-effects Scale for Clozapine (GASS-C scale)
Dragana Ignjatovic Ristic, Serbia and Montenegro
J. Jovic, D. Cohen

005 Pharmacological characterization of receptor-mediated Gi/o activation in postmortem human prefrontal cortical membranes
Yuji Odagaki, Japan
M. Kinoshita, T. Ota, J. J. Meana, L. F. Callado, J. A. Garcia Sevilla

006 Mania induced by levetiracetam treatment: A case report
João Fonseca, Portugal
D. Vilaverde, P. Morgado

007 Improvement of social interaction and cognition by oxytocin for autism-like behaviors in valproic acid-exposed rats
Kohji Fukunaga, Japan
K. Matsuo, Y. Yabuki

008 Melatonin improved PTSD-like behaviors observed in FABP3 null mice
Kohji Fukunaga, Japan
Y. Yabuki, Y. Shinoda

009 Memantine activates CaMKII and improves cognition via KATP channels
Kohji Fukunaga, Japan
S. Moriguchi

010 Modafinil for the treatment of Attention Deficit Hyperactivity Disorder (ADHD): A meta-analysis
Sheng-Min Wang, Republic of Korea
C.-U. Pae

012 The use of statins for the treatment of depression in patients with acute coronary syndrome
Sung-Wan Kim, Republic of Korea

013 No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia
Bjørn Ebdrup, Denmark
P. Ishay, B. Fagerlund, B. Broberg, N. Bak, F. Knop, B. Glenthøj

014 Neuro-PGx Card: A new approach to the personalized treatment of CNS disorders
Juan C. Carril, Spain
R. Cacabelos

015 The associations between polymorphisms HTR2A and development of antipsychotic-induced metabolic disturbances: Preliminary results of prospective study in Russian patients
Regina Nasyrova, Russia
S. Dmiriy, T. Vera, J. Dmityr, S. Kristina, E. Evgeniy, N. Nicolay

016 Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patience with alcohol use disorder
Mikhail Zastrozhin, Russia

017 The impact of a single nucleotide polymorphism in SIGMAR1 on depressive symptoms in major depressive disorder and Bipolar Disorder (BP)
Laura Mandelli, Italy
C.-U. Pae, A. Serretti

018 Association of the Leptin Receptor gene (LEPR) polymorphism with blood pressure in patients with schizophrenia who are taking clozapine
Shi-Hyun Kang, Republic of Korea
J.-I. Lee

020 Establishment of evidence-based CYP2C19 genotype-guided escitalopram dosing recommendations – a naturalistic study based on 2,088 patients
Marin Jukic, Sweden
E. Molden, M. Ingelman-Sundberg

001 The effects of intestinal endotoxemia on APP, PS1 and BACE expression in Alzheimer's Disease
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

002 A novel Alzheimer's Disease vaccine: A promising dual effect for preventing and treating neuro pathological hallmarks
Iván Carrera, Spain
L. Fernandez Novoa, C. Vigo, R. Cacabelos

004 A case of psychiatric presentation of anti NMDA receptor encephalitis
Jose Ildefonso Pérez Revuelta, Spain
J. Pascual Juliá, J. M. Pascual Paño, C. Rodríguez Gómez, J. M. Villagran Moreno
005 Effects of intestinal endotoxemia on learning memory ability and brain levels of Aβ; Tau protein in rats with Alzheimer's Disease (AD)
Bai Han, People’s Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

007 Characteristics of oxygenated hemoglobin concentration changes in patients with major depressive disorder measured by multi-channel NIRS during pleasant and unpleasant image recall tasks
Akihiko Kondou, Japan

008 Single-event-related changes in Oxy-Hb during verbal discrimination tasks in patients with schizophrenia spectrum disorders
Youhei Ishii, Japan

010 Comparison of changes in the oxygenated hemoglobin level during Baum task pairing between healthy subjects and patients with schizophrenia
Yoshihisa Shoji, Japan

011 Modulation of the Serotonin system in an animal model of psilocin-induced psychosis: Time-course of quantitative EEG changes
Filip Tyls, Czech Republic
C. Vejmola, L. Kaderabek, V. Piorecka, V. Koudelka, T. Novak, T. Palenicek

012 Bright light enhances precocious expression of motor skill consolidation while optimizing speed-accuracy trade-off in humans
Takuya Yoshiike, Japan
M. Honma, K. Kuriyama

P-20 POSTER TOUR
13:00–14:30 Congress Hall A1
Genetics
Chair: Thomas Werge, Denmark

001 Relevance of vascular risk polymorphisms in cognitive deterioration
Juan C. Carril, Spain
R. Cacabelos

002 Risk polymorphisms associated with dementia in the Spanish population
Juan C. Carril, Spain
O. Teijido, R. Cacabelos

003 Association between ULK2 gene polymorphisms and the risk of schizophrenia in Korean population
Jong-Woo Kim, Republic of Korea
W.-S. Kang, J.-W. Paik, J.-Y. Song

004 Association of MCBP2 gene polymorphisms to schizophrenia susceptibility in Korean population
Won-Sub Kang, Republic of Korea
J.-Y. Song, J.-W. Paik, J.-W. Kim

005 Association between cytokine gene polymorphisms with panic disorder
Yong-Ku Kim, Republic of Korea
H.-J. Kim

006 Genetic role of 5-HTTLPR on psychological resilience of the patients with Mood Disorder (MD)
Eun-Jeong Joo, Republic of Korea
K.-Y. Lee, J.-K. Lee, K.-S. Choi

007 Importance of polygenic risk scores to predict lipid levels and dyslipidemia development in a psychiatric population receiving dyslipidemia-inducing psychotropic drugs
Aurélie Delacréta, Switzerland

008 Epigenomic profile in dementia-related disorders
Oscar Teijido, Spain
I. Carrera, J. C. Carril, R. Cacabelos

009 Epigenomics for advanced understanding of psychiatric diseases
Oscar Teijido, Spain
I. Carrera, J. C. Carril, R. Cacabelos

010 Influence of the APOE4 allele on brain networks in healthy elderly subjects
Ivan Tellado, Spain
J. C. Carril, C. Fraile, R. Cacabelos

011 Associations between disease trajectory and genomics in schizophrenia
Morten Dybdahl Krebs, Denmark

013 Money breaks the rhythm in your head: CLOCK gene polymorphisms interact with financial status to affect migraine
Xénia Gonda, Hungary
D. Baksa, G. Juhasz

016 Statistical epistasis between COMT, PRODH and ZDHHHC8 on chromosome 22q11 for schizophrenia in Koreans
Yu-Sang Lee, Republic of Korea
K. S. Hong, S. Y. Lee, E.-Y. Cho
001 Variability of 128 schizophrenia-associated gene variants across distinct ethnic populations
Kazutaka Ohi, Japan
T. Shimada, T. Yasuyama, T. Uehara, Y. Kawasaki

002 Association study between Dysbindin gene and schizophrenia in a Korean population
Kyu-Young Lee, Germany
E.-J. Joo

003 Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects
Yuta Yoshino, Japan

005 Gender-specific associations of the brain-derived neurotrophic factor Val66Met polymorphism with neurocognitive and clinical features in schizophrenia
Sung-Wan Kim, Republic of Korea

006 Sequencing of neurotrophic tyrosine receptor kinase 1 gene region in Armenian schizophrenia patients
Roksana Zakharayan, Armenia
A. Arakelyan

007 Clinical characteristics of formal thought disorder in schizophrenia
Ho-Seon Lee, Republic of Korea
S.-C. Park

009 SorCS1 regulates inhibitory networks and gamma-oscillations – a link to schizophrenia?
Peter Lund Ovesen, Denmark
U. Bølcho, K. M. Pedersen, S. Mølgaard Jensen, S. Glerup, M. M. Holm, A. Nykjær

010 Impact of familial loading on prefrontal activation in major psychiatric disorders: A Near-Infrared Spectroscopy (NIRS) study
Kazutaka Ohi, Japan

011 Total and high-affinity-state dopamine D2 receptors in the striatum of antipsychotic-free patients with schizophrenia: A PET study with [11C] raclopride and [11C] MNPA
Manabu Kubota, Japan

013 Brain anatomy of symptom stratification in schizophrenia: A voxel based morphometry study
Giuseppe Delvecchio, Italy
A. Lorandi, C. Perlini, M. Barillari, M. Ruggeri, A. C. Altamura, M. Bellani, P. Brambilla

014 White matter correlates of impaired gesture performance and recognition in schizophrenia
Peto Viber, Switzerland

015 Is the perception of language cues different in schizophrenia?: A pilot study
Marie Bendova, Czech Republic
Y. Zaytseva, M. Kolarova, M. Mojzisek, J. Rydlo, R. Gaspar, F. Spaniel

016 Amelioration of abnormal beliefs in subjects at ultra high-risk for psychosis linked to longitudinal increase in ventral striatal function during salience processing
André Schmidt, Switzerland

017 The N-Methyl D-Aspartate glutamate receptor antagonist ketamine disrupts the functional state of the corticothalamic pathway
Paul Anderson, The Netherlands
N. Jones, T. O’Brien, D. Pinault

018 Impact of trauma on negative symptoms of schizophrenia
Ombline Bolloré, France
D. Fouques, C. Isaac, D. Januel

020 Formal thought disorder in schizophrenia patients: Gender differences
Joon-Ho Choi, Republic of Korea
J.-E. Park, S.-C. Park

021 The validity and sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
Søren Dinesen Østergaard, Denmark
L. Foldager, O. Mors, P. Bech, C. U. Correll

022 Novel strategies of treatment of mental disorders based on D-cell hypothesis
Keiko Ikemoto, Japan
002 Functional connectivity pattern between the fornix and other brain regions in mild cognitive impairment: A resting-state functional magnetic resonance imaging study
Dong-Woo Kang, Republic of Korea
I.-H. Paik

005 Morphological and functional connectivity change of basal ganglia in amnestic mild cognitive impairment
Dong-Woo Kang, Republic of Korea
I.-H. Paik

006 The effects of tanshinone II A on a rat model of Alzheimer’s Disease (AD) with Intestinal Endotoxemia (IETM)
Bai Han, People’s Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

007 The mixture of rhubarb and salvia miltiorrhiza, Tanshinone II A on the prevention and treatment of Alzheimer’s Disease (AD)
Bai Han, People’s Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu

008 25-Hydroxyvitamin D levels in dementia and psychiatric disorders
Ivan Tellado, Spain
L. Corzo, S. Rodriguez, R. Cacabelos

009 Comorbidity of psychiatric disorders and the characteristics of the therapy of the hospitalized patients
Balázs Móra, Hungary
L. Péter

010 DNA methylation changes at TREM2 intron 1 and TREM2 mRNA expression in patients with Alzheimer’s Disease
Yuki Ozaki, Japan

011 Blood and CSF markers of inflammation related to anxiety and depression in older adults with and without cognitive impairment
Julius Popp, Switzerland

012 Disruptions on cortical networks associated with vascular dementia
Ivan Tellado, Spain
C. Fraile, R. Cacabelos

013 Polypharmacy, drug compliance and cognitive decline in elderly population: A nationwide population-based survey
Chih-Ming Cheng, Taiwan
W.-H. Chang, C.-H. Yang, C.-F. Tsai

014 Relationship between delusion of theft and cognitive functions in patients with mild Alzheimer’s disease
Hae Ran Na, Republic of Korea

T25: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL

S-68 SYMPOSIUM
15:00 – 16:30 Auditorium 15
Dynamical brain: How brain complexity changes with aging and mental illness?
Chair: Chih-Chieh Yang, USA
Co-Chair: Tetsuya Takahashi, Japan

001 Dynamical analysis of brain activity: A new research dimension
Chih-Chieh Yang, USA

002 Assessment of neurophysiological changes with electroconvulsive therapy in mental disorders using nonlinear approach
Ryoko Okazaki, Japan

003 Increasing signal variability during development and its relevance to autism spectrum disorders
Tetsuya Takahashi, Japan

004 Neurophysiological basis of creativity in healthy elderly people using nonlinear approach
Kanji Ueno, Japan

T19: INFLAMMATION PSYCHIATRY

S-69 SYMPOSIUM
15:00 – 16:30 Congress Hall A 3
Increased intestinal permeability and bacterial translocation in neuro-psychiatric disorders
Chair: Michael Maes, Thailand
Co-Chair: Yolanda Sanz, Spain

001 Increased intestinal permeability and bacterial translocation in depression and chronic fatigue syndrome
Michael Maes, Thailand

002 Increased intestinal permeability and bacterial translocation in chronic stress animal models
Javier Caso, Spain

003 Increased intestinal permeability and bacterial translocation in neurodevelopmental disorders
Yolanda Sanz, Spain

004 Increased intestinal permeability and bacterial translocation in schizophrenia
Emily Severance, USA
## T26: NEUROPHYSIOLOGY

<table>
<thead>
<tr>
<th>S-70</th>
<th>SYMPOSIUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00–16:30</td>
<td>Auditorium 12</td>
</tr>
<tr>
<td><strong>Current use of EEG-based techniques in psychiatry</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: Martijn Arns, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Co-Chair: Adam Wichniak, Poland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>001</th>
<th><strong>Epilepsy spectrum disorders and episodic psychiatric symptoms</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nash Boutros, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>002</th>
<th><strong>Results of the international multi-center iSPOT-A study in ADHD: EEG predictors of treatment outcome to methylphenidate</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Martijn Arns, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>003</th>
<th><strong>Did the No-Go P300 component help to predict relapse in recently detoxified alcoholic patients?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Salvatore Campanella, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>004</th>
<th><strong>Polysomnographic measures of sleep in psychiatry: Implications for diagnosis and treatment</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Wichniak, Poland</td>
<td></td>
</tr>
</tbody>
</table>

## T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>S-71</th>
<th>SYMPOSIUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00–16:30</td>
<td>Auditorium 10</td>
</tr>
<tr>
<td><strong>Sex-specific neuroendocrinological findings in conduct disorder</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: Sabine Herpertz, Germany</td>
<td></td>
</tr>
<tr>
<td>Co-Chair: Christine Freitag, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>001</th>
<th><strong>The brain oxytocin system in intermale and female aggression in rodents</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Trynke De Jong, Germany I. Neumann</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>002</th>
<th><strong>Sex-specific differences in oxytocin effects on the brain’s salience circuit</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Haang Jeung, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>003</th>
<th><strong>Sex-specific differences and the effects of puberty on emotional processing in adolescents with and without conduct disorder</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kerstin Konrad, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>004</th>
<th><strong>The role of basal and reactive steroid hormones and neuropeptides in female conduct disorder</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Freitag, Germany A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD study team</td>
<td></td>
</tr>
</tbody>
</table>

## T6: BIPOLAR DISORDERS: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>S-72</th>
<th>SYMPOSIUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00–16:30</td>
<td>Auditorium 11</td>
</tr>
<tr>
<td><strong>Socio-demographic and clinical differences between Bipolar I and II Disorder (BP) and implications for treatment</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: Terence Ketter, USA</td>
<td></td>
</tr>
<tr>
<td>Co-Chair: Bernardo Dell’Osso, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>001</th>
<th><strong>Bipolar I vs II Disorder (BP): Characterization of socio-demographic and clinical variables in Italian and American samples</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernardo Dell’Osso, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>002</th>
<th><strong>Clinical implications of predominant polarity and polarity index in Bipolar Disorders (BP)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eduard Vita, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>003</th>
<th><strong>Epidemiology and clinical correlates of suicide and suicide attempts in Bipolar Disorders (BP)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Maurizio Pompili, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>004</th>
<th><strong>Do we have evidence for differentiating pharmacological treatment of Bipolar I from Bipolar II Disorder (BP)?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Terence Ketter, USA</td>
<td></td>
</tr>
</tbody>
</table>

## T43: SCHIZOPHRENA: BASIC / CLINICAL

<table>
<thead>
<tr>
<th>S-73</th>
<th>SYMPOSIUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00–16:30</td>
<td>B3 M1-M2</td>
</tr>
<tr>
<td><strong>Neuropathologic implication of abnormal cortico-basal ganglia connectivity in schizophrenia hallucination and its models</strong></td>
<td></td>
</tr>
<tr>
<td>Chair: Hiroyuki Nawa, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>001</th>
<th><strong>Neuropathologic implication of pallidal hyperactivity in the auditory abnormality of schizophrenia animal models</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hiroyuki Nawa, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>002</th>
<th><strong>The rat ketamine model of schizophrenia shows aberrant oscillatory activity in the cortico-basal ganglia circuit</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Miguel Valencia, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>003</th>
<th><strong>Prefrontal – Basal ganglia circuit dysfunction associated with psychosis in schizophrenia</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Jong Yoon, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>004</th>
<th><strong>Subcortical modulation in auditory processing and auditory hallucinations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Toshikazu Ikuta, USA</td>
<td></td>
</tr>
</tbody>
</table>
**FC-16 FREE COMMUNICATION SESSION**

15:00 – 16:30  B3 M3-M4

**Childhood & adolescent disorders**

Chair: Ryo Kimura, Japan  
Co-Chair: Marina Mitjans, Germany

002 Management of impulsivity in adult ADHD comorbid groups: A factor analysis  
Srinivas Kandrakonda, India  
S. K. Jaiswal, P. Sravana Sandhya, J. Shyam Kumar

003 Multiple environmental hits before adulthood predict violent aggression  
Marina Mitjans, Germany  

004 Aberrant expression of microRNAs as specific blood-based biomarkers for autism spectrum disorder  
Ryo Kimura, Japan  

005 Randomised controlled trial of prolonged exposure therapy and supportive counselling for adolescent posttraumatic stress disorder: Task-shifting to nurses in a low resource setting  
Jaco Rossouw, South Africa  
E. Yadin, D. Alexander, S. Seedat

**CC-01 CLOSING CEREMONY**

16:30 – 17:30  Auditorium 15  
Closing Ceremony
Congress Information

CONGRESS VENUE
Bella Center Copenhagen
Conference Entrance
Center Boulevard 5
2300 Copenhagen S, Denmark

CONGRESS REGISTRATION COUNTER
The congress counter will be located in the Congress Foyer.

Opening hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 17 June 2017</td>
<td>16:00 – 19:00</td>
</tr>
<tr>
<td>Sunday, 18 June 2017</td>
<td>07:30 – 19:00</td>
</tr>
<tr>
<td>Monday, 19 June 2017</td>
<td>08:00 – 18:30</td>
</tr>
<tr>
<td>Tuesday, 20 June 2017</td>
<td>08:00 – 18:30</td>
</tr>
<tr>
<td>Wednesday, 21 June 2017</td>
<td>08:00 – 18:30</td>
</tr>
<tr>
<td>Thursday, 22 June 2017</td>
<td>08:00 – 17:30</td>
</tr>
</tbody>
</table>

During these hours the congress registration counter can be reached at: +45 – 3247 2952

CONGRESS AND EXHIBITION OFFICE
CPO Hanser® Service
Phone: +49 – 30 – 300 669-0
Email: wfsbp2017@cpo-hanser.de

NAME BADGES
All participants are kindly requested to wear their name badge at all times during the congress including the Opening Ceremony and Welcome Reception.

The colours of the name badges have the following significance:
- Congress delegate: orange
- Exhibitor: purple
- Staff: grey

CONGRESS LANGUAGE
The official language of the WFSBP Congress 2017 is English.

CERTIFICATE OF ATTENDANCE / CME CERTIFICATES
For certificates of attendance and CME certificates, please contact the staff at the registration counter.
From 27 June 2017 on, you can also print your CME certificate online at www.wfsbp-congress.org by logging in with your participant number or with your congress login credentials.

CONGRESS INFORMATION SYSTEM
The web based Congress Information System CO CONGRESS ONLINE® has been installed at www.wfsbp-congress.org

CO CONGRESS ONLINE® will provide information on:
- Updated scientific programme
- Programme by day
- Programme by format with accepted abstracts
- Programme search
- List of exhibitors and sponsors
- General congress information
- City of Copenhagen
- Travel information
- Private mailbox

TECHNICAL EXHIBITION
The WFSBP Congress 2017 will be accompanied by a technical exhibition taking place in Congress Hall A1 of the Bella Center.

Exhibition hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, 19 June 2017</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Tuesday, 20 June 2017</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Wednesday, 21 June 2017</td>
<td>09:00 – 17:00</td>
</tr>
</tbody>
</table>

WFSBP 2017 CONGRESS APP
The WFSBP 2017 Congress App is free for congress participants and provides iPhone/iPad and android smartphone users at WFSBP 2017 in Copenhagen with on-the-go access to the congress. The most up-to-date congress schedule is available at your fingertips during the congress.

- Mark your favorite sessions and personalise your experience.
- Quickly find your way through the most up-to-date congress schedule.
- Access vital information around the congress.
- Receive push notifications regarding important sessions
- Network with other WFSBP participants

The WFSBP 2017 App is powered by GLOBIT GmbH in cooperation with esanum GmbH.

Further information is given at www.wfsbp-congress/app.
WIFI
Please select the WiFi network BC Guest, no password is required.

SPEAKERS’ CENTRE
The Speakers’ Centre is located in Meeting Room 6. Speakers are asked to hand in their CD-ROM or USB stick containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their presentation, but at the latest three hours prior to the presentation. On-site technical staff will offer support.

Due to time and technical reasons we kindly ask the speakers not to use their own notebook. In the Speakers’ Centre there are several PC working stations, where speakers can also work on their presentation charts in a quiet area. Technical staff will be happy to assist.

Operated by ESTENSIS

Opening hours
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 17 June</td>
<td>16:00 – 19:00</td>
</tr>
<tr>
<td>Sunday, 18 June</td>
<td>07:30 – 18:30</td>
</tr>
<tr>
<td>Monday, 19 June</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, 20 June</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, 21 June</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Thursday, 22 June</td>
<td>08:00 – 15:30</td>
</tr>
</tbody>
</table>

POSTER EXHIBITION
The poster exhibition is located in Congress Hall A1. Posters will be changed daily and are on display for the entire day of the respective poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster exhibition times for P-01 to P-05
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, 19 June</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Guided Poster Tours</td>
<td>13:00 – 14:30</td>
</tr>
</tbody>
</table>

Poster exhibition times for P-06 to P-10
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, 20 June</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Guided Poster Tours</td>
<td>13:00 – 14:30</td>
</tr>
</tbody>
</table>

Poster exhibition times for P-11 to P-17
<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, 21 June</td>
<td>09:00 – 17:00</td>
</tr>
<tr>
<td>Guided Poster Tours</td>
<td>13:00 – 14:30</td>
</tr>
</tbody>
</table>

Poster exhibition times for P-18 to P-22
Thursday, 22 June 09:00 – 17:00
Guided Poster Tours 13:00 – 14:30

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set-up and dismantling times for posters
Posters need to be put up and dismantled on the day of the respective poster tour within the following times:

Set-up: 08:00 – 09:00
Dismantling: 17:00 – 18:00

Posters which have not been removed will be disposed of. Poster material to put up the poster is available at the poster service desk.

BEST POSTER AWARDS
All posters will be evaluated on site by the WFSBP Prize Committee. The WFSBP Prize Committee will shortlist 5 posters per day that will be exhibited at a Best Poster area in Congress Hall A1 in the afternoon. Two of these will win a Best Poster Award which will be announced on the day of the session. A total of 8 Best Poster Awards for young investigators under 40 years will be presented. All Best Poster Award winners will also be mentioned during the Closing Ceremony on Thursday, 22 June 2017.

PROGRAMME CHANGES
The organisers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances.

SNACK BARS
The congress provides snack bars in the exhibition area in Congress Hall A1 and in the Auditorium Foyer close to the Registration Counter. Beverages and snacks can be purchased there.

CASH MACHINE
An ATM/cash machine is located in the Bella Sky Hotel, adjacent to Bella Center, next to the front desk.
FIRST AID
In case of emergency, please contact the registration counter.

CURRENCY
The Danish currency is the Danish Krone (DKK). The Danish Krone is pegged to the Euro and convertible on world currency markets. The exchange rate fluctuates daily depending on the money market.

www.oanda.com

VISA
The entry formalities for Denmark vary according to the country of origin. The Ministry of Foreign Affairs of Denmark provides a list of countries that require a visa to enter the country. Please visit the website http://um.dk/en.

INSURANCE
Please note that the congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is strongly recommended and will need to be purchased in the country of origin.

FORCE MAJEURE
For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any natural disaster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 13th World Congress of Biological Psychiatry (WFSBP 2017) and its corresponding activities in Copenhagen, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

CLIMATE
Copenhagen is in the oceanic climate zone. Summer months are moderately warm and quite pleasant. June is the sunniest month of the year with an average of about eight hours of sunshine a day and the temperature varies between 11°C (52 °F) and 19°C (66°F).

COPENHAGEN INFORMATION COUNTER
A Copenhagen Information Counter is located in the registration area and open during the congress. Please contact the staff for city information on Copenhagen or reservations.

SHUTTLE BUS FROM / TO AIRPORT
Bella Center offers a complimentary shuttle bus connecting Copenhagen Airport with Crowne Plaza Copenhagen Towers and AC Hotel Bella Sky Copenhagen.
It runs twice an hour and is offered on a first come first served basis for hotel and conference guests.
CITY OF COPENHAGEN

Copenhagen is not only the capital of Denmark. It is a cultural and economic center of Northern Europe. More than 1.2 million citizens live in the greater Copenhagen region.

The city is located on the Danish Island „Saeland“ (Danish: Sjælland) and next to the „Øresund“ – a Baltic sea seagate and natural borderline to Sweden. Due to this geographic location, Copenhagen – together with the Swedish city Malmö – represents the binational „Øresund Region“. It is a unique metropolis area, where two countries and cities are connected via the 8 km „Øresund Bridge“.

The Copenhagen Palaces Christiansborg and Amalienborg are the seat of the Danish Parliament and the residence of the Danish Queen Margrethe II. Architecture, design and music make Copenhagen an outstanding cultural hotspot in Northern Europe. It is famous for its innovative improvements which can be seen and experienced throughout the city.

Also, Copenhagen has great museums to offer, for example Louisiana and The National Gallery of Denmark. The Royal Danish Opera, located directly at the harbor front, is combining modern Danish architecture with international performances. The main sightseeing spots and touristic attractions are the Tivoli Gardens, Christiansborg, and of course the „Little Mermaid“ – the famous sculpture of Edvard Eriksen at the waterside.

The University of Copenhagen offers a wide range of academic disciplines. With over 40,000 students and more than 9,000 employees, the University of Copenhagen is one of the largest institutions of research and education in the Nordic countries.

Due to short distances within the city of Copenhagen, its good public transportation system, and especially the well developed cycle paths, Copenhagen is a convenient place for meetings.

Our passion ignites progress

At Eisai, human health care is our goal. We give our first thoughts to patients and their families as well as helping to increase the benefits health care provides. Our therapies are designed to make a difference and have an impact on patients’ lives. We are Eisai, where medicine is more than just our business — it’s our passion.
### List of Exhibitors / Exhibition Floor Plan

#### LIST OF EXHIBITORS

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actelion Pharmaceuticals Ltd</td>
<td>5</td>
</tr>
<tr>
<td>Attention Deficit Hyperactivity Disorder – ADHD Congress 2019, Lisbon</td>
<td></td>
</tr>
<tr>
<td>European College of Neuropsychopharmacology – ECNP 2017</td>
<td>16</td>
</tr>
<tr>
<td>European Conference on Schizophrenia Research – ECSR Congress 2017</td>
<td>15</td>
</tr>
<tr>
<td>INPDA</td>
<td>11</td>
</tr>
<tr>
<td>International Society for the Study of Personality Disorders – ISSPD 2017, Heidelberg</td>
<td>11</td>
</tr>
<tr>
<td>John Wiley &amp; Sons Ltd.</td>
<td>3</td>
</tr>
<tr>
<td>MagVenture A/S</td>
<td>6</td>
</tr>
<tr>
<td>Neuroelectrics</td>
<td>13</td>
</tr>
<tr>
<td>REMED Co., Ltd.</td>
<td>9</td>
</tr>
<tr>
<td>Sunovion</td>
<td>4</td>
</tr>
<tr>
<td>Taylor &amp; Francis Group</td>
<td>14</td>
</tr>
<tr>
<td>The International College of Neuropsychopharmacology – CINP 2017 Prague/CINP 2018</td>
<td>18</td>
</tr>
<tr>
<td>The World Journal of Biological Psychiatry</td>
<td>10</td>
</tr>
<tr>
<td>World Association for Stress-related and Anxiety Disorders – WASAD 2017, Würzburg, Germany</td>
<td>12</td>
</tr>
<tr>
<td>Wisepress Ltd</td>
<td>17</td>
</tr>
<tr>
<td>WFSBP</td>
<td>2</td>
</tr>
<tr>
<td>WPA XVII WORLD CONGRESS OF PSYCHIATRY BERLIN 2017</td>
<td>1</td>
</tr>
<tr>
<td>ybrain Inc.</td>
<td>8</td>
</tr>
</tbody>
</table>

#### Exhibition Floor Plan

- **Congress Hall A1**
  - Lounge Area
  - Poster Exhibition
  - Coffee
  - Best Posters
  - Entrance Exhibition Hall

- **Lounge Area**
  - Entrance Exhibition Hall

- **Exhibition Hall**
  - Entrance Exhibition Hall
Acknowledgements

The organisers of the 13th World Congress of Biological Psychiatry gratefully acknowledge the support of the following companies (as per May 2017)

**MAJOR SPONSOR**

- Sunovion Pharmaceuticals
- Sumitomo Dainippon Pharma

**SPONSORS**

- Actelion
- Eisai Japan
- John Wiley

70% off for new subscribers!

Pharmacopsychiatry

**Editor-in-Chief:** M. Bauer

2017/Volume 50/6 issues p.a./ISSN 0176-3679

**Americas**

- **Individuals:** starting at $297 (contact customerservice@thieme.com)
- **Institutions:** starting at $1,298 (contact esales@thieme.com)

**Europe, Africa, Asia, Australia, New Zealand**

- **Individuals:** starting at €208 (contact customerservice@thieme.de)
- **Institutions:** starting at €848 (contact eproducts@thieme.de)

(please add shipping charges: Germany €39.40, Europe €43.90, Africa, Asia, Australia, New Zealand €49.90)

**Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka**

For subscription rates in INR, please contact customerservice@thieme.in

[Subscribe at www.thieme.com/pharma](http://www.thieme.com/pharma)

Indexed in: Current Contents (LS), Science Citation Index, MEDLINE, EMBASE and SCOPUS

Special introductory rates are only valid for new subscribers and are limited to the first year of subscription. Only qualified professionals and students are eligible for individual subscriptions. Orders from individuals must include the recipient’s name and private address, and be paid by private funds.
Industry Sessions

► Monday, 19 June 2017

SA-01 INDUSTRY SPONSORED SATELLITE SYMPOSIUM
13:15 – 14:45 Auditorium 12
Psychopharmacology in management of schizophrenia: Recent advances and challenges
(Sunovion)
Chair: John Kane, USA

001 Findings from scientific trials and clinical reality: How much progress did we make?
John Kane, USA

002 Managing metabolic outcomes of antipsychotic treatment: A balancing act with individualised approach
David Taylor, United Kingdom

003 Cognitive and functional outcomes in treatment of schizophrenia: Current options and future hope
Stein Opjordsmoen, Norway

► Tuesday, 20 June 2017

SA-02 INDUSTRY SPONSORED SATELLITE SYMPOSIUM
13:15 – 14:45 Auditorium 12
Orchestrating the differential diagnosis of organic psychosis: Shining a spotlight on NP-C
(Actelion)
Chair: Hans-Hermann Klünemann, Germany

001 Think NP-C: An insidious yet treatable psychiatric disease
Hans-Hermann Klünemann, Germany

002 Spotting the signs: When does psychosis point to NP-C?
Oliver Bonnot, France

003 Diagnostic challenges in NP-C: Using the right tools to make the diagnosis
Christian Hendriksz, United Kingdom

004 Challenging differential diagnoses: Recognising NP-C in frontotemporal dementia
Alessandro Padovani, Italy

Q & A
Summary and close
Hans-Hermann Klünemann, Germany
List of Chairpersons, Authors and Co-Authors
**List of Chairpersons, Authors and Co-Authors**

<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wachtel, L.</td>
<td>47</td>
</tr>
<tr>
<td>Waddington, J.</td>
<td>27, 35</td>
</tr>
<tr>
<td>Wade, R.</td>
<td>44</td>
</tr>
<tr>
<td>Wadsak, W.</td>
<td>41</td>
</tr>
<tr>
<td>Wadsworth, G.</td>
<td>49</td>
</tr>
<tr>
<td>Wahiba, D.</td>
<td>57</td>
</tr>
<tr>
<td>Wahlisted, K.</td>
<td>43, 48</td>
</tr>
<tr>
<td>Walder, K.</td>
<td>23, 24, 44</td>
</tr>
<tr>
<td>Wallace, C.</td>
<td>34</td>
</tr>
<tr>
<td>Walsh, D.</td>
<td>23</td>
</tr>
<tr>
<td>Walter, H.</td>
<td>55</td>
</tr>
<tr>
<td>Walter, M.</td>
<td>44</td>
</tr>
<tr>
<td>Walthers, A.</td>
<td>32</td>
</tr>
<tr>
<td>Walthers, S.</td>
<td>39, 43, 45, 61, 68</td>
</tr>
<tr>
<td>Wang, H.-N.</td>
<td>23</td>
</tr>
<tr>
<td>Wang, L.-J.</td>
<td>44</td>
</tr>
<tr>
<td>Wang, S.-M.</td>
<td>45, 66</td>
</tr>
<tr>
<td>Wang, X.-X.</td>
<td>23</td>
</tr>
<tr>
<td>Warhaftig, G.</td>
<td>37</td>
</tr>
<tr>
<td>Warner, E. M.</td>
<td>39, 41</td>
</tr>
<tr>
<td>Watmuff, B.</td>
<td>61</td>
</tr>
<tr>
<td>Weber, B.</td>
<td>43</td>
</tr>
<tr>
<td>Wehbeiner, C.</td>
<td>41</td>
</tr>
<tr>
<td>Weidekirk, D.</td>
<td>42</td>
</tr>
<tr>
<td>Wedervang-Rosell, K.</td>
<td>42</td>
</tr>
<tr>
<td>Wegener, G.</td>
<td>22, 25, 39,</td>
</tr>
<tr>
<td></td>
<td>51, 64, 66</td>
</tr>
<tr>
<td>Weickert, C. S.</td>
<td>37, 63</td>
</tr>
<tr>
<td>Weickert, T.</td>
<td>37</td>
</tr>
<tr>
<td>Weidensauer, A.</td>
<td>34</td>
</tr>
<tr>
<td>Weiller, E.</td>
<td>45</td>
</tr>
<tr>
<td>Weiner, I.</td>
<td>39</td>
</tr>
<tr>
<td>Weiland, C.</td>
<td>32</td>
</tr>
<tr>
<td>Weinheimer, S.</td>
<td>48</td>
</tr>
<tr>
<td>Weinstein, A.</td>
<td>46, 50</td>
</tr>
<tr>
<td>Weiser, M.</td>
<td>64</td>
</tr>
<tr>
<td>Weiss, C.</td>
<td>45</td>
</tr>
<tr>
<td>Weismann, D.</td>
<td>51</td>
</tr>
<tr>
<td>Wellsted, D.</td>
<td>55</td>
</tr>
<tr>
<td>Werge, T.</td>
<td>48, 61, 67</td>
</tr>
<tr>
<td>Wernke, U.</td>
<td>59</td>
</tr>
<tr>
<td>Wesolowski, J.</td>
<td>71</td>
</tr>
<tr>
<td>Westrin, A.</td>
<td>57</td>
</tr>
<tr>
<td>Whitfield-Gabrieli, S.</td>
<td>43</td>
</tr>
<tr>
<td>Wierchok, A.</td>
<td>55, 70</td>
</tr>
<tr>
<td>Wierzyk, M.</td>
<td>41</td>
</tr>
<tr>
<td>Wiest, R.</td>
<td>43, 68</td>
</tr>
<tr>
<td>Wigg, K.</td>
<td>41</td>
</tr>
<tr>
<td>Winkens, S.</td>
<td>34</td>
</tr>
<tr>
<td>Willeit, M.</td>
<td>34</td>
</tr>
<tr>
<td>Wimberley, T.</td>
<td>42</td>
</tr>
<tr>
<td>Windschibeler, C.</td>
<td>37</td>
</tr>
<tr>
<td>Windsetter, T. F.</td>
<td>48</td>
</tr>
<tr>
<td>Wissnegski, J.</td>
<td>54</td>
</tr>
<tr>
<td>Wójcikowsky, J.</td>
<td>65</td>
</tr>
<tr>
<td>Wosletz, M.</td>
<td>37</td>
</tr>
<tr>
<td>Wolf, H.</td>
<td>71</td>
</tr>
<tr>
<td>Wolf, R. C.</td>
<td>63</td>
</tr>
<tr>
<td>Wong, S.</td>
<td>33</td>
</tr>
<tr>
<td>Wright, M.</td>
<td>61</td>
</tr>
<tr>
<td>Wu, F.</td>
<td>25, 66, 67, 69</td>
</tr>
<tr>
<td>Wu, Y.-T.</td>
<td>48, 51</td>
</tr>
<tr>
<td>Wuehrlich, F.</td>
<td>43</td>
</tr>
<tr>
<td>Wydra, K.</td>
<td>61</td>
</tr>
<tr>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Xu, Y.</td>
<td>62</td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Yabuki, Y.</td>
<td>66</td>
</tr>
<tr>
<td>Yadid, G.</td>
<td>57</td>
</tr>
<tr>
<td>Yadin, E.</td>
<td>71</td>
</tr>
<tr>
<td>Yalcin, I.</td>
<td>22</td>
</tr>
<tr>
<td>Yamashita, Y.</td>
<td>67</td>
</tr>
<tr>
<td>Yamazaki, K.</td>
<td>68</td>
</tr>
<tr>
<td>Yangagimoto, H.</td>
<td>67</td>
</tr>
<tr>
<td>Yang, C.-C.</td>
<td>69</td>
</tr>
<tr>
<td>Yang, C.-H.</td>
<td>69</td>
</tr>
<tr>
<td>Yang, J.-C.</td>
<td>58</td>
</tr>
<tr>
<td>Yang, Y. K.</td>
<td>34</td>
</tr>
<tr>
<td>Yao, J.</td>
<td>42</td>
</tr>
<tr>
<td>Yasuyama, T.</td>
<td>45, 68</td>
</tr>
<tr>
<td>Yathar, L.</td>
<td>28, 43, 44, 46</td>
</tr>
<tr>
<td>Yeum, T.-S.</td>
<td>57</td>
</tr>
<tr>
<td>Yolken, R.</td>
<td>61</td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
<tr>
<td>Zaita, C.</td>
<td>62</td>
</tr>
<tr>
<td>Zaita, G.</td>
<td>41</td>
</tr>
<tr>
<td>Zainal, N. Z.</td>
<td>34</td>
</tr>
<tr>
<td>Zakharyan, R.</td>
<td>54, 68</td>
</tr>
<tr>
<td>Zannas, A.</td>
<td>64</td>
</tr>
<tr>
<td>Zapico Merayo, Y.</td>
<td>61</td>
</tr>
<tr>
<td>Zarate, C.</td>
<td>39</td>
</tr>
<tr>
<td>Zastrozhin, M.</td>
<td>66</td>
</tr>
<tr>
<td>Zaytseva, Y.</td>
<td>43, 68</td>
</tr>
<tr>
<td>Zeria, O.</td>
<td>60</td>
</tr>
<tr>
<td>Zetterberg, H.</td>
<td>24, 26</td>
</tr>
<tr>
<td>Zhang, D.</td>
<td>41</td>
</tr>
<tr>
<td>Zhang, Z.-J.</td>
<td>23</td>
</tr>
<tr>
<td>Zhu, C.</td>
<td>60</td>
</tr>
<tr>
<td>Ziifman, N.</td>
<td>57</td>
</tr>
<tr>
<td>Zilles, D.</td>
<td>42</td>
</tr>
<tr>
<td>Zimmermann, W.-H.</td>
<td>37</td>
</tr>
<tr>
<td>Zipursky, R.</td>
<td>61</td>
</tr>
<tr>
<td>Zinga, M.</td>
<td>42, 54</td>
</tr>
<tr>
<td>Zohar, J.</td>
<td>34</td>
</tr>
<tr>
<td>Zugman, A.</td>
<td>42</td>
</tr>
<tr>
<td>/Z</td>
<td></td>
</tr>
</tbody>
</table>
WELCOME TO VANCOUVER

WFSBP Congress 2019

14th World Congress of Biological Psychiatry

2 – 6 June 2019 | Vancouver, Canada
Vancouver Convention Centre East

www.wfsbp-congress.org
TREAT THE MIND
RESPECT THE BODY

FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS (≥18 YEARS)

Latuda®® (lurasidone)
PRESCRIBING INFORMATION SCHIZOPHRENIA FILM-COATED TABLETS

[Please refer to the full Summary of Product Characteristics (SPC) before prescribing, particularly in relation to adverse reactions, precautions and contraindications. Presentations: Latuda film-coated tablets, containing lurasidone hydrochloride equivalent to 16mg, 32mg, and 48mg lurasidone. Indications: Latuda is indicated for the treatment of schizophrenia in adults (≥18 years). Dosage and Administration: Oral administration. Adult: Recommended starting dose 1.5mg once daily with a meal. No initial dose titration is required. Effective dose range 1.5-4.5mg once daily. Dose increase should be based on physician judgment and observed clinical response. Maximum dose 14mg per day. Not for patients <18 years. Cautions when treating with higher doses: Parkinson and cerebellum (<18 years). Not recommended. Safety and efficacy not established. Dose adjustments are required in moderate and severe hepatic and renal impairment, see SPC for further details. Contraindications: Hypersensitivity to the active substance or any excipients. Concurrent administration of strong CYP3A4 inhibitors and inducers. Warnings and Precautions: Clinical improvement may take a few days to some weeks; closely monitor patient during this period. May occur in elderly patients with dementia who have risk factors for stroke. Not studied in elderly patients with dementia. Discontinue if patient develops signs or symptoms of neuroleptic malignant syndrome. Consider discontinuation if signs of tardive dyskinesia appear. May exacerbate underlying parkinsonism symptoms. Risk of extrapyramidal symptoms. Caution and clinical monitoring is recommended in patients with a history of seizures or conditions which potentially reduce seizure threshold. Cardiovascular disorders, orthostatic hypotension, diabetes or risk factors for diabetes and weight gain. May elevate prolactin levels. Adverse drug reactions (ADRs) should be identified before and during treatment and preventative measures taken. Caution in patients with a family history of CPD prolactination. Hypersalivation and consequent medication known to prolong the QT interval. Close supervision high risk patients for risk of suicide, Avoid grapefruit juice. Pregnancy and lactation: Do not use during pregnancy unless potential benefits override potential risks to the fetus. Breastfeeding should be considered only if the benefit to the patient justifies the potential risk to the child. Interactions: Caution is advised when combining with other CNS active medications, and medicines known to cause QT prolongation. P-gp and BCRP inhibitors may increase exposure to lurasidone. Lurasidone is an inhibitor of P-gp and BCRP. See SPC for details. These adjustments are recommended in combination with CYP3A4 inhibitors and inducers. See SPC for details. Monitoring recommended when lurasidone and CYP3A4 substrates known to have a narrow therapeutic index are coadministered. Undesirable effects: In clinical trials, the following adverse drug reactions were reported: most common: ≥10%: akathisia, somnolence, somnolence: ≥1% to <10%: weight gain, insomnia, agitation, anxiety, restlessness, parkinsonism, dizziness, dystonia, dyskinesia, nausea, vomiting, dyspepsia, salivary hypersecretion, dry mouth, upper abdominal pain, stomach discomfort, musculoskeletal stiffness, blood creatinine phosphokinase increase, serum creatinine increase, fatigue, pruritus: ≥1% (≥1%) increased appetite, blood glucose increased, cataract, tardive dyskinesia, gynecomastia, hyperprolactinaemia, akathisia, amnesia, weight increase, blood products increased: alanine aminotransferase increase ≥25% to 50%, C-reactive protein increased ≥20% to ≤50%, eosinophilia, hyperkalaemia, neuroleptic malignant syndrome (NMS). This is not a complete list of adverse reactions. Prescribers should consult the SPC in relation to all adverse reactions. Special precautions for storage: Store in the original package in order to protect from light.

Special precautions for disposal and other handling: Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Legal classification: Prescription Only Medicine (POM). Package Quantities and Sizes: Country specific. Marketing Authorisation Holder: Sunovian Pharmaceuticals Europe Ltd, Southside, 97 – 105 Victoria Street, London, SW1E 6ZU, Latuda is a registered trade mark. Marketing Authorisation Number: EU/1/14/111/001-021. Date of Preparation: February 2016 (MLA/2020/B6).

Latuda® (lurasidone) 18.5mg | 37mg | 74mg

LATUDA is a once-daily oral atypical antipsychotic which demonstrated:

Efficacy: At doses between 37mg/day and 148mg/day LATUDA separated significantly from placebo at week 6, both in PANSS total score (primary endpoint) and CGI-S score (key secondary endpoint). In a post-hoc analysis, LATUDA was not significantly different from olanzapine in efficacy at week 6. LATUDA showed statistical separation from placebo from as early as day 4 and at all subsequent study visits on PANSS total score.

Tolerance: Low risk for effect on metabolic parameters.
LATUDA had a negligible effect on mean weight in both short and long term studies. Some patients may gain weight and this was identified as a common side effect of LATUDA.

Safety: In clinical trials less than 1% of Patients on LATUDA had hyperprolactinaemia reported as an adverse event.

[This medicinal product is subject to additional monitoring. This will be a quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse reactions should be reported to the Competent Authority in your country. Adverse reactions should also be reported to Sunovian Pharmaceuticals Europe Ltd. on +44(0)20 3199 3990.]


[#16] and LATUDA are registered trademarks of Sunovian Pharmaceuticals Co., Ltd. © 2016 Sunovian Pharmaceuticals Europe Ltd. All rights reserved, 6/16.
Orchestrating the differential diagnosis of organic psychosis: shining a spotlight on NP-C
Chaired by Hans-Hermann Klünemann (Regensburg, Germany)

Satellite Symposium at the 13th World Congress of Biological Psychiatry
Supported by an educational grant provided by Actelion Pharmaceuticals Ltd